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Abstract 
 
Epstein-Barr virus (EBV) establishes a latent infection in the human host.  In 
order to produce infectious virus particles EBV must reactivate from latency and 
enter its lytic cycle.  BZLF1 is the immediate early gene in EBV that mediates 
the switch between latency and the lytic cycle.  The BZLF1 gene is under the 
control of the Zp promoter.   
Reactivation from latency is studied in EBV positive Akata cell lines 
where EBV can be reactivated by crosslinking the B-cell receptor (BCR) using 
antibodies to mimic antigen binding.  This system uses stably transfected 
reporter plasmids to study Zp regulation.  Mutagenesis identified additional 
regions of the promoter that contribute to regulation and the ZID MEF2 binding 
site was demonstrated to be functionally important during the initial stages of Zp 
activation.  XBP-1 splicing, previously implicated in Zp reactivation, was found 
to occur rapidly in this system in response to BCR crosslinking and parallels the 
transient induction of Zp.  Chromatin remodelling also plays an important role in 
Zp regulation.  An inducible BZLF1 expression system, independent of BCR 
signalling, was developed in Akata cells that accurately mimics BZLF1 activity 
and provides a novel approach to study repression at Zp.        
The BZLF1 protein is related to the bZIP family of transcription factors.  
BZLF1 contains a bZIP motif in which C-terminal residues fold back against a 
zipper region that forms an α-helical coiled-coil.  The 208SSENDRLR215 
sequence in the zipper region is conserved between BZLF1 and C/EBP.  Point 
mutagenesis in this sequence revealed the importance of individual residues for 
transactivation and progression to DNA replication.  The restoration of BZLF1 
DNA replication activity by complementation of two deleterious mutations 
(S208E and D236K) indicated that the interaction of the C-terminal tail and the 
core zipper region is required for DNA replication, identifying a functional role 
for this structural feature unique to BZLF1.      
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1.  Introduction 
 
1.1  Overview 
 
1.1.1  Epstein-Barr virus 
In 1957 Dennis Burkitt, an English physician, identified an endemic lymphoma 
affecting the jaws of young children in equatorial Africa (Burkitt, 1958).  He 
suspected that these tumours, now referred to as Burkitt’s lymphoma (BL), were 
the result of a vector born virus (Burkitt, 1962).  In 1964 Epstein, Achong and 
Barr isolated a herpesvirus particle from a BL biopsy (Epstein et al., 1964).  The 
virus was named Epstein-Barr virus (EBV).   
EBV is a ubiquitous human herpesvirus that infects over 90% of the 
world population (Henle et al., 1969).  The virus is transmitted orally by salivary 
exchange (Niederman et al., 1976).  The primary site of infection is the 
Waldeyer’s ring, consisting of the tonsils and adenoids, where infection of B 
lymphocytes occurs.  Primary infection with EBV usually occurs during early 
childhood and is asymptomatic (Joncas et al., 1974).  However, if primary 
infection is delayed until adolescence or early adulthood it can result in an acute 
self limiting lympohproliferative disorder known as infectious mononucleosis 
(IM) (Escobar et al., 1970).  The symptoms of IM are the result of a vigorous 
cytotoxic T cell response.  Primary infection, whether asymptomatic or indicated 
by IM, results in the establishment of a latent infection which persists for life 
(Kieff & Rickinson, 2007).         
EBV primarily infects B cells and certain epithelial cells.  Infection with 
EBV is associated with numerous B cell and epithelial cancers.  The virus is 
found in a latent state in several human cancers including BL, nasopharyngeal 
carcinoma (NPC), Hodgkin’s disease and gastric carcinoma (Kieff & Rickinson, 
2007).  
 
1.1.2  The herpesvirus family 
Herpesviruses are classified based on the architecture of the virion.  The virion 
particle consists of a linear double stranded genome surrounded by an 
icosahedral capsid.  This is surrounded by an amorphic tegument and an 
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envelope containing viral glycoprotein spikes on its surface (Pellet & Roizman, 
2007).  
 
 
Figure 1.1.  Human herpesvirus taxonomy  
 
Herpesviruses are widely distributed in nature and it is estimated that 
there are over 200 herpesviruses in total.  Eight of these herpesviruses infect 
humans as their primary host; Herpes Simplex virus 1 (HSV-1), Herpes Simplex 
virus 2 (HSV-2), Human Cytomegalovirus (HCMV), Varicella-zoster virus (VZV), 
Epstein-Barr virus (EBV), Kaposi Sarcoma associated herpesvirus (KSHV) and 
Human herpesviruses 6 and 7 (HHV-6 and HHV-7).  Most herpesviruses have a 
narrow host specificity as the viruses coevolved with their host over long 
periods of time.  Many of these viruses are subsequently avirulent in their 
natural host (Ackermann, 2004). 
The herpesvirus family (herpesviridae) is divided into three subfamilies, 
the alpha, beta and gamma-herpesviruses (herpesvirinae), based on biological 
properties (Figure 1.1) (Roizman et al., 1981).  The alpha-herpesvirus subfamily 
is characterised by a variable host range, including mammalian, avian and 
reptilian hosts, a short reproductive cycle and rapid spread in culture.  This 
subfamily includes HSV-1 and VZV.  The beta-herpesviruses are characterised 
by a restricted host range, long reproductive cycle and slow infection in culture, 
and include HCMV and HHV-6.  EBV belongs to the gamma-herpesvirus 
subfamily which is defined by a limited host range consisting of the family or 
Herpesviridae
Alphaherpesvirinae
Gammaherpesvirinae
Betaherpesvirinae
Cytomegalovirus:
Roseolovirus:
Lymphocryptovirus:
Rhadinovirus:
Varicellovirus:
Simplexvirus: HHV-1/2 (HSV-1/2)
HHV-3 (VZV)
HHV-5 (HCMV)
HHV-6/7
HHV-4 (EBV)
HHV-8 (KSHV)
Family Sub-family Genus Species
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order of the natural host.  The viruses are usually specific for either T or B 
lymphocytes and can replicate in vitro in lymphoblastoid, epitheloid and fibrotic 
cells.  The gamma-herpesvirus subfamily is further subdivided into the 
Lymphocryptovirus (LCV) genera, to which EBV belongs, and Rhadinovirus 
(RDV) genera, to which KSHV belongs.  EBV is the only known human LCV.  
LCVs are also found in new and old world primates (Pellet & Roizman, 2007).  
 
1.1.3  EBV virion and genome structures 
The EBV virion, like other herpesviruses, consists of a DNA core surrounded by 
a nucleocapsid, a protein tegument and an envelope with viral glycoprotein 
spikes on its surface.  The EBV nucleocapsid consists of 162 capsomeres and 
is approximately 100-110 nm in diameter (Kieff & Rickinson, 2007).  The 
tegument is composed of several viral proteins in addition to cellular proteins 
including actin, tubulin, cofilin and heat shock proteins.  The major viral 
envelope glycoproteins include gp350, gH, gB, gp42 and gp150 (Johannsen et 
al., 2004).   
The B95-8 EBV genome is approximately 172 kb long and contains 
around 85 genes (Baer et al., 1984).  It shares structural features with other 
LCVs including 0.5 kb terminal repeats (TR), short internal direct repeats (IR) 
and unique long and short regions (UL and US), which contain most of the 
coding capacity of the genome (Kieff & Rickinson, 2007).  In the virus particle 
the genome is present as a linear molecule.  However, when the virus infects B 
cells it rapidly circularises through the TRs and is maintained as an episome in 
the nucleus, where it acquires a nucleosomal structure (Bankier et al., 1983; 
Dyson & Farrell, 1985). 
The B95-8 strain of EBV was the first herpesvirus genome to be 
sequenced (Baer et al., 1984).  The B95-8 genome contains a 13.6 kb deletion 
and this region was later sequenced in the Raji strain (Parker et al., 1990).  
Sequencing was performed with overlapping cloned fragments, resulting from 
BamHI and EcoRI digestion of the genome.  Open reading frames were 
designated names based on the corresponding BamHI fragment and their order 
in a leftward or rightward direction within each fragment.  The BamHI fragments 
were named alphabetically in order of size.  For example, the immediate early 
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gene BZLF1 corresponds to the first leftward open reading frame starting in the 
BamHI Z fragment.  
Comparison of EBV sequences resulted in further subdivision of EBV 
into two subclasses, Type 1 and Type 2, based on conserved differences 
between the EBNA2 and EBNA3 genes (Adldinger et al., 1985; Sample et al., 
1990).  Type 1 is prevalent in western countries but the two types are found 
almost equally in equatorial Africa (Zimber et al., 1986).  Type 1 is more efficient 
at immortalising B cells in vitro (Rickinson et al., 1984).     
Comparison of the EBV sequence with that of other herpesviruses 
revealed several genes that are highly conserved amongst the herpesviruses.  
These genes generally encode lytic cycle proteins involved in viral DNA 
replication, virion structure (capsid, envelope and tegument proteins) and DNA 
packaging (Kieff & Rickinson, 2007; Ryon et al., 1993).  The latent genes show 
little conservation (Davison & Taylor, 1987) but EBV does share a set of 
proteins involved in latency and transformation with other LCVs.  BLLF1, which 
encodes the viral glycoprotein gp350, is a unique LCV gene (Kieff & Rickinson, 
2007).  In addition, EBV encodes some genes that are similar to cellular genes.  
The lytic genes BZLF1, BHRF1 and BCRF1 are similar to c-Fos, Bcl-2 and IL10 
respectively (Farrell et al., 1989; Moore et al., 1990; Pearson et al., 1987). 
 
1.2  EBV life cycle  
 
1.2.1  Primary infection 
EBV infects naïve B cells in the Waldeyer’s ring but the mechanism of infection 
is still unclear.  The role of epithelial cells in primary infection has long been 
debated.  It is suggested that access to B lymphocytes during primary infection 
may be facilitated by replication in mucosal epithelial cells (Borza & Hutt-
Fletcher, 2002).  However, examination of tonsillar tissues from primary 
infections of IM has consistently failed to identify infected epithelial cells, 
whereas both latent and replicating EBV can be detected in intra-epithelial B 
cells.  These observations resulted in a model of infection where EBV directly 
infects B cells in the lymphoepithelium of the tonsillar crypts (Faulkner et al., 
2000).   
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In favour of a dual tropism model where EBV infects both B cells and 
epithelial cells in the oropharynx, EBV has been detected in several epithelial 
malignancies including oral hairy leukoplakia (Loning et al., 1987), NPC 
(Andersson-Anvret et al., 1979) and gastric carcinoma (Burke et al., 1990).  
Also, in vitro, epithelial cells are more easily infected in the presence of B cells 
and EBV particles produced in epithelial cells have a higher efficiency for 
infecting B cells and vice versa (Borza & Hutt-Fletcher, 2002; Shannon-Lowe et 
al., 2006).   
A recent model proposes that resting B cells in the tonsils act as a 
transfer vehicle for infection of epithelial cells, where access of EBV to 
epithelium does not require an intermediate round of replication in B cells but 
instead, binding of EBV to the B cell surface is sufficient to transfer infection 
(Shannon-Lowe et al., 2006).  In this study, following virus loading of primary B 
cells, virus particles remained attached to the B cell surface for up to two days 
and appeared to enhance infection of epithelial cell lines.  Transfer infection 
was associated with the formation of B cell/epithelial conjugates, with gp350 
and CD21 localised at the site of cell contact.  Transfer infection additionally 
required expression of the EBV gH and gB glycoproteins, which are involved in 
epithelial fusion and penetration (discussed below), but was independent of 
gp42 mediated entry into B cells and lytic replication (Shannon-Lowe et al., 
2006).             
 
1.2.2  Attachment and cell entry  
Entry of EBV into B lymphocytes is initiated by attachment of the viral 
glycoprotein gp350/220 to the C3d cluster differentiation antigen CD21, also 
known as complement receptor CR2 (Nemerow et al., 1987; Nemerow et al., 
1985).  EBV and CD21 colocalisation on the cell surface is followed by receptor 
mediated endocytosis into smooth vesicles (Fingeroth et al., 1984).  A complex 
of three proteins, gH (gp85), gL (gp25) and gp42, mediates membrane fusion 
and mediates penetration and cell entry (Li et al., 1995).  This process is 
triggered by the interaction of gp42 and human leukocyte antigen (HLA) class II, 
which acts as an essential coreceptor for B cell infection (Haan et al., 2000; Li 
et al., 1997).  The gH-gL complex is essential for penetration into B cells 
(Molesworth et al., 2000) and gB has also been implicated in this process (Haan 
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et al., 2001; McShane & Longnecker, 2004).  Following endocytosis, the virus 
envelope fuses with the endocytic membrane and capsids are released into the 
cytoplasm (Nemerow & Cooper, 1984).  The nucleocapsid disperses and the 
genome is translocated to the nucleus where it is maintained as an episome.  
Infection of B cells can occur in the absence of gp350/220, although with much 
lower efficiency, indicating that EBV can infect B cells via an alternative 
pathway (Janz et al., 2000).   
EBV also infects epithelial cells lacking CD21 and HLA class II.  Entry 
into epithelial cells lacking HLA class II is mediated by complexes lacking gp42 
and requires interaction of gH-gL with an unknown glycoprotein (Borza et al., 
2004; Wang et al., 1998).  In epithelial cells lacking CD21, gH is required for 
both attachment and penetration (Molesworth et al., 2000; Oda et al., 2000) but  
the use of gH-gL for attachment as well as penetration appears to compromise 
the ability of the virus to mediate entry (Borza et al., 2004).  This mechanism of 
entry into epithelial cells is supported by the observation that mutant viruses 
lacking gp350/220 infect epithelial cells (Janz et al., 2000) and a more recent 
study subsequently demonstrated that the absence of gp350/220 actually 
increases the infection efficiency of epithelial cells (Shannon-Lowe et al., 2006).  
In addition, antibodies to gp350/220 enhanced infection of epithelial cells (Turk 
et al., 2006).  It was suggested that this facilitated access of proteins 
responsible for virus penetration with the epithelial surface.   
 The virus contains both three part gH-gL-gp42 and two part gH-gL 
complexes affecting the tropism of the virus for B cells and epithelial cells 
respectively (Borza & Hutt-Fletcher, 2002).  Alternate replication of EBV in HLA 
class II positive B cells and HLA class II negative epithelial cells modified the 
ratio of these complexes and the tropism of the virus (Borza & Hutt-Fletcher, 
2002).     
       
1.2.3  Latent gene expression in vitro  
In vitro three forms of latency were identified and are referred to as latency I, II 
and III (Rowe et al., 1992).  These forms of latency have been associated with 
several cancers and are similar to the EBV gene expression pattern observed at 
different stages of infection in vivo.   
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When primary B cells are infected in vitro, EBV immortalises the B cells 
forming continuously proliferating lymphoblastoid cell lines (LCLs) (Henle et al., 
1967).  LCLs establish a latency III pattern of gene expression consisting of six 
EBV nuclear antigens, EBNA-1, -2, -3A, -3B, -3C and -LP, three latent 
membrane proteins, LMP-1, -2A and -2B, two non-polyadenylated EBV 
encoded RNAs, EBER-1 and -2, the BHRF1 microRNAs (miRNAs) and the 
BamHI rightward transcripts (BARTs) (Alfieri et al., 1991; Kieff & Rickinson, 
2007).  EBNA2 and EBNA-LP are the first genes expressed from the Wp 
promoter.  Both are encoded from the same primary transcript which is spliced 
into two specific mRNAs.  EBNA2 can switch expression of the EBNAs from the 
Wp to the Cp promoter (Woisetschlaeger et al., 1991) and EBNA2 and EBNA-
LP upregulate specific EBV and cellular promoters, resulting in expression of 
the EBNA3 proteins and the LMPs (Alfieri et al., 1991). 
The latency III pattern of gene expression results in a dramatic change in 
cellular phenotype.  B cell surface activation markers, CD23, CD30, CD39 and 
CD70, and adhesion molecules, LFA-1, ICAM-1 and LFA-3, are upregulated.  
As a result the cells aggregate and grow in clumps.  LCLs also express the 
cellular oncogene Bcl-2 and are phenotypically similar to activated B blasts in 
vivo (growth programme) (Joseph et al., 2000; Rowe et al., 1992). 
More restricted forms of latency have been associated with EBV related 
malignancies.  These forms of latency were studied in vitro in BL cell lines.  BL 
cell lines carry a translocation of c-MYC to the immunoglobulin (Ig) heavy or 
light chain gene loci, resulting in deregulated c-MYC expression which drives 
cell proliferation (Dalla-Favera et al., 1983).   
BL cell lines are divided into three groups, I, II and III, each expressing 
different sets of genes (Rowe et al., 1992).  Group III BL cell lines express a 
latency III pattern of gene expression, with the full set of EBV latency genes 
expressed in the LCLs.  Group II BL cell lines express a latency II pattern of 
gene expression, characterised by coexpression of EBNA1, the LMP proteins, 
the EBERs and BARTs.  An equivalent pattern of gene expression is found 
during infection in vivo in germinal centre B cells (default programme) (Babcock 
& Thorley-Lawson, 2000; Thorley-Lawson & Gross, 2004).  The latency II form 
of infection is also found in several human cancers including NPC (Young et al., 
1988) and Hodgkin’s disease (Pallesen et al., 1991).   
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Latency I cells have a highly restricted pattern of gene expression and 
only express EBNA1, the EBERs and BARTs (Sample et al., 1991; Schaefer et 
al., 1991).  Group I BL cell lines express a latency I phenotype where EBNA1 is 
expressed from the Qp promoter.  In contrast to LCLs, these cells express low 
levels of B cell activation antigens and cell adhesion molecules, and as a result 
do not grow in clumps.  Instead they express the germinal centre B cell markers 
CD10 and CD77, which are not expressed in LCLs (Gregory et al., 1988).  The 
latency I phenotype is expressed in vivo when latently infected memory cells 
divide, allowing the viral DNA to replicate (Hochberg et al., 2004).  This 
phenotype is characteristic of most BL tumours in vivo (Rooney et al., 1986).      
     
1.2.4  Establishment of a latent infection in vivo  
EBV infection of naïve B cells in the tonsils results in a latent infection where the 
virus persists in the memory B cell pool for life.  Although, the mechanism that 
leads to this persistence is not fully understood.  The current model is based on 
the theory that EBV persistence parallels B cell activation in response to 
antigen, where EBV provides the necessary signals for cell growth and 
differentiation.  According to the model, EBV transforms B cells into proliferating 
blasts that differentiate into resting memory B cells through the germinal centre 
reaction (Figure 1.2) (Thorley-Lawson & Babcock, 1999).  There are several 
lines of evidence supporting this model.   
According to the model, following infection, EBV activates and transforms 
naïve B cells.  In support of this hypothesis, latently infected naïve B cells in the 
tonsils express a latency III pattern of gene expression, where all of the latent 
proteins are expressed (growth programme), and resemble antigen activated B 
cells in both surface and morphological features (Babcock et al., 2000; Joseph 
et al., 2000). 
Naïve B cells are normally activated through signals generated from the 
BCR in response to antigen engagement.  To survive and differentiate, B cells 
require additional signals from antigen specific T-helper cells via CD40 and 
other costimulatory molecules (Liu et al., 1989).  EBV is believed to mimic these 
signals through expression of two EBV latent proteins, LMP1 and LMP2A, 
tricking the cell into becoming an activated B blast (Zimber-Strobl et al., 1996).  
LMP1 is a functional homologue of CD40 (Kilger et al., 1998) and LMP2A can 
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mimic the B cell survival signal usually provided by the BCR (Caldwell et al., 
1998).   
 
 
Figure 1.2.  Schematic representation of EBV life cycle 
EBV infects naïve B cells in the Waldeyer’s ring and activates the B cells entering the growth 
programme (Latency III).  The antigen activated B cells migrate into the follicles and expand to 
form germinal centres, entering the default programme (Latency II).  The cells then exit the cell 
cycle and enter the memory B cell pool.  Memory B cells circulate back to the Waldeyer’s ring 
and differentiate into plasma cells in order to produce infectious virus particles.    
 
Expression of the latency genes is believed to block terminal 
differentiation, allowing the B cells to remain activated and continue to 
proliferate.  This is a short lived process as the virus must establish persistence 
before the cytotoxic T cell response arises.  EBV uses this short time to 
proliferate and expand its genome copy number. 
Antigen activated B cells migrate into the follicles where they proliferate, 
forming germinal centres that produce both antibody producing plasma cells 
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and memory cells.  Here the immunoglobulin genes undergo isotype switching 
and affinity maturation.  Only a small fraction of these cells, with mutated Ig that 
still recognises antigen and binds to T-helper cells, are rescued from apoptosis 
(Liu & Arpin, 1997; MacLennan, 1994).   
It is proposed that EBV infected B blasts differentiate into memory B cells 
in the same way as antigen activated B blasts.  This occurs through the default 
programme where EBV expresses a latency II pattern of gene expression, 
including EBNA1, LMP1 and LMP2A.  LMP1 and LMP2A are proposed to 
provide the necessary signals to rescue the cells from apoptosis and move to 
the memory compartment (Thorley-Lawson, 2001).  In support of this model, 
cells in the tonsil expressing the phenotypic GC marker CD10 were shown to 
express a latency II pattern of gene expression, where EBNA2 is switched off 
(Babcock et al., 2000).  This is necessary for germinal centre progression as 
EBNA2 blocks differentiation.  In addition, latency II expressing cells from the 
tonsils have now been shown to be physically located in germinal centres and 
express the functional germinal centre markers AID and Bcl-6 (Roughan & 
Thorley-Lawson, 2009).   
Once in the memory compartment, all viral protein expression is shut 
down, referred to as latency 0 (Babcock et al., 1999).  EBNA1 is expressed only 
when latently infected memory cells divide, allowing the viral DNA to replicate 
(latency I) (Hochberg et al., 2004).  However, for long term survival, memory B 
cells require survival signals provided by a functional BCR (Maruyama et al., 
2000).  Memory cells in the tonsil, unlike the peripheral circulation, express the 
default programme (Babcock & Thorley-Lawson, 2000).  It is suggested that 
memory B cells circulate back to lymph nodes where local signals allow re-
expression of LMP1 and LMP2A, providing the necessary signals to ensure 
survival in the memory compartment (Thorley-Lawson, 2001).     
By gaining access to the memory B cell pool, EBV has found a niche 
where it can persist for life, avoiding immune surveillance.  In order to produce 
infectious virus progeny, the virus must reactivate from this resting memory 
state.  It is proposed that resting memory B cells circulate between the 
Waldeyer’s ring and the peripheral blood without being detected by the immune 
system.  In the Waldeyer’s ring, memory cells differentiate into plasma cells 
producing infectious virus particles that are subsequently shed into the saliva 
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and transmitted to a new host (Laichalk & Thorley-Lawson, 2005; Thorley-
Lawson & Gross, 2004).    
The relationship of EBV associated lymphomas to specific stages of B 
cell differentiation further supports this model. In post-transplant 
lymphoproliferative disease (PTLD), the virus expresses a latency III pattern of 
gene expression or the growth programme (Thomas et al., 1990).  It is 
proposed that PTLD occurs when EBV infects non-naïve B cells in the 
Waldeyer’s ring and transforms these cells into activated B blasts.  These cells 
are unable to exit the growth programme and form germinal centres.  Due to 
immunosuppression in these post-transplant patients, the cells are not 
destroyed by the cytotoxic T cell response (Thorley-Lawson & Gross, 2004; 
Timms et al., 2003).       
In EBV positive Hodgkin’s disease, tumours express a latency II pattern 
of gene expression characteristic of the default programme (Deacon et al., 
1993).  The immunoglobulin genes of the Reed-Sternberg tumour cells are 
hypermutated similarly to germinal centre B cells, suggesting that Hodgkin’s 
disease originates from an EBV infected germinal centre B cell (Kuppers & 
Rajewsky, 1998).  These cells probably contain mutations involved in tumour 
development that prevent them from differentiating into memory cells.   
BL cells express a latency I pattern of gene expression.  These cells 
have the same pattern of immunoglobulin gene hypermutation as germinal 
centre and memory B cells (Klein et al., 1995).  They also express the same cell 
surface markers as germinal centre cells (Gregory et al., 1987).  The only non-
tumour cells expressing only the EBNA1 protein are latently infected memory 
cells that divide.  In BL the c-MYC oncogene is deregulated.  It is suggested 
that BL arises if a translocation in the c-MYC gene occurs in an EBV infected 
germinal centre cell on its way to becoming a memory cell, where the cell 
becomes stuck in a proliferating mode expressing the EBNA1 protein (Thorley-
Lawson & Gross, 2004).  
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1.3  Latency 
 
1.3.1  The latent genes  
The proliferation and transformation of B cells following EBV infection is 
mediated by the viral latent genes.  EBNA2 and EBNA-LP are the first genes 
expressed from the Wp promoter following EBV infection.  EBNA2 is a 
transcriptional activator and is essential for B cell transformation and 
immortalisation (Cohen et al., 1989).  EBNA2 does not bind directly to DNA but 
interacts with cellular transcription factors, such as RBP-Jκ, to transactivate 
cellular and viral genes (Grossman et al., 1994; Ling et al., 1993).  EBNA2 is a 
functional homologue of NotchIC, a cellular binding partner of RBP-Jκ involved 
in activation of Notch signalling pathways (Hsieh et al., 1996; Tamura et al., 
1995). 
The acidic activation domain of EBNA2 interacts directly with cellular 
transcription factors, including TFIIB, TBP, TFIIH and CBP/p300, involved in 
pre-initiation complex formation (Tong et al., 1995a; Tong et al., 1995b; Wang 
et al., 2000).  In addition EBNA2 can modify chromatin structure through 
recruitment of the SW1/SNF1 complex (Wu et al., 2000).              
EBNA2 switches expression from the Wp to the Cp promoter resulting in 
upregulation of its own expression and expression of the full set of EBNA 
proteins (Woisetschlaeger et al., 1991).  EBNA2 also specifically transactivates 
the LMP1, LMP2A and LMP2B promoters (Fahraeus et al., 1990).  In addition to 
its role in regulation of latent gene expression, EBNA2 alters expression of 
cellular genes.  Many of these genes function in B cell activation and 
proliferation.  For example EBNA2 upregulates expression of the cell surface 
marker CD23, the complement receptor CD21 (Cordier et al., 1990), the cellular 
oncogene c-MYC (Kaiser et al., 1999), the Runt domain transcription factor 
RUNX-3 (Spender et al., 2002) and chemokine receptor CXCR7 (Lucchesi et 
al., 2008).     
 
EBNA-LP (Leader Protein) is expressed at the same time as EBNA2 and 
enhances B cell transformation (Mannick et al., 1991).  EBNA-LP also 
enhances EBNA2 transactivation of cellular and viral targets including cyclin D2, 
LMP1, LMP2B and the Cp promoter (Harada & Kieff, 1997; Nitsche et al., 1997; 
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Palmero et al., 1993; Peng et al., 2005; Sinclair et al., 1994).  EBNA-LP 
localises in both the nucleus and the cytoplasm in infected LCLs (Kawaguchi et 
al., 2000; Petti et al., 1990).  In the nucleus, EBNA-LP is associated with 
promyelocytic leukaemia (PML) bodies (Szekely et al., 1996) where it displaces 
Sp100 and its binding partner heterochromatin protein 1α (Ling et al., 2005).  
Displacement of Sp100 was associated with the ability of EBNA-LP to 
coactivate induction of LMP1, suggesting that Sp100 is a mediator of EBNA-LP 
coactivation.  
EBNA-LP has been reported to interact with several other cellular 
proteins including p53, Rb, hsp72/73, hEER1 and Hax-1, although the biological 
significance of many of these interactions remains to be elucidated (Igarashi et 
al., 2003; Kawaguchi et al., 2000; Mannick et al., 1995; Szekely et al., 1993).  
Hax-1 is a cytoplasmic protein reported to be involved in regulation of B cell 
signal transduction and apoptosis (Sharp et al., 2002; Suzuki et al., 1997).  Hax-
1 can interact with the anti-apoptotic proteins Bcl-2 and BHRF1.  EBNA-LP can 
form a complex with Bcl-2 and BHRF1 through Hax-1, indicating that EBNA-LP 
plays a role in regulation of apoptosis (Matsuda et al., 2003).       
 
EBNA1 is a dimeric site specific DNA binding protein that plays an 
essential role in maintenance and replication of the viral episome (Rawlins et 
al., 1985).  EBNA1 is expressed in all EBV infected cell lines and EBV 
associated malignancies.  Only resting memory cells, that do not undergo cell 
division, lack EBNA1 expression (latency 0).  EBNA1 is also expressed during 
the lytic cycle (Heller et al., 1982).   
EBNA1 binds to the origin of latent replication (oriP) (Rawlins et al., 
1985) and tethers the viral episome to the host chromosome, which ensures 
that the genome is replicated during the S phase of cell division (discussed in 
section 1.3.2).       
Although EBNA1 is expressed in all forms of latency it is not essential for 
B cell immortalisation but it greatly enhances the efficiency of this process 
(Humme et al., 2003).  EBNA1 has additional roles during latency.  EBNA1 acts 
as a transcriptional regulator enhancing expression of several viral genes from 
the Cp promoter (Sugden & Warren, 1989).  EBNA1 also functions in escaping 
cytotoxic T lymphocyte surveillance, through a glycine-alanine repeat region 
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that inhibits EBNA1 processing through proteasomes and surface major 
histocompatibility complex (MHC) presentation (Levitskaya et al., 1995). 
EBNA1 has been reported to contribute to tumourigenesis.  Recent 
reports indicate that EBNA1 provides a growth advantage to BL cells and 
protection from apoptosis.  Knockdown of EBNA1 in EBV positive BL cell lines 
inhibited cell proliferation and resulted in apoptosis (Hong et al., 2006; Kennedy 
et al., 2003).  EBNA1 also contributes to genomic instability through 
transcriptional activation of the leukocyte NADPH oxidase NOX-2, which 
induces production of reactive oxygen species (Gruhne et al., 2009).  EBNA1 
induced chromosomal aberrations, DNA double stranded breaks and 
engagement of the DNA damage response in B cell lines, suggesting a potential 
contribution of EBNA1 to malignant transformation and tumour progression.   
EBNA1 binds to the ubiquitin specific protease USP7/HAUSP, a key 
regulator of the p53 pathway, suggesting a mechanism of how EBNA1 can 
protect cells from p53 induced apoptosis (Holowaty et al., 2003b).  p53 binds to 
the same site on USP7 as EBNA1 but with less extensive contacts (Saridakis et 
al., 2005).  Interaction of EBNA1 with USP7 blocked p53 binding in vitro, 
suggesting that EBNA1 could affect p53 function in vivo by competing for USP7 
(Holowaty et al., 2003a).  The interaction of EBNA1 and USP7 was associated 
with disruption of PML nuclear bodies in NPC cell lines (Sivachandran et al., 
2008).  EBNA1 also impaired p53 activation, DNA repair and apoptosis in NPC 
cells, all functions dependent on PML nuclear bodies.  This provides further 
evidence that EBNA1 can promote survival in cells with DNA damage and 
contribute to tumourigenesis (Sivachandran et al., 2008).      
 
The EBNA3 proteins are encoded by alternatively spliced transcripts 
initiated at the Cp promoter.  EBNA3A and EBNA3C are essential for B cell 
transformation whereas EBNA3B is not (Tomkinson & Kieff, 1992; Tomkinson et 
al., 1993).  The EBNA3 proteins interact with RBP-Jκ and compete with EBNA2 
binding, inhibiting transcriptional activation of EBNA2 responsive promoters, to 
counterbalance EBNA2 function (Le Roux et al., 1994; Waltzer et al., 1996). 
Consistent with their role in repression, EBNA3A and EBNA3C interact 
with histone deacetylases (HDACs) and bind directly to the cellular repressor 
CtBP (Hickabottom et al., 2002; Radkov et al., 1999; Touitou et al., 2001).  
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EBNA3C represses transcription from the Cp promoter.  This is dependent on 
the RBP-Jκ binding site, binding to HDAC1 and also requires interaction of the 
atypical bZIP domain of EBNA3C with RBP-Jκ (Radkov et al., 1997; Radkov et 
al., 1999; West et al., 2004).  All three EBNA3 proteins also disrupt LMP2 
promoter activation through EBNA2 (Le Roux et al., 1994) but the EBNA3 
proteins are not only involved in negative regulation of EBNA2 function.  
EBNA3C cooperates with EBNA2 in the induction of the LMP1 promoter (Zhao 
& Sample, 2000). 
 Studies with EBNA3 knockout viruses in BL cells showed that EBNA3A 
and EBNA3C cooperate to repress expression of the pro-apoptotic tumour 
suppressor Bim, a Bcl-2 family member, providing a survival advantage to the 
cells and increasing the oncogenic potential of the virus (Anderton et al., 2008). 
In addition to its transcriptional function, EBNA3C has been reported to 
have cell cycle regulatory functions and can interfere with the cell cycle by 
controlling the G2/M checkpoint (Leao et al., 2007; Parker et al., 2000).  
EBNA3C can facilitate the degradation of several cell cycle regulatory proteins, 
including Rb and p27, by recruitment of the SCFSkp2 E3 ubiquitin ligase complex 
(Knight et al., 2005a; b).  p27 is commonly downregulated in LCLs and its 
expression was shown to correlate inversely to proliferation in BJAB cells (Frost 
et al., 2001a; Frost et al., 2001b).  EBNA3C can also function as a 
deubiquitination enzyme and can efficiently deubiquitinate itself and the cellular 
protein oncogene Mdm2, which is overexpressed in several cancers (Saha et 
al., 2009).        
EBNA3B epitopes are recognised by cytotoxic T lymphocytes and 
EBNA3B is one of the dominant targets for recognition of immortalised cells 
(Rickinson & Moss, 1997).  The fact that this gene has not been selected 
against by EBV indicates that it must have an essential role in infection in vivo.   
 
LMP1, LMP2A and LMP2B are located in close proximity on the viral 
genome and their expression is induced by EBNA2.  LMP1 is an integral 
membrane protein consisting of a short hydrophilic cytoplasmic N-terminus, six 
hydrophobic transmembrane domains separated by short turns and a 200 
amino acid long cytoplasmic C-terminus (Kieff & Rickinson, 2007).  LMP1 
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localises in patches of the plasma membrane similar to growth factor receptors 
stimulated by ligand binding (Liebowitz et al., 1986). 
LMP1 acts as a constitutively active tumour necrosis factor (TNF) 
receptor and mimics the CD40 signalling pathway to activate NF-κB signalling, 
which is involved in B cell activation and survival (Gires et al., 1997; Mosialos et 
al., 1995).  NF-κB has recently been shown to bind to the LMP1 promoter and 
can transactivate its expression, consistent with a positive regulatory loop 
between NFκB activation and LMP1 expression (Demetriades & Mosialos, 
2009; Johansson et al., 2009).  Activation by NFκB is independent of EBNA2.     
Expression of LMP1 is essential for B cell transformation (Kilger et al., 
1998) and induces phenotypic changes associated with EBV infection such as 
upregulation of cell adhesion molecules, activation markers and cytokine 
production (Wang et al., 1988).  LMP1 has been described as an oncogene as it 
can transform rodent fibroblasts and is tumourigenic in transgenic mice 
(Kulwichit et al., 1998; Wang et al., 1985).  LMP1 upregulates anti-apoptotic 
genes including Bcl-2 and A20 (Henderson et al., 1991) and downregulates Bcl-
6, a protein involved in germinal centre formation (Carbone et al., 1998). 
LMP1 suppresses virus reactivation, inhibiting both anti-IgM and phorbol 
ester induced transcription of the immediate early gene BZLF1, controlling entry 
of the virus into the lytic cycle (Adler et al., 2002).   
LMP2A and LMP2B are expressed from the same gene by alternative 
promoter usage (Laux et al., 1988).  Both LMP2A and LMP2B are integral 
membrane proteins which share 12 transmembrane domains and a short C-
terminal tail.  The major difference between the two proteins is that LMP2A has 
an additional 119 amino acid hydrophilic N-terminal cytoplasmic signalling 
domain.  This signalling domain contains eight tyrosine residues which are part 
of an immunoreceptor tyrosine-based activation motif (ITAM), that is 
constitutively phosphorylated (Kieff & Rickinson, 2007).  Similar to LMP1, 
LMP2A forms aggregates at the membrane, mimicking an activated receptor 
(Bornkamm & Hammerschmidt, 2001).   
LMP2A and LMP2B are not required for B cell transformation although 
LMP2A can enhance the efficiency of transformation (Brielmeier et al., 1996; 
Longnecker et al., 1992).  LMP2A acts as a constitutively active BCR and 
provides survival signals to the B cells.  In LMP2A transgenic mice experiments, 
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LMP2A rescued B cells with non-functional BCRs from apoptosis, through its 
ITAM motif (Caldwell et al., 2000; Merchant et al., 2000).  Other studies also 
indicated that LMP2A can rescue human B cells with inactivated 
immunoglobulin genes from apoptosis (Chaganti et al., 2005; Mancao et al., 
2005). 
In addition to its role in B cell survival, LMP2A interferes with normal 
BCR signalling through interaction with specific cell kinases, including  Lyn, Syk 
and Btk, via its cytoplasmic N-terminal domain (Fruehling et al., 1998).  Since 
Zp, the promoter of the immediate early gene BZLF1, responds to BCR 
signalling, LMP2A blocks EBV reactivation (Miller et al., 1994).  This may be 
relevant in vivo when LMP2A is expressed in memory cells recirculating through 
the lymph nodes (Thorley-Lawson, 2001).  LMP2A also inhibited BCR induced 
apoptosis in BL cell lines and similarly, genistein, a specific inhibitor of tyrosine 
specific protein kinases, inhibited BCR induced apoptosis and EBV reactivation.  
This suggests that LMP2A may inhibit the activation of tyrosine kinases by BCR 
crosslinking (Fukuda & Longnecker, 2005).  LMP2A binds to members of the 
Nedd4 like ubiquitin protein ligase family, resulting in ubiquitination and 
degradation of LMP2A and LMP2A associated proteins (Portis et al., 2004).    
Recent work has shown that LMP2A allows survival of EBV infected 
germinal centre B cells with potentially deleterious somatic hypermutations of 
their immunoglobulin genes (Mancao & Hammerschmidt, 2007).  This suggests 
that LMP2A could play an essential role in survival of B cells in certain 
malignancies, such as Hodgkin’s disease, which contain similar defective 
rearrangements of their immunoglobulin genes.  LMP2A also protected against 
c-MYC induced apoptosis in LMP2A transgenic mice, with a BL translocation of 
c-MYC (Bultema et al., 2009).   
The role of LMP2B in latency is unclear.  It is proposed that LMP2B 
forms aggregates with LMP2A and since it lacks the N-terminal signalling 
domain, modulates LMP2A activity (Bornkamm & Hammerschmidt, 2001).  In 
support of this hypothesis, overexpression of LMP2B in Akata BL cells 
increased the magnitude of lytic gene expression in response to BCR 
crosslinking, compared to vector only transfected cells and cells overexpressing 
LMP2A (Rechsteiner et al., 2008).  In addition, silencing of LMP2B in Akata 
cells reduced levels of BZLF1 mRNA and conversely silencing of LMP2A 
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resulted in higher BZLF1 mRNA and protein expression (Rechsteiner et al., 
2007).  LMP2B also colocalised with LMP2A and restored calcium mobilisation 
in response to BCR crosslinking, a process that is blocked by LMP2A 
(Rechsteiner et al., 2008).  Similarly, overexpression of LMP2B in EBV negative 
BJAB cells overexpressing LMP2A, restored Lyn levels and calcium 
mobilisation (Rovedo & Longnecker, 2007).       
 
EBV expresses two EBV encoded non-polyadenylated (non-coding) 
small RNAs, EBER1 and EBER2, during all forms of latency (Arrand & Rymo, 
1982).  The EBERs are the most abundant EBV transcripts in latently infected 
cells but their precise role in latency remains undetermined.  EBER1 and 
EBER2 localise to the nucleus where they are complexed with the cellular 
proteins La and L22 (Howe & Steitz, 1986; Kieff & Rickinson, 2007).  The 
EBERs are not essential for B cell transformation (Swaminathan et al., 1991) 
but increase its efficiency (Yajima et al., 2005).  This was related to expression 
of EBER2.  Deletion of EBER2 and not EBER1 impaired the transforming ability 
of recombinant EBVs (Wu et al., 2007).           
It is suggested that the EBERs have oncogenic and anti-apoptotic roles 
as EBER expression in EBV negative Akata cells resulted in the tumourigenic 
phenotype found in EBV positive Akata cells, expressing EBNA1, the EBERs 
and the BARTs (Komano et al., 1999; Komano & Takada, 2001; Ruf et al., 
2000).  In addition, the EBERs may enhance cell growth through induction of 
the autocrine growth factor IL10 in BL cells (Kitagawa et al., 2000).     
 
EBV encodes multiple miRNAs from two primary transcripts, BHRF1 and 
BART.  To date EBV has been shown to encode approximately 40 mature EBV 
miRNAs (Cosmopoulos et al., 2009) but their biological function remains 
unclear.  They do not appear to be required for EBV infection, immortalisation or 
LCL outgrowth in vitro (Kieff & Rickinson, 2007).   
The BARTs are differentially spliced RNAs that are expressed at low 
levels in all forms of latency and during lytic infection (Brooks et al., 1993).   
They are also expressed in EBV associated carcinomas where they are 
particularly abundant (Chen et al., 1992; van Beek et al., 2003).  The BART 
region contains a number of potential protein coding regions.  Two of these 
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open reading frames encode the putative A73 and RPMS1 proteins but analysis 
of several cell lines indicated that these proteins are not expressed in natural 
infection (Al-Mozaini et al., 2009).  Four miRNAs are derived from the BHRF1 
gene, which contains the BHRF1 open reading frame (Pfeffer et al., 2004).  In 
contrast to the BARTs, expression of the BHRF1 miRNAs is dependent on the 
type of viral latency.  BHRF1 miRNAs are highly expressed in latency III cells 
but not in other forms of latency (Cai et al., 2006).   
NPC is associated with high levels of BART transcripts and the absence 
of BHRF1 miRNAs.  Two recent studies reported highly variable expression of 
all BART miRNAs but no detectable expression of the BHRF1 miRNAs in NPC 
tumour biopsies (Cosmopoulos et al., 2009; Zhu et al., 2009)  
Roles for some of the miRNAs have been indicated.  BART2 targets the 
DNA polymerase BARF5 for degradation suggesting that it inhibits the transition 
from latent to lytic DNA replication (Barth et al., 2008).  Cluster 1 BART miRNAs 
have been reported to downregulate expression of LMP1 and miRNAs from the 
BHRF1 region have been implicated in downregulation of the interferon 
inducible T cell attracting chemokine CXCL-11 (Lo et al., 2007; Xia et al., 2008).             
 
1.3.2  DNA replication during latency  
During latency the EBV genome exists as a closed circular plasmid or episome 
and contains a nucleosome structure similar to that of the host chromosome 
(Dyson & Farrell, 1985).  The EBV episome is replicated once during early S 
phase (Adams, 1987) and is divided between the daughter cells during mitosis 
(Yates et al., 1984).  The origin of latent replication (oriP) and the EBNA1 
protein are necessary and sufficient for replication of the viral episome (Yates et 
al., 1984; Yates et al., 1985).  oriP consists of two principal components, the 
family of repeats (FR) region, which contains 20 EBNA1 binding sites, and the 
dyad symmetry (DS) region, which contains 4 EBNA1 binding sites (Rawlins et 
al., 1985).   
The DS region is the functional replicator where bidirectional DNA 
replication initiates and is sufficient for DNA synthesis in the presence of 
EBNA1 (Yates et al., 2000).  The FR region is essential for segregation of viral 
episomes during mitosis, whereas the DS region is dispensable, suggesting that 
the function of the FR region is to tether the plasmid to the host chromosome 
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via EBNA1 (Kanda et al., 2001; Mackey & Sugden, 1997; Norio et al., 2000).  
Binding of EBNA1 to the host mitotic chromosomal protein EBNA1 binding 
protein 2 (EBP2) was implicated in this process.  EBP2 enabled EBNA1 to 
segregate FR containing plasmids in yeast, facilitating attachment of EBNA1 to 
mitotic chromosomes (Kapoor & Frappier, 2003).  Moreover, silencing of human 
EBP2 in HeLa cells affected the ability of EBNA1 and oriP plasmids to associate 
with mitotic chromosomes (Kapoor & Frappier, 2003; Kapoor et al., 2005).   
The FR region also acts as an enhancer, revealing the additional role of 
EBNA1 as a transcriptional activator.  EBNA1 can enhance transcription of both 
the Cp promoter and the LMP1 promoter from this element (Gahn & Sugden, 
1995; Sugden & Warren, 1989).  A recent study indicated that EBNA1 can 
functionally interact with the host bromodomain protein Brd4 and enhance 
transcriptional activation from the FR element (Lin et al., 2008).      
Replication of latent EBV relies heavily on cellular replication machinery 
(Norio et al., 2000).  When EBNA1 is bound to the DS element, members of the 
pre-Replicative Complex are recruited.  The origin recognition complex (ORC1-
6) and the putative replicative helicase have both been reported to associate 
with oriP.  Replication of oriP containing plasmids is dependent on the cellular 
initiation factors ORC2 and Cdt1 (Chaudhuri et al., 2001; Dhar et al., 2001).     
 
1.4  Reactivation of EBV 
 
Lytic cycle reactivation is an essential part of the EBV life cycle as the virus 
must spread to a new host in order to ensure its survival.  The latent virus 
reactivates into the lytic cycle producing infectious virus particles.  Lytic 
replication is initiated at the origin of lytic replication (oriLyt) and results in over 
100 fold replication of the viral genome (Hammerschmidt & Sugden, 1988). 
 
1.4.1  The lytic cycle  
Herpesvirus lytic replication occurs in a sequential manner and is regulated by 
three sets of genes, the immediate early genes, the early genes and the late 
genes (Clements et al., 1977; Honess & Roizman, 1974; 1975).  For the 
majority of herpesviruses lytic replication is initiated upon primary infection but 
infection with members of the gamma-herpesvirus subfamily rarely results in 
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production of infectious virus particles.  EBV establishes latency following 
infection and the lytic cycle only occurs after reactivation of the virus. 
Immediate early genes are transcribed in the absence of protein 
synthesis.  Two immediate early mRNAs were described for EBV encoding the 
BZLF1 and BRLF1 proteins (Biggin et al., 1987).  BZLF1 is the major immediate 
early gene in EBV and expression of BZLF1 alone is sufficient to trigger the 
entire lytic cascade (Countryman & Miller, 1985).  BZLF1 is a transcriptional 
activator and transactivates several early genes, cellular genes and 
autoactivates its own expression.  BRLF1 has been described as the second 
immediate early gene but evidence suggests that the BRLF1 promoter cannot 
be directly induced by BCR signalling in Akata EBV reactivation (Amon et al., 
2004).  BRLF1 is also a transactivator of cellular and viral genes.   
BZLF1 upregulates expression of BRLF1 and BRLF1 may also regulate 
BZLF1 expression though an indirect mechanism (Adamson et al., 2000; 
Sinclair et al., 1991).  Several early genes contain both BZLF1 and BRLF1 
binding sites and both BZLF1 and BRLF1 are required for induction of the entire 
lytic cascade (Feederle et al., 2000).  
The early genes are expressed after the immediate early genes but 
before the onset of DNA replication.  There are over 30 early genes that are 
expressed in the presence of inhibitors of viral DNA replication and fulfil various 
functions.  BZLF1 and BRLF1 upregulate the expression of several early genes 
including SM, which encodes an mRNA export factor (Sergeant et al., 2008), 
and BMRF1, the polymerase processivity factor (Holley-Guthrie et al., 1990; 
Kenney et al., 1989).  Many of the early genes code for proteins involved in 
replication of viral DNA and have homologues in other herpesviruses.  BALF5, 
BALF2 and BBLF4 encode the DNA polymerase, the single stranded DNA 
binding protein and the helicase, respectively, which are homologous to HSV-1 
UL30, UL29 and UL5 proteins (Challberg, 1986; Fixman et al., 1992; McGeoch 
et al., 1988).  EBV also encodes the early protein BHRF1, a homologue of the 
anti-apoptotic protein Bcl-2 (Henderson et al., 1993).  BHRF1 is important for 
lymphocyte survival, consistent with the observation that lytic gene expression 
protects from cell death and apoptosis (Inman et al., 2001).       
True late gene expression is strictly dependent on the onset or 
completion of lytic DNA replication and is sensitive to inhibitors that block lytic 
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replication such as phosponoacetic acid and acyclovir (Kieff & Rickinson, 2007). 
There are approximately thirty late EBV genes encoding proteins and 
glycoproteins of the viral envelope.  Most of the virion proteins are homologues 
of proteins found in other herpes virions (Johannsen et al., 2004).  The BLLF1 
late gene encodes the major envelope glycoprotein gp350 (Beisel et al., 1985).  
BXLF2 and BALF4 code for gH and gB respectively, which are involved in initial 
envelopment.  BPLF1, BBLF1 and BOLF1 encode tegument proteins and 
BCLF1, BDLF1 and BORF1 encode capsid proteins (Johannsen et al., 2004).  
EBV also encodes the late protein BCRF1, an IL10 homologue, which may be 
involved in reducing the natural killer and cytotoxic T cell responses (Hsu et al., 
1990).   
 
1.4.2  Reactivation in vitro and in vivo  
EBV reactivation is difficult to study in vivo due to the low frequency of infected 
memory cells.  Only 1 in 10000 to 1 in 100000 memory cells are infected with 
EBV (Laichalk et al., 2002).  It was proposed that latently infected memory B 
cells circulating in the peripheral blood periodically return to the Waldeyer’s ring, 
where a small number of memory B cells differentiate into plasma cells, 
producing virions, which are subsequently shed into the saliva (Laichalk et al., 
2002; Thorley-Lawson & Gross, 2004).  The evidence for this is that EBV is 
present in plasma cells in the tonsil and that cells expressing BZLF1 in the 
tonsils have a plasma cell phenotype.  It was also demonstrated in vitro that the 
BZLF1 promoter is activated only when memory cells are fully differentiated into 
plasma cells (Laichalk & Thorley-Lawson, 2005).  The origin of this 
differentiation signal is unknown but it is unlikely to be provided by the virus as 
no viral proteins are expressed in latently infected memory cells.         
EBV reactivation is studied in vitro using latently infected BL and LCL cell 
lines.  The lytic cycle can be reactivated using various reagents including 
transforming growth factor β (TGF-β), phorbol esters, calcium ionophores and 
antibodies directed against surface immunoglobulins (anti-Ig).  Phorbol esters, 
such as TPA, are broadly used to induce the lytic cycle and function by 
activating protein kinase C, a downstream target of BCR signalling, and the 
mitogen activated protein kinase ERK pathway (Fenton & Sinclair, 1999; 
Flemington & Speck, 1990d; zur Hausen et al., 1978).  TPA induction, however, 
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results in indirect activation of BZLF1 and asynchronous gene expression.  Anti-
Ig induction, on the other hand, is believed to be a physiologically relevant 
mechanism of induction as anti-Ig binding mimics antigen binding to the BCR 
(Shimizu & Takada, 1993; Takada, 1984).  In vivo, antigen stimulated memory 
cells differentiate towards the plasma cell stage.  Induction of the lytic cycle with 
TGF-β is also likely to represent a physiologically relevant mechanism of 
induction as BZLF1 induces expression of TGF-β, which can contribute to 
induction of the EBV lytic cycle (Cayrol & Flemington, 1995; di Renzo et al., 
1994).       
The Akata BL cell line provides a model for studying lytic cycle 
reactivation in vitro using a physiologically relevant inducer of the lytic cycle 
(Shimizu & Takada, 1993; Takada & Ono, 1989).  Akata BL cells express a 
latency I phenotype and surface IgG.  Most importantly latency I cells lack 
expression of LMP2A which interferes with signal transduction from the BCR 
(Miller et al., 1994).  The lytic cycle can therefore be induced by crosslinking the 
surface immunoglobulin with anti-IgG, resulting in rapid activation of the lytic 
cycle.  Anti-IgG crosslinking of the BCR activates a number of signal 
transduction pathways that have been implicated in activation of EBV (Bryant & 
Farrell, 2002).  The Akata system is used in this thesis to study Zp reactivation 
in response to anti-IgG.   
 
1.5  The BZLF1 protein  
 
BZLF1 is the immediate early gene in EBV and mediates the switch between 
latency and the lytic cycle.  The BZLF1 protein is approximately 38 KD in size 
and the gene comprises three exons (Biggin et al., 1987; Rooney et al., 1989).  
BZLF1 is a member of the basic region leucine zipper (bZIP) family of 
transcription factors and is related to both c-Fos and CCAAT/enhancer binding 
protein (C/EBP) (Farrell et al., 1989; Kouzarides et al., 1991).   
BZLF1 functions as a sequence specific transcription factor and 
transactivates viral genes, cellular genes and autoactivates its own expression.  
BZLF1 is also required for lytic DNA replication and contributes to lytic 
replication though a variety of mechanisms.  BZLF1 binds to the origin of lytic 
replication and initiates viral replication by the recruitment and assembly of the 
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replication complex (discussed in section 1.7.1).  BZLF1 also manipulates the 
host cell environment providing favourable conditions for viral replication and 
downregulates expression from the Cp and Wp promoters to facilitate the latent 
to lytic transition (Sinclair et al., 1992).    
 
1.5.1  bZIP transcription factors 
bZIP transcription factors bind to specific double stranded DNA sequences as 
either homodimers or heterodimers to either activate or repress gene 
transcription (Vinson et al., 2002).  In general, bZIP transcription factors contain 
a transactivation domain, a basic DNA binding domain and an α-helical coiled-
coil dimerisation domain (Landschulz et al., 1988).  The human bZIP proteins 
are divided into several subfamilies, each recognising a unique palindromic 
DNA binding motif (Vinson et al., 2002).  The canonical bZIP motif consists of a 
60 to 80 amino acid long α-helix, juxtaposed to a basic DNA binding domain 
and is required for both dimerisation and DNA binding (Vinson et al., 1989).  
The distance between the DNA binding and dimerisation domains is highly 
conserved in bZIP proteins, including BZLF1, placing the basic domain in the 
correct conformation for DNA binding to occur (Kouzarides et al., 1991).  The 
transactivation domains of bZIP proteins are typically acidic regions that form 
flexible structures, which interact with the transcriptional machinery (Ptashne & 
Gann, 1990).      
 In the bZIP DNA complex, the dimerisation domain forms an α-helical 
coiled-coil or zipper structure, generally consisting of four to five heptads, that 
lies perpendicular to the DNA.  Coiled-coil α-helices are characterised by a 
seven residue heptad repeat motif, (abcdefg)n, with hydrophobic residues at the 
a and d positions.  bZIP proteins, also known as leucine zipper proteins, 
typically contain leucine residues at all the d positions of the heptad.  There are 
3.5 residues per turn in each α-helix, so that every seventh residue occupies an 
equivalent position and the two helices dimerise to form an α-helical coiled-coil 
structure.  Interhelical contacts are mediated by the hydrophobic a and d 
residues forming the hydrophobic core, which is essential for dimer stability 
(Thompson et al., 1993).  The e and g residues, which border the hydrophobic 
core, are frequently charged residues and electrostatic interactions between 
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these residues either promote or prevent dimer formation (Figure 1.3) (Vinson 
et al., 1993).   
 
 
 
Figure 1.3.  Helical wheel representation of an α-helical coiled-coil   
The location of each heptad site is shown.  The coiled-coil is stabilised by hydrophobic 
interactions between a and d residues and electrostatic interactions between e and g residues.     
 
The basic region of bZIP proteins is approximately 30 amino acids in 
length and is required for DNA binding.  DNA binding sites are recognised 
through base specific contacts mediated by five residues in the basic motif that 
are conserved for each subfamily.  The positions of these five residues are 
highly conserved amongst the bZIP family and all contain a conserved 
asparagine and arginine residue (Ellenberger et al., 1992; Glover & Harrison, 
1995).   
 At the junction between the leucine zipper region and the DNA binding 
region the two α-helices diverge from the dimer axis, creating a fork.  This fork 
creates a smooth bend in the α-helix, displacing the dimer region away from the 
dimer interface so that each α-helix can pass through the major groove of the 
DNA, with one on each side.  Each basic region binds to one half site in the 
binding site (Vinson et al., 1989).           
The leucine zipper motif was first identified in the amino acid sequences 
of the yeast transcription factor GCN4, the mammalian transcription factor 
C/EBP and three oncogene products c-Fos, c-Jun and c-MYC, which also act 
as transcription factors (Landschulz et al., 1988).  Some leucine zipper proteins 
can form either homodimers or heterodimers in which the monomers are from 
either the same or different transcription factors respectively.  GCN4 forms 
homodimers whereas the mammalian transcription factor AP1 (activator protein 
d
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1) is a heterodimer of c-Fos and c-Jun.  The C/EBP family consists of six 
different proteins and can form both homo and heterodimers.  The ability of the 
leucine zipper proteins to form heterodimers expands their DNA binding 
specificities.  
   
1.5.2  BZLF1 structure  
The BZLF1 gene encodes a 1 kb mRNA consisting of three exons, each 
encoding a separate functional domain (Biggin et al., 1987; Farrell et al., 1989; 
Rooney et al., 1989).  Exon 1 encodes the N-terminal transactivation domain 
(Flemington et al., 1992), exon 2 encodes the basic DNA binding domain and 
exon 3 encodes the α-helical coiled-coil dimerisation domain (Flemington & 
Speck, 1990c; Kouzarides et al., 1991).  BZLF1 has sequence similarity to both 
c-Fos and C/EBP in the dimerisation and DNA binding domains (Farrell et al., 
1989; Kouzarides et al., 1991).   
 Initial studies linking BZLF1 to the bZIP family of proteins, identified a 
structure in BZLF1 homologous to the basic motif found in the DNA binding 
domains of c-Fos and c-Jun (Farrell et al., 1989).  A dimerisation domain 
adjacent to the basic motif was later confirmed and predicted to form an α-
helical coiled-coil structure (Chang et al., 1990; Flemington & Speck, 1990c; 
Kouzarides et al., 1991).  BZLF1 differs from other members of the bZIP family, 
however, as its zipper region lacks the usual heptad repeat of leucine residues, 
with other hydrophobic residues taking their place.  Domain swapping 
experiments with the known bZIP protein GCN4 showed that the dimerisation 
domain of BZLF1 homodimerises in a way that is functionally equivalent to a 
leucine zipper but BZLF1 is not able to heterodimerise with other bZIP proteins 
(Kouzarides et al., 1991).  The coiled-coil dimerisation region of BZLF1 was 
also predicted to be shorter than other bZIP proteins because of a proline 
residue at position 223, expected to interrupt the helical coiled structure (Farrell 
et al., 1989; Kouzarides et al., 1991).   
 Sequence analysis of exons 2 and 3 from natural variants of EBV 
revealed that the BZLF1 coding sequence in this region is remarkably 
conserved.  Three natural variants were identified; the B95-8 reference strain, 
the A205S variant and the A206S variant (Grunewald et al., 1998; Hicks et al., 
2001; Packham et al., 1993).  Biophysical analysis with synthetic peptides, 
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corresponding to the variants, supported the prediction that the dimerisation 
region folds through an α-helical coiled-coil structure but the thermal stability of 
these structures was lower than that of the coiled-coil domains of canonical 
members of the bZIP family (Hicks et al., 2001).  Residues C-terminal to the 
zipper region (222 to 245) were predicted to contribute to BZLF1 functions 
(Hicks et al., 2003).      
 
Figure 1.4.  Structure of BZLF1-DNA complex 
Side view of C-terminal domain of BZLF1 in complex with the ZRE from the SM promoter.  The 
four heptads of the coiled-coil are indicated (Petosa et al., 2006).   
  
 The crystal structure of the C-terminal domain of BZLF1 (residues 175-
236) in complex with the BZLF1 responsive element (ZRE) from the promoter of 
SM was subsequently solved (Figure 1.4) (Petosa et al., 2006).  The structure 
showed that the basic domain of BZLF1, like other bZIP proteins, contacts the 
major groove of the DNA via its basic residues and as predicted the 
dimerisation domain forms an α-helical coiled-coil or zipper structure that 
breaks at P223.  The structure also revealed that a hairpin turn forms from 
residues M221 to S224 and BZLF1 residues C-terminal to P223 fold back 
against the coiled-coil, forming a four helix bundle, with stabilising interactions 
between the zipper and the C-terminal tail (discussed further in chapter 4).  It 
was proposed that the C-terminal tail contributes to the stability of the BZLF1 
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coiled-coil, which lacks the characteristic leucine heptad repeat (Petosa et al., 
2006).  Chemical crosslinking in the C-terminal region, with purified fragments 
of BZLF1, and biophysical analysis of synthetic peptides were consistent with 
the crystal structure and these results are discussed further in chapter 4 
(Schelcher et al., 2007). 
 
1.5.3  DNA binding specificity  
BZLF1 is a sequence specific transcriptional activator.  Upon lytic cycle 
reactivation BZLF1 expression is induced.  BZLF1 then transactivates BRLF1 
and both of these transcription factors act in concert to induce the entire lytic 
cascade (Feederle et al., 2000).  Several early gene promoters contain binding 
sites for BZLF1 and BRFL1, including the BMRF1 and BHLF1 promoter sites. 
BZLF1 has broader binding specificity than most bZIP proteins and binds 
more tightly to the phosphate backbone compared to c-Fos and c-Jun (Petosa 
et al., 2006).  BZLF1 can bind to both consensus AP1 (TGAGTCA) (Farrell et 
al., 1989; Packham et al., 1993) and C/EBP sites (TTNNGCAAT) (Kouzarides 
et al., 1991), and also binds a set of ZREs with a less specific DNA binding 
sequence (TG/TT/AGT/CC/AA) (Lieberman & Berk, 1990; Lieberman et al., 1990; 
Packham et al., 1990).  This accounts for the ability of BZLF1 to transactivate a 
wide range of viral and cellular genes.   
A unique feature of BZLF1 is its ability to transactivate methylated 
promoters and evidence suggests that it preferentially binds and transactivates 
certain EBV promoters in their methylated state (Bhende et al., 2004; Karlsson 
et al., 2008b).  DNA methylation is associated with inhibition of gene expression 
and promotes gene silencing.  Cytosine methylation occurs at CpG 
dinucleotides and is mediated by cellular methyltransferases, leading to 
epigenetic silencing of genomes (Bestor, 2000).  The EBV genome is heavily 
methylated in several latently infected cell lines (Ernberg et al., 1989; Minarovits 
et al., 1991; Robertson & Ambinder, 1997) and methylation may be involved in 
inhibiting lytic cycle gene expression and maintenance of latency.  The fact that 
BZLF1 can specifically activate some methylated promoters, including Rp, 
provides a means of overcoming epigenetic silencing, if these promoter 
elements are protected from reactivation by DNA methylation.  Activation of the 
BRLF1 promoter, Rp, by BZLF1 is a key event in lytic cycle reactivation.  
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Evidence suggests that Rp is highly methylated in latently infected cells and 
methylation of Rp enhances activation by BZLF1 (Bhende et al., 2004).  
Methylation of the Rp promoter may provide a means of protecting the virus 
from reactivation, in the absence of BZLF1. 
The Rp promoter contains three ZRE sites and two of these sites contain 
CpG motifs (Figure 1.5).  Rp ZRE2 contains one CpG motif in its left half site 
and ZRE3 contains two CpG motifs, one in each half site.  The left half sites of 
ZRE2 and ZRE3 are identical.  BZLF1 only binds to the methylated form of Rp 
ZRE3 and binding to Rp ZRE2 is enhanced by methylation (Bhende et al., 
2004; Karlsson et al., 2008a).  Rp ZRE1 does not contain any CpG motifs and 
hence cannot be methylated.  
A recent study identified two CpG containing ZRE sites, with CpG motifs 
in both half sites, in the BRRF1 early gene promoter Nap (Dickerson et al., 
2009).  The Nap ZRE sites only bound BZLF1 in their methylated state and 
methylation of Nap was required for efficient activation of Nap reporter 
plasmids.  In addition, it was demonstrated in vitro that binding of BZLF1 to the 
promoter of the host target gene egr1 is enhanced by methylation (Heather et 
al., 2009).  egr1 encodes a transcription factor that is induced by BZLF1 during 
lytic cycle activation (Chang et al., 2006).  The egr1 promoter contains a 
tandem pair of ZREs with a CpG motif in the distal site.  The ability of BZLF1 to 
transactivate an egr1 promoter reporter plasmid was enhanced by methylation, 
suggesting that BZLF1 can overcome epigenetic silencing of both viral and host 
promoters (Heather et al., 2009).             
Two residues in the DNA binding domain of BZLF1 were implicated in 
binding to methylated ZRE sites, S186 and C189 (Bhende et al., 2005; 
Dickerson et al., 2009; Karlsson et al., 2008a).  C189 is conserved amongst the 
bZIP transcription factors and is required for reactivation of EBV from latency in 
293-ZKO cells (Schelcher et al., 2005).   On the other hand, no other bZIP 
proteins contain a serine residue equivalent to S186.  In fact, the residues that 
bind to DNA in both BZLF1 and the c-Fos/c-Jun dimer are identical with the 
exception of residue S186 in BZLF1 (Bhende et al., 2004; Glover & Harrison, 
1995).  Mutation of S186 affected binding to both methylated and unmethylated 
Rp ZRE sites and methylated Nap ZRE sites.  Mutation of S186 also affected 
the ability of BZLF1 to transactivate Rp and Nap in 293-ZKO cells (Bhende et 
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al., 2005; Dickerson et al., 2009).  Mutation of C189 significantly reduced 
binding to methylated Rp ZRE3, caused a slight reduction in binding to 
methylated Rp ZRE2 but did not affect binding to the Nap ZREs.  Mutation of 
C189 to serine severely impaired endogenous Rp transactivation in Raji cell 
(Karlsson et al., 2008a) but had little effect in 293-ZKO cells (Wang et al., 
2005).  Interestingly, Rp ZRE2 and the distal egr ZRE have strong similarity; six 
of the seven core residues are conserved and mutation of either S186 or C189 
also affected the ability of BZLF1 to bind to the methylated egr1 ZRE (Heather 
et al., 2009).    
 
Figure 1.5.  Rp promoter ZRE binding sites and CpG motifs 
BZLF1 binds to ZRE1 and ZRE2 in their unmethylated state.  Binding to ZRE2 is enhanced by 
methylation.  BZLF1 only binds to ZRE3 in its methylated state.    
 
Structural modelling predicted that C189 contacts both methyl groups in 
the left half site of Rp ZRE3 (and hence the corresponding site in Rp ZRE2) and 
one methyl group in the right half site, unique to Rp ZRE3.  Therefore mutation 
of C189 was predicted to destabilise contacts in both half site of ZRE3 and in 
one half site in ZRE2 (Karlsson et al., 2008a).  S186 was predicted to contact 
both methyl groups in the left half site of Rp ZRE3 and a similar interaction was 
predicted for binding to the left half sites of the Nap ZREs (Dickerson et al., 
2009).  Methyl cytosines were also predicted to interact with R190 (Karlsson et 
al., 2008a).    
 
 
 
TGGCTCA
ACCGAGT
TCGCTCA
AGCGAGT
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1.5.4  Transactivation function  
The transactivation domains of activator proteins are flexible structures 
accommodating multiple interactions with distinct targets (Ptashne & Gann, 
1990).  The N-terminal transactivation domain of BZLF1 contains several 
hydrophobic aromatic clusters and acidic stretches, next to glutamine and 
proline regions, typical of flexible transcriptional activation domains (Deng et al., 
2001; Ptashne & Gann, 1990).   
Eukaryotic transcription initiation requires the formation of an active 
preinitiation complex.  The preinitiation complex consists of a set of general 
transcription factors, RNA polymerase II and coactivator proteins.  The general 
transcription factor TFIID interacts with the TATA box (Colgan & Manley, 1992).  
This is followed by binding of TFIIB, a complex of TFIIF and RNA polymerase, 
TFIIE, TFIIH and TFIIJ.  TFIIA can bind to the complex at any time following 
binding of the TATA box-binding protein (TBP) (Orphanides et al., 1996).  
Binding of activator proteins, such as BZLF1, to TFIID is believed to stimulate 
transcription by stabilising preinitiation complex formation.    
TFIID is a multiprotein complex consisting of TBP and at least eight TBP-
associated factors (TAFs) (Burley & Roeder, 1996; Goodrich & Tjian, 1994).  
TFIIA binds directly to TBP and stabilises TBP binding to the TATA box.  
Formation of the TFIIA-TFIID complex (D-A complex) is the rate limiting step in 
transcription initiation.  BZLF1 binds directly to the TBP subunit through the 
transactivation domain and stabilises the D-A complex (Lieberman & Berk, 
1991; 1994).  
Many of the EBV lytic promoters contain non-canonical TATA elements 
that have reduced affinity for TFIID.  BZLF1 has evolved to stimulate 
preinitiation complex formation, suggesting that these weak TATA elements 
serve as a mechanism to maintain latency by ensuring that lytic cycle promoters 
are not activated in the absence of BZLF1 (Lieberman et al., 1997).  BZLF1 can 
stabilise the interaction of TFIID with the weak TATA element (GATAA) in the 
BHLF1 promoter.  TFIID binding requires residues 25 to 85 in the 
transactivation domain of BZLF1, which are critical for BZLF1 transcription 
activation function (Flemington et al., 1992; Lieberman & Berk, 1991). 
Formation of the preinitiation complex was examined in EMSAs and 
DNaseI footprinting assays (Lieberman & Berk, 1994).  BZLF1 stimulated D-A 
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complex formation at a very early step in the assembly pathway, forming a 
BZLF1-TFIIA-TFIID (Z-D-A) complex.  Z-D-A complex formation occurred 
rapidly in comparison to D-A complex formation in the absence of BZLF1 and 
was dependent on both TAFs and the BZLF1 transactivation domain.  BZLF1 
decreased the dissociation rate of TFIID from TATA elements, indicating that it 
stabilises complex formation.  Moreover, conditions that limited TBP-DNA 
binding increased dependence on BZLF1 to stimulate D-A complex formation 
(Lieberman et al., 1997). 
BZLF1 also interacts with other cellular transcription factors and 
coactivator proteins to enhance its transcription activation function.  BZLF1 
interacts with CREB binding protein (CBP) and p300.  These coactivator 
proteins function as histone acetyl transferase (HAT) proteins and CBP also 
stabilises the preinitiation complex, acting as a bridging factor between 
transcription factors and RNA polymerase II (Nakajima et al., 1997; Ogryzko et 
al., 1996).  CBP and p300 enhance BZLF1 induced activation of the BMRF1 
and BHLF1 early gene promoters and reactivation in latently infected cells 
(Adamson & Kenney, 1999; Zerby et al., 1999).  BZLF1 also interacts with 
TORC2, enhancing activation of the Zp promoter (Murata et al., 2009).   
Mutation of combinations of hydrophobic aromatic residues, between 
residues 25 to 85, severely impaired the transactivation function of BZLF1.  
These mutations affected Z-D-A complex formation and binding of CBP to 
BZLF1 (Deng et al., 2001).  Mutational analysis also revealed a set of acidic 
residues required for the transcription activation function of BZLF1, independent 
of Z-D-A complex formation (Deng et al., 2001; Lieberman et al., 1997).  These 
acidic residues may be involved in binding to other components of the 
transcription machinery. 
 
1.5.5  BZLF1 and host cell environment  
BZLF1 manipulates the host cell environment, providing favourable conditions 
for viral replication.  Lytic replication of herpesviruses, including EBV, CMV, 
HSV and KSHV, occurs preferentially in cells arrested in G1 (Flemington, 2001).  
These viruses encode many of the proteins required for DNA replication and 
therefore do not depend on the host cell machinery.  Cell cycle arrest may be 
 46 
advantageous to the virus, allowing viral replication while the host cell resources 
are not mediating cellular DNA replication. 
BZLF1 interacts at multiple distinct points with components of the cell 
cycle machinery, resulting in G0/G1 cell cycle arrest.  BZLF1 upregulates 
expression of the cell cycle kinase inhibitors p21 and p27 and down regulates 
expression of c-MYC, which is involved in EBV latency and oncogenesis 
(Cayrol & Flemington, 1996a; Cayrol & Flemington, 1996b; Rodriguez et al., 
2001).  BZLF1 interacts with p53 and inhibits its transcriptional function, 
preventing p53 induced apoptosis in response to lytic infection (Zhang et al., 
1994).  BZLF1 also interacts directly with the cellular transcription factor 
C/EBPα.  This interaction enhances C/EBPα mediated upregulation of C/EBPα 
and p21, linking C/EBPα to BZLF1 induced cell cycle arrest (Wu et al., 2003).  
BZLF1 induced cell cycle arrest involves the basic DNA binding domain but is 
independent of its DNA binding function (Rodriguez et al., 1999; Wu et al., 
2003; Wu et al., 2004).  Mutation of C189 to serine, in the DNA binding domain, 
affected the ability of BZLF1 to induce G0/G1 cell cycle arrest in HeLa cells and 
was also independent of its ability of bind C/EBPα (Schelcher et al., 2005).       
BZLF1 induces dispersion of PML nuclear bodies and this is linked to 
lytic DNA replication.  PML nuclear bodies are believed to function in the anti-
viral response (discussed in section 1.7.2) (Adamson & Kenney, 2001; Bell et 
al., 2000).          
Interaction of BZLF1 with immune modulators contributes to evasion of 
the host immune responses.  BZLF1 inhibits the interferon (IFN)-γ signalling 
pathway, decreasing the ability of IFN-γ to activate expression of its 
downstream targets genes IRF-1, p48 and CIITA.  BZLF1 also prevents IFN-γ 
induced class II MHC surface expression and decreases the expression of the 
IFN-γ receptor (Morrison et al., 2001).  BZLF1 negatively regulates IFN 
regulatory factor 7, which is essential for the production of α and β IFNs (Hahn 
et al., 2005).   
BZLF1 modulates the host cell environment by transactivating cellular 
target genes but few putative host cellular targets are known.  BZLF1 induces 
expression of TGF-β, TGF-βigh3 and c-Fos (Cayrol & Flemington, 1995; 
Flemington & Speck, 1990b).  BZLF1 also activates the p38 kinase and c-Jun 
N-terminal signalling cascades (Adamson et al., 2000).   
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Interaction of BZLF1 with the host cell environment results in post-
translational modification of BZLF1 by host cell factors.  BZLF1 becomes 
SUMO-1 (small ubiquitin-related modifier 1) modified at lysine 12 in response to 
lytic cycle reactivation (Adamson & Kenney, 2001).   SUMO-1 is structurally 
homologous to ubiquitin but instead of targeting proteins for degradation, it is 
involved in protein stabilisation and localisation.  In addition, BZLF1 is 
constitutively phosphorylated in vivo at serine and threonine residues clustered 
in the transactivation and DNA binding domains (Daibata et al., 1992; El-Guindy 
et al., 2006).  BZLF1 is phosphorylated at S167 and S173 by casein kinase II 
and at T159 and S186 by protein kinase C (Baumann et al., 1998; El-Guindy et 
al., 2002; Kolman et al., 1993). The physiological consequences of 
phosphorylation at these sites remain unclear.  Phosphorylation at S167 and 
S173 is essential for the ability of BZLF1 to repress activation of the late lytic 
gene BLRF2 by BRLF1, suggesting that phosphorylation can modulate the 
ability of BZLF1 to act as an activator or a repressor of gene expression (El-
Guindy & Miller, 2004).  Results also indicate that phosphorylation at S173 
alters the DNA binding activity of BZLF1, where phosphorylation is required for 
BZLF1 to function as an origin binding protein but is not required for BZLF1 
mediated transcriptional activation (El-Guindy et al., 2007).       
 
1.5.6  BZLF1 and K-bZIP 
KSHV encodes a protein related to the bZIP family of transcription factors, 
referred to as K-bZIP.  It remains a matter of debate, however, as to whether K-
bZIP conforms to the bZIP model.  K-bZIP is encoded from the KSHV K8 gene 
and was initially identified as a potential homologue of BZLF1 due to its position 
in the genome (Lin et al., 1999).  K-bZIP does not have much overall sequence 
homology with BZLF1 but they do share some predicted structural similarity in 
the dimerisation region, which was also predicted to form a coiled-coil in K-bZIP 
and mediates homodimerisation (Lin et al., 1999).  One of the most significant 
differences in overall structure is that K-bZIP lacks the characteristic basic DNA 
binding domain associated with bZIP family members and there is no evidence 
that it actually binds directly to DNA (Al Mehairi et al., 2005; Sinclair, 2003).  
Also, biophysical analysis with synthetic peptides of K-bZIP indicated that the 
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proposed leucine zipper motif is required for dimer formation but does not fold in 
an α-helical conformation (Al Mehairi et al., 2005).   
Despite the homologous locations of BZLF1 and k-bZIP on their 
respective genomes, k-bZIP does not induce lytic KSHV reactivation.  ORF50 
was identified as the lytic switch gene in KSHV and encodes the RTA protein, a 
functional homologue of the EBV BRLF1 transcriptional activator (Lukac et al., 
1998).  Unlike BZLF1, K-bZIP is unable to enhance RTA mediated reactivation 
(Polson et al., 2001).  
These results indicate that these proteins are not direct homologues but 
BZLF1 and K-bZIP share some conserved functions.  Like BZLF1, K-bZIP 
interacts with the host cell environment providing favourable conditions for lytic 
replication.  Lytic replication of KSHV also occurs preferentially in cells arrested 
in G1 and K-bZIP interacts with several components of the cell cycle machinery 
to induce cell cycle arrest.  K-bZIP interacts directly with C/EBPα, enhancing 
expression of both C/EBPα and its downstream target p21 (Wu et al., 2002), 
and with cyclin-CDK2, downregulating its kinase activity (Izumiya et al., 2003).  
K-bZIP also interacts with p53 and downregulates p53 mediated transcription 
(Park et al., 2000).   
Like BZLF1, K-bZIP interacts with CBP but K-bZIP represses CBP 
mediated transcription (Hwang et al., 2001).    K-bZIP is also SUMO-1 modified, 
which is important for its transcriptional repressive activity (Izumiya et al., 2005).    
With respect to an origin binding function, K-bZIP interacts with the 
KSHV oriLyt but this interaction appears to be indirect.  It is attributed to clusters 
of C/EBP binding sites in oriLyt, indicating that K-bZIP is associated with oriLyt 
though interaction with C/EBPα (Ganem, 2007; Lin et al., 2003).  Like BZLF1, 
K-bZIP is essential for lytic DNA replication but the exact role of K-bZIP in lytic 
DNA replication remains unclear (AuCoin et al., 2004).            
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1.6  The Zp promoter 
 
The BZLF1 gene is under the control of the Zp promoter.  Regulation of the Zp 
promoter has been studied extensively and several binding sites for both 
cellular and viral transcription factors have been identified (Figure 1.6).  The Zp 
promoter is also regulated by a repressive chromatin structure (Binne et al., 
2002).  Transcription factors bound to Zp undergo post translational 
modifications during reactivation, allowing transcription of BZLF1 (Binne et al., 
2002; Bryant & Farrell, 2002; Jenkins et al., 2000).   
   
 
Figure 1.6.  Schematic diagram of the Zp promoter 
Relative positions of important regulatory elements in the -221 region of the promoter.  
Transcription factors that bind to these sites are indicated above them.    
 
1.6.1  Zp promoter elements 
Initial studies on Zp regulation were based on regions of the promoter protected 
from DNaseI activity in footprinting studies, followed by mutagenesis of 
promoter elements in transient transfection assays (Flemington & Speck, 
1990a; d).  This led to the identification of the ZI, ZII, ZIIIA and ZIIIB promoter 
elements (Figure 1.6).  The footprinting profile of the Zp promoter did not 
change with viral reactivation by TPA, indicating that the transcription factors 
may be bound to Zp during latency.     
Four AT-rich elements with significant homology were identified in the Zp 
promoter and named the ZI elements (ZIA, ZIB, ZIC and ZID) (Flemington & 
Speck, 1990d).  Mutagenesis of the ZIA/B (MIA/B) and ZIC (MIC) elements in 
CAT reporter assays was marked by a decrease in Zp promoter activity in 
response to TPA.  When these regions were cloned upstream of homologous 
promoters they functioned as silencers (Flemington & Speck, 1990d) and ZIA, 
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ZIC and ZID exhibited strong TPA inducibility (Borras et al., 1996).  ZIA, ZIC 
and ZID were shown to bind the ubiquitous cellular transcription factors Sp1 and 
Sp3 in EMSAs with DG75 nuclear extracts and binding of these factors was 
related to TPA inducibility (Liu et al., 1997a; Liu et al., 1997b).  The MIA/B and 
MIC mutations, and truncation of these sites, also affected anti-IgG inducibility 
(Daibata et al., 1994; Shimizu & Takada, 1993).  Anti-IgG inducibility was 
related to binding of the cellular transcription factor myocyte enhancer factor 2D 
(MEF2D) to the ZIA, ZIB and ZID promoter elements and calcium mediated 
signalling from the BCR (Liu et al., 1997b).  However, deletion analysis 
indicated that ZID does not contribute significantly to Zp promoter regulation in 
response anti-IgG (Daibata et al., 1994; Flemington & Speck, 1990d). 
Footprinting analysis identified the TPA responsive element ZII, located 
upstream of the TATA box (Figure 1.6) (Flemington & Speck, 1990d).  Mutation 
of ZII also affected anti-IgG inducibility in EBV positive and negative BL cells but 
activity was greater in EBV infected cell lines, indicating that ZII is not essential 
for anti-IgG mediated Zp activation in the presence of BZLF1 (Daibata et al., 
1994).  The ZII promoter element has homology with the consensus AP1 and 
CRE binding sites and binds the transcription factors ATF1, ATF2 and CREB 
(Liu et al., 1998; Ruf & Rawlins, 1995; Wang et al., 1997).  Recent studies 
indicated that the ZII site can also bind the plasma cell transcription factor XBP-
1s (Sun & Thorley-Lawson, 2007).   
The adjacent elements ZIIIA and ZIIIB both bind BZLF1 (Figure 1.6) but 
ZIIIB was identified as the higher affinity site and functions in autoactivation of 
the promoter (Flemington & Speck, 1990a).  The ZIIIA site shares homology 
with the AP1 consensus sequence whereas the ZIIIB site contains a unique 
BZLF1 binding site.  The ZIIIA element is responsive to both TPA and anti-IgG, 
and mutagenesis of ZIIIA in CAT reporter assays resulted in a decrease in Zp 
promoter activity in response to both inducers (Flemington & Speck, 1990d).  
The factor involved in this response is unknown.  The ZIIIB site is not 
responsive to TPA and mutagenesis of this site only caused a partial reduction 
in anti-IgG responsiveness in EBV positive Akata cells, indicating its role in 
autoactivation of the promoter (Daibata et al., 1994). 
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1.6.2  Repressive chromatin structure at Zp 
Initial studies on Zp promoter regulation involved transient transfection assays 
with the Zp promoter linked to reporter genes.  However, a number of studies 
indicated that the Zp promoter is protected from reactivation during latency and 
that this regulation is not reconstituted on transiently transfected plasmids.  
Transfection of BZLF1 into EBV infected cells resulted in expression of the early 
genes BRLF1 and BMRF1 and activation of the EBV lytic cycle but not in 
activation of the endogenous Zp promoter (Kolman et al., 1996; Le Roux et al., 
1996).  In contrast, it is well established that BZLF1 can activate transiently 
transfected Zp promoters (Flemington & Speck, 1990a; Kolman et al., 1996).  
Evidence of nucleosome associated chromatin structures on Zp suggested that 
the promoter may be regulated by a repressive chromatin structure (Jenkins et 
al., 2000).     
This observation led to the development of an alternative system to study 
Zp regulation, based on stably transfected episomes expressing BZLF1 and its 
promoter (Jenkins et al., 2000).  The plasmids contained an oriP sequence and 
the EBNA1 gene allowing maintenance of the plasmid in the absence of the 
EBV genome.  In this system, BZLF1 expression was used as a readout for Zp 
activity in response to anti-IgG induction.  Anti-IgG crosslinks the BCR, which 
mimics antigen binding and is believed to be a physiologically relevant 
mechanism of induction.  Mutagenesis of the Zp promoter was performed in this 
system to identify sequences that mediate induction of Zp in response to signal 
transduction from the BCR.  The importance of the ZIA/B, ZIC and ZIIIA 
elements in Zp activation was confirmed as mutagenesis of these elements 
resulted in a substantial reduction in Zp activity.  Mutation of ZID also caused a 
significant reduction in anti-IgG responsiveness, suggesting that this site is 
important in Zp reactivation (Jenkins et al., 2000).   
The importance of histone acetylation at the Zp promoter was 
demonstrated in this system.  Chromatin immunoprecipitation (ChIP) analysis at 
the Zp promoter correlated an increase in histone acetylation with lytic cycle 
reactivation.  In addition, the HDAC inhibitor trichostatin A rescued the anti-IgG 
inducibility of the MIA/B and MIC Zp promoter mutations, indicating that these 
promoter elements are involved in recruiting histone acetylase activity to the 
promoter (Jenkins et al., 2000).   
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1.6.3  Quantitative Zp reporter assay 
Zp studies were further developed with a quantitative reporter assay to study 
the kinetics of promoter activity in EBV positive cells.  This assay was based on 
the pHEBo:Zp-luc reporter plasmid which was stably transfected into Akata BL 
cells, using luciferase as a readout for Zp activity (Binne et al., 2002).  This 
system uses anti-IgG to induce the lytic cycle.  The main advantage of this 
system is that it allows kinetic analysis of Zp regulation in a system where all 
the trans-acting viral factors are provided from the endogenous EBV genome, 
with the correct timing and at physiologically normal concentrations.     
This approach was used to study the kinetics of Zp regulation and test 
the significance of promoter elements in a more quantitative manner.  
pHEBo:Zp-luc constructs carrying mutations in the known promoter elements 
were tested for their impact on anti-IgG responsiveness in Akata BL cell lines 
(Binne et al., 2002).  The importance of the ZIA/B, ZIC and ZIIIA sites in Zp 
regulation was highlighted as mutation of these elements rendered the Zp 
promoter unresponsive to anti-IgG induction at the early time points and activity 
only increased minimally after 8 hours.  Mutation of ZIIIB, which binds BZLF1, 
only affected promoter activity after 3 hours, confirming its role in autoactivation 
of the promoter.  The ZII element was important for the rapid early activation of 
the promoter but was dispensable once autoactivation of the promoter occurred, 
supporting the earlier conclusion that this site is not required in the presence of 
BZLF1 (Flemington & Speck, 1990d).  The ZID site was not studied in this 
system.    
 
1.6.4  Negative regulation of the Zp promoter 
A number of negative regulatory elements were also identified within the Zp 
promoter.  The distal region of the promoter, from -552 to -221 relative to the 
transcription start site, contains several weak negative regulatory elements.  
Three negative cis-regulatory elements, termed the ZIV elements (ZIVA, ZIVB 
and ZIVD), were identified in this region and were shown to bind the cellular 
transcription factor Yin Yang 1 (YY1) (Montalvo et al., 1995; Montalvo et al., 
1991).  Deletion of ZIVA and ZIVB in CAT reporter constructs resulted in 8 fold 
upregulation of Zp promoter activity, while overexpression of YY1 was shown to 
downregulate Zp activity (Montalvo et al., 1995).  Five HI motifs were also 
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identified in the Zp promoter (Schwarzmann et al., 1994).  Four were mapped to 
the distal region of the promoter and the fifth close to the ZII site.  Mutagenesis 
of these sites in CAT reporter constructs caused an increase in Zp activity.  The 
transcription factors bound to these sites are unknown but binding was 
abrogated upon induction of the lytic cycle, suggesting that these sites function 
in downregulating Zp activity during latency (Schwarzmann et al., 1994).   
Deletion of the distal region of the Zp promoter (-552 to -221) in stably 
transfected episomes expressing BZLF1 caused a moderate increase in BZLF1 
expression in response to anti-IgG (Jenkins et al., 2000) and in promoter activity 
in quantitative Zp reporter assays (Binne et al., 2002).  This supported a role for 
some weak negative regulatory elements in the distal region of the promoter but 
it was concluded that they do not account for the repressed state at Zp in 
latency.  
A negative regulatory element ZIIR was identified immediately upstream 
of the ZII CRE binding site and mutagenesis of this site in transient transfection 
assays caused a 5 to 10 fold increase in Zp promoter activity in response to 
TPA (Liu et al., 1998).  Specific protein complexes binding to this domain were 
not identified and mutation of this site in luciferase reporter assays showed no 
effect on anti-IgG responsiveness in Akata BL cell lines (Binne et al., 2002).  
Another negative regulatory element, ZV, was identified at -17 to -12 
relative to the transcription start site (Figure 1.6).  To date, the ZV site has the 
most potential as a true negative regulatory element involved in repression of 
the Zp promoter during latency.  Mutation of ZV in transient transfection assays 
caused a 2 to 4 fold increase in basal transcription and superactivation of the 
promoter in response to TPA treatment (Kraus et al., 2001).  Mutation of ZV in 
stably transfected episomes caused a 5 fold increase in basal transcription and 
rapid activation of the Zp promoter in response to anti-IgG induction.  Levels of 
promoter activity were 8 fold higher than the wild type in response to anti-IgG 
(Binne et al., 2002).  ZV binds the zinc finger E-box binding factor ZEB1 (Kraus 
et al., 2003).  An additional ZEB1 binding site, ZV’, was identified in Zp at +5 to 
+12 relative to the transcription start site (Yu et al., 2007).  ZEB1 does not 
dissociate from Zp in response to TPA induction, suggesting that it may limit 
activation of the promoter during the lytic cycle (Kraus et al., 2001).   
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Mutation of ZV in the context of the entire EBV genome caused 
derepression of the Zp promoter in 293 cells and spontaneous production of 
infectious virus in a subset of cells, indicating that ZEB1 binding to ZV 
contributes to repression at Zp (Yu et al., 2007).  Overexpression of ZEB1 in 
gastric carcinoma AGS cells, which express high levels of lytic viral proteins, 
reduced Zp activity from both a Zp reporter plasmid and the EBV genome (Feng 
et al., 2007).  These results suggest that ZEB1 plays a significant role in 
regulating the switch between latency and lytic cycle replication in EBV, in 
combination with other factors bound to the Zp promoter, such as MEF2D.   
 
1.6.5  Transcription factor modifications and reactivation 
A two step model for reactivation has been proposed in which the Zp promoter 
is kept inactive by a repressive chromatin structure during latency and in 
response to signalling, promoter elements at Zp recruit histone remodelling 
factors, such as HATs, to facilitate the switch from latency to the lytic cycle.  It is 
only possible after these initial signalling events for BZLF1 to autoactivate the 
promoter and lead to the high level expression of BZLF1 (Binne et al., 2002; 
Bryant & Farrell, 2002; Jenkins et al., 2000).       
Several transcription factors that bind to the Zp promoter elements have 
been identified (Figure 1.6) and modifications in response to signal transduction 
have been linked to Zp reactivation.  Transcription factors bound to Zp become 
rapidly modified in response to BCR crosslinking by anti-IgG (Bryant & Farrell, 
2002).  One of the major events linked to reactivation is dephosphorylation of 
MEF2D, which binds to the ZI promoter elements.  MEF2D is dephosphorylated 
within just 10 minutes of anti-IgG treatment in Akata BL cells and remains 
dephosphorylated for several hours (Bryant & Farrell, 2002).  This modification 
was mapped to the phospholipase C γ pathway and is blocked by cyclosporin A.   
MEF2 proteins are known to associate with class II HDACs, resulting in 
repression of transcription (Lu et al., 2000; Miska et al., 1999).  HDAC7 was 
identified in both Akata and Raji BL cells suggesting that it might be involved in 
repression at Zp (Bryant & Farrell, 2002).  The dephosphorylated form of 
MEF2D, on the other hand, is involved in HAT recruitment and is the 
transcriptionally active form of the protein (Corcoran & Means, 2001).  It is 
proposed that MEF2D plays a central role in mediating latency and lytic cycle 
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reactivation in EBV, where during latency the phosphorylated form of MEF2D 
binds to the ZI elements and recruits class II HDACs, contributing to the 
repressive chromatin structure at Zp.  In response to signal transduction from 
the BCR, MEF2D is dephosphorylated, resulting in the recruitment of histone 
acetylase activity to the promoter, relieving the repressive chromatin structure 
and allowing transcription of the BZLF1 gene (Bryant & Farrell, 2002).  The 
dephosphorylated form of MEF2D is known to associate with the HAT proteins 
such as p300 and CBP (Corcoran & Means, 2001).  
ATF1 and CREB, which bind to the ZII promoter element, are 
phosphorylated within 10 minutes of anti-IgG treatment in Akata BL cells but 
this modification is rapidly reversed (Bryant & Farrell, 2002).  This modification 
was mapped to the Ras/ERK pathway.  The physiological relevance of these 
factors binding to ZII is unclear.   
Transcription factors bound to Zp also interact with coactivator proteins 
to enhance Zp activity.  A recent study demonstrated that CREB recruits 
Transducer of Regulated CREB 2 (TORC2), a CREB coactivator protein, to the 
Zp promoter (Murata et al., 2009).  This is independent of CREB 
phosphorylation which is usually required for its activation.  TORC2 can also 
interact with BZLF1 and enhance transcription of BZLF1 through both the ZII 
and ZIII elements (Murata et al., 2009).  TORC2 is activated by calcium 
mediated signalling via calcineurin, which is also required for dephosphorylation 
of MEF2D.     
 
1.6.6  Role of XBP-1s in lytic cycle reactivation  
It is still unclear how reactivation of Zp is regulated in vivo but evidence 
suggests that lytic cycle reactivation occurs in the tonsils after terminal 
differentiation of memory B cells into antibody secreting plasma cells (Laichalk 
& Thorley-Lawson, 2005; Thorley-Lawson & Gross, 2004).  It was therefore 
hypothesised that X-box-binding protein 1 (XBP-1), which is essential for 
terminal differentiation, may be involved in lytic cycle reactivation.  Recent 
studies showed that the ZII promoter element can bind this plasma cell specific 
transcription factor, suggesting that it may be involved in lytic cycle reactivation 
(Sun & Thorley-Lawson, 2007).  
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XBP-1 is a member of the CREB/ATF family of transcription factors and 
is essential for plasma cell differentiation (Liou et al., 1990); (Reimold et al., 
2001).  It is also involved in the unfolded protein response (UPR) and links the 
UPR and terminal differentiation (Figure 1.7) (Iwakoshi et al., 2003).  A model 
has been proposed where the UPR is activated in two phases.  The initial 
phase, involved in plasma cell differentiation, is protein load independent and 
preparative, whereas the second phase is driven by the classical mechanism of 
protein accumulation in the endoplasmic reticulum (ER) (Skalet et al., 2005).    
In the classical UPR, in the absence of ER stress, XBP-1 mRNA is not 
cleaved and encodes a transcriptionally inactive form of the protein, XBP-1u.  In 
response to ER stress, BiP, an ER chaperone protein, binds to misfolded 
proteins in the ER and is removed from its binding partner inositol-requiring 
enzyme 1 (IRE1) (Bertolotti et al., 2000).  IRE1 homodimerises and 
subsequently auto-phosphorylates.  This causes precise endonucleolytic 
cleavage of its substrate XBP-1 mRNA, removing a 26 nucleotide intron.  This 
results in a frameshift, fusing two open reading frames to yield a larger product, 
and translation of the more stable and transcriptionally active XBP-1s protein 
(Calfon et al., 2002; Ron & Walter, 2007).  XBP-1s is an activator of UPR 
genes.  It functions by increasing the capacity of the secretory apparatus and 
relieving stress due to the high level immunoglobulin production in the ER 
(Shaffer et al., 2004). 
The UPR also takes place in normal cellular development processes 
such as differentiation of B lymphocytes into plasma cells and XBP-1s is 
essential for this process (Reimold et al., 2001).  XBP-1 splicing was 
demonstrated prior to significant immunoglobulin production in murine B cell 
lymphoma cell lines, in response to differentiation signal such as LPS and IL4 
(Gass et al., 2002).  This was accompanied by upregulation of UPR targets 
including the ER chaperones BiP and GRP94 but did not result in increased 
expression of UPR gene CHOP, indicating that this initial activation of the UPR 
differs from regulation in response to misfolded proteins.  In splenic B cells 
XBP-1s induced expression of IL6.  IL6 can drive plasma cell differentiation and 
is an important growth factor for malignant plasma cells (Iwakoshi et al., 2003).  
This initial UPR results in plasma cell differentiation, followed by 
immunoglobulin production and upregulation of the UPR (Figure 1.7).
 57 
 
 
 
 
 
 
Figure 1.7.  XBP-1 links terminal differentiation and the UPR 
IRE1 oligomerises in the ER membrane in response to differentiation signals or ER stress and 
subsequently autophosphorylates.  IRE1 mediates sequence specific cleavage of its substrate 
mRNA, XBP-1, and excises a small RNA fragment (intron).  The two ends of the mRNA are 
ligated which leads to a frameshift in the coding sequence and translation of XBP-1s, the 
transcriptionally active form of the protein.  XBP-1s upregulates a subset of UPR genes that 
promote ER associated degradation (ERAD) of misfolded proteins and chaperone proteins that 
aid protein folding.  In the absence of ER stress the precursor mRNA encodes XBP-1u, the 
transcriptionally inactive form of the protein.  During differentiation XBP-1s additionally induces 
IL6 expression, which drives plasma cell differentiation, upregulating Ig production and the UPR 
(Ron & Walter, 2007).     
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The role of the XBP-1s in lytic cycle reactivation was examined in two 
systems, using either multiple myeloma cell lines (Sun & Thorley-Lawson, 2007) 
or early passage LCLs and NPC cell lines (Bhende et al., 2007).  Results 
indicated that XBP-1s contributes to lytic cycle reactivation but it is not clear if 
XBP-1s is sufficient to induce the lytic cycle.  Overexpression of XBP-1s in 
multiple myeloma cells upregulated endogenous BZLF1 transcripts (Sun & 
Thorley-Lawson, 2007).  In contrast, in latently infected epithelial cells (NPC cell 
lines) and early passage LCLs, XBP-1s in combination with activated protein 
kinase D, a HDAC inhibitor, was required to activate lytic gene expression 
(Bhende et al., 2007).  In both systems knockdown of cellular XBP-1 transcripts 
inhibited the low level constitutive BZLF1 transcripts from the endogenous 
genome (Bhende et al., 2007; Sun & Thorley-Lawson, 2007).  Given the 
evidence that lytic cycle reactivation occurs in plasma cells this could provide 
another example of how EBV exploits the host cell environment, in this case to 
induce lytic cycle reactivation.   
Two putative XBP-1 binding sites were identified in the Zp promoter, one 
overlapping the ZII CRE site and the other in between the ZID and ZII sites 
(Figure 1.6).  Only the CRE site bound purified XBP-1s in EMSAs.  ChIP 
analysis additionally revealed that recombinant XBP-1s is recruited to the 
endogenous Zp promoter in multiple myeloma cells (Sun & Thorley-Lawson, 
2007).  The XBP-1 binding site overlapping the CRE motif was previously 
mutated in quantitative reporter assays (MII mutation) and tested in the Akata 
system (Binne et al., 2002).  The ZII site was important for the rapid early 
activation of the promoter in response to anti-IgG but was dispensable at the 
later time points.  The contribution of the second ‘’XBP-1’’ binding site to Zp 
activation is unknown.  This site overlaps the single CpG motif in the -221 
region of the promoter.   
 
1.7  Lytic DNA replication  
 
Lytic DNA replication is initiated at the origins of lytic replication (oriLyt) where 
multiple rounds of lytic replication result in over 100 fold amplification of the viral 
genome (Hammerschmidt & Sugden, 1988).  DNA replication occurs in two 
phases.  During the initial phase DNA is amplified to yield monomeric plasmid 
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progeny (theta mode).  This depends on oriLyt in cis with BZLF1 bound 
(Schepers et al., 1993a).  These circular progeny molecules have few negative 
supercoils and serve as a template for the second phase of replication.  The 
second phase occurs via a rolling circle method and results in large head to tail 
concatemeric molecules, which are subsequently cleaved into individual 
genomes and packaged in virions in the nucleus (Pfuller & Hammerschmidt, 
1996).    
EBV contains two copies of oriLyt but one is sufficient for lytic cycle 
replication.  The left copy is located within the promoter regions of the BHLF1 
and BHRF1 genes and is the most studied copy.  oriLyt consists of two 
essential core elements, the upstream and downstream components, flanked by 
non-essential auxiliary elements (Hammerschmidt & Sugden, 1988; Schepers 
et al., 1993b).  oriLyt contains seven ZRE sites.  Four are located in the 
upstream component and are essential for replication (Schepers et al., 1996).  
The downstream component contains binding sites for cellular transcription 
factors including Sp1 and ZBP89 (Baumann et al., 1999).  BZLF1 binds to the 
upstream component and Sp1 and ZBP89 bind to the downstream component, 
enhancing oriLyt replication (Baumann et al., 1999).  The auxiliary elements 
contain binding sites for BRLF1 and BZLF1 and enhance replication efficiency 
(Schepers et al., 1993b).     
 
1.7.1  BZLF1 and the replication complex 
The lytic phase of EBV DNA replication is dependent on seven viral replication 
proteins (Fixman et al., 1992; 1995).  These are the BZLF1 protein, which acts 
as the oriLyt binding protein; BALF5, the DNA polymerase catalytic subunit; the 
polymerase processivity factor BMRF1; BALF2, the single stranded-DNA 
binding protein; and BBLF4, BSLF1 and BBLF2/3, the helicase, primase and 
helicase-primase-associated factor, respectively.  These proteins are 
homologues of HSV-1 proteins that participate directly in DNA replication, with 
the exception of the origin binding protein (McGeoch et al., 1988).  The origin 
binding protein, UL9, in HSV-1 has both ATP binding and DNA helicase motifs 
that are essential for viral DNA replication.  UL9 binds to sequence specific sites 
in the origin of replication and its ATPase and helicase activity are required for 
initiation of DNA synthesis (Koff et al., 1991; Lee & Lehman, 1997).     
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BZLF1 plays a central role in lytic DNA replication through recruitment 
and assembly of the replication complex on oriLyt.  The transactivation domain 
of BZLF1 is absolutely required for its replication function and cannot be 
replaced with the transactivation domains of other transcription factor (Schepers 
et al., 1993a).  BZLF1 binds to some of the core replication machinery and other 
core replication proteins are tethered by interactions with one or more of these 
proteins.  The cellular transcription factors Sp1 and ZBP89, which bind to the 
downstream component, may also play an additional role in tethering the 
replication complex to oriLyt (Baumann et al., 1999).     
The replication complex requires the assembly of the tripartite helicase 
primase complex consisting of the helicase, primase and helicase primase 
associated factor (Yokoyama et al., 1999).  BZLF1 interacts with the primase 
subcomplex (BSLF1-BBLF2/3) through residues 11 to 25, which were identified 
as having a replication specific function (Gao et al., 1998; Sarisky et al., 1996).  
The helicase (BBLF4) interacts with the adjacent region of BZLF1, residues 22-
86, which is also required for its transactivation function, and targets BZLF1 to 
the replication compartments (Liao et al., 2001).  The helicase primase 
subcomplex interacts with the polymerase (BALF5) (Fujii et al., 2000) and the 
single stranded DNA binding protein (BALF2) (Gao et al., 1998).  BZLF1 also 
interacts with the polymerase through residues 25-86 (Baumann et al., 1999) 
and the polymerase processivity factor (BMRF1) through the bZIP domain 
(Zhang et al., 1996).   
BZLF1 interacts with other cellular factors that may be involved in lytic 
DNA replication.  BZLF1 interacts with the mitochondrial single stranded DNA 
protein, mtSSB.  This interaction is believed to inhibit mitochondrial DNA 
replication and enhance EBV lytic DNA replication (Wiedmer et al., 2008).  
Interaction of BZLF1 with the HAT CBP may also function in oriLyt mediated 
replication by modifying the chromatin structure present at oriLyt (Adamson & 
Kenney, 1999).      
 
1.7.2  Replication compartments and PML nuclear bodies  
EBV lytic DNA replication occurs at discrete sites in the nucleus called 
replication compartments.  Upon lytic cycle induction, viral replication proteins 
localise at these sites where newly synthesized viral DNA accumulates 
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(Daikoku et al., 2005).  BZLF1 and BRLF1 are dispersed in the nucleus at the 
immediate early stages of lytic replication but colocalise at replication 
compartments as the lytic cycle progresses.  The polymerase processivity factor 
(BMRF1) is homogenously distributed throughout the replication compartment, 
associated with newly replicated DNA, whereas BALF2, BALF5 and BBLF2/3 
colocalise at distinct spots, indicative of viral replication factories (Daikoku et al., 
2005).       
The replication compartments colocalise with structures called 
promyelocytic leukaemia (PML) bodies, also known as nuclear domain 10 
(ND10) bodies (Bell et al., 2000).  There are about 10 to 30 PML bodies present 
in the nucleus which appear as speckled subnuclear structures.  They are made 
up of several proteins including PML, Sp100, Daxx, CBP, SUMO-1, p53 and Rb 
but only PML is essential for their formation (Zhong et al., 2000a).  PML 
becomes covalently modified by SUMO-1 and is required for formation of these 
nuclear structures (Adamson & Kenney, 2001).  The exact role of PML bodies is 
unclear but they are involved in transcriptional control, apoptosis, tumour 
suppression and interferon induced anti-viral responses (Zhong et al., 2000b; 
Zhong et al., 2000c).   
Several herpesviruses including EBV, HSV-1, HCMV and KSHV 
associate with and disrupt PML bodies.  HSV-1 and HCMV replicate in 
association with PML bodies after entering the cell and their immediate early 
proteins HSV-1 ICP0 and HCMV IE1 are responsible for PML body dispersion 
(Korioth et al., 1996; Maul et al., 1993).  The function of this process is still 
unclear but may be due to anti-viral activity associated with these sites (Lavau 
et al., 1995).   
EBV only associates with the PML bodies during the lytic cycle, as the 
latent genome remains tethered to the host chromosomes during latency (Bell 
et al., 2000).  PML bodies become disrupted during reactivation of EBV but the 
PML protein is not dispersed until after DNA replication (Bell et al., 2000).  
BZLF1 is sufficient for PML dispersion and the N-terminus of the transactivation 
domain is required for this function.  Dispersion was associated with the loss of 
SUMO-1 modified PML, which is required for PML body formation.  BZLF1 can 
out compete PML for SUMO-1 modification (Adamson & Kenney, 2001).    
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1.8  Aims of thesis  
 
This thesis focuses on the regulation of the EBV immediate early gene BZLF1 
and how this protein functions as both a transcriptional activator and an origin 
binding protein required for lytic DNA replication.   
 
Zp promoter regulation  
• Do the known promoter elements account for the regulation at Zp? 
• Is the ZID promoter element functionally important during Zp regulation? 
• What factors bind to the ZID element in Akata BL cells? 
• Is XBP-1s present during lytic cycle reactivation in Akata BL cells? 
• Is it possible to develop a system to study the repressive chromatin 
structure present in the endogenous genome? 
 
Functional analysis of the BZLF1 structure 
• Is the conserved motif in the dimerisation domains of BZLF1 and 
C/EBPα functionally significant? 
• Is the C-terminal tail of BZLF1 required for its transactivation and 
replication functions? 
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2.  Materials and methods 
 
2.1  Tissue culture 
 
2.1.1  Cell lines 
AK2003/AK31  
The Akata cell line is an EBV positive Burkitt’s lymphoma cell line derived from 
a Japanese patient (Takada et al., 1991).  The AK2003 cell line was generated 
by single cell cloning the Akata cell line (Bryant & Farrell, 2002).  EBV positive 
Akata cell lines spontaneously lose the EBV genome at a low rate (Shimizu et 
al., 1994).  The AK31 cell line was generated by single cell cloning to isolate an 
EBV negative cell line (Jenkins et al., 2000).    
 
B95-8ZHT 
The cell line B95-8 is a lymphoblastoid cell line made by transforming marmoset 
B-lymphocytes with the B95-8 strain of EBV (Miller et al., 1972).  The B95-8ZHT 
cell line was generated by stable transfection of the linearised pcDNA3-ZHT 
plasmid into B95-8 cells.  The cell line expresses the BZLF1-4-
hydroxytamoxifen-dependent mutant estrogen receptor fusion protein (ZHT) 
(Johannsen et al., 2004).   
 
293/293-ZKO 
The 293 cell line is a human embryonic kidney cell line (Graham et al., 1977).  
The 293-ZKO cell line was generated by stably transfecting 293 cells with an 
EBV bacterial artificial chromosome with a deletion in the BZLF1 gene 
(Feederle et al., 2000).       
 
2.1.2  Cell maintenance 
All cells were maintained at 37°C in a humidified i ncubator with 10% carbon 
dioxide.  Akata cell lines were grown in RPMI 1640 (Gibco-BRL) supplemented 
with 10% (v/v) heat inactivated Serum Supreme (BioWhittaker).  293 and B95-
8ZHT cell lines were grown in DMEM (Gibco-BRL) or RPMI respectively, 
supplemented with 10% (v/v) heat inactivated foetal calf serum (FCS) (Autogen 
Bioclear).  All cell lines were grown in the presence of 2 mM L-Glutamine 
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(Gibco-BRL), 200 U/ml penicillin and 200 U/ml streptomycin (Gibco-BRL).  293-
ZKO cells were grown in the presence of 0.1 mg/ml hygromycin B (Roche).   
Akata cells and B95-8ZHT cells were fed 2 to 3 times per week by dilution in 
prewarmed fresh medium.  293 cells were split 1:15 twice per week using 
trypsin-EDTA (Gibco) to disaggregate the cells. 
 
2.1.3  Induction of the lytic cycle  
The EBV lytic cycle was induced in Akata cells by crosslinking surface 
immunoglobulin G with 5 µg/ml goat anti-human IgG antibody (Sigma), raised 
against the constant (γ) region of IgG.  Cells were split 1:2 the day prior to 
induction.  
 
2.1.4  Activation of the ZHT fusion protein 
The ZHT fusion protein was activated by treating cells with 0.2 µM 4-
hydroxytamoxifen (Sigma).  Cells were split 1:2 the day prior to activation of the 
fusion protein.    
 
2.2  Transfection of eukaryotic cell lines 
 
2.2.1  Electroporation of eukaryotic cells and generation of 
stable cell lines 
8 x 106 cells (5 x 106 cells for siRNA transfections) were harvested by 
centrifugation (490 x g, 4°C, 5 min), per transfect ion.  The cell pellet was 
resuspended in unsupplemented RPMI medium at a density of 3.2 x 107 
cells/ml (or 2 x 107 cells/ml for siRNA transfections).  A 250 µl sample was 
transferred to a Bio-Rad electroporation cuvette (0.4 cm electrode gap) and 10 
µg sterile plasmid DNA (or appropriate amount of siRNA) was added in 10 µl of 
water.  Electroporation was performed at 250 kV and 960 µF using a Bio-Rad 
Genepulser.  Cells were transferred into 10 ml of supplemented fresh medium 
(RPMI, 10% (v/v) serum supreme, 2 mM L-Glutamine, 200 U/ml penicillin and 
streptomycin).   
For generation of stable cell lines:  24 hours later, 0.25 mg/ml hygromycin B 
(Roche) or 1 µg/ml puromycin (Sigma), depending on the drug resistance 
provided by the plasmid, was added to select for successful transformants.  The 
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cells were plated into 6 wells of a 24 well plate.  Every 2 to 3 days the 
supernatant was partially aspirated and replenished with fresh medium 
supplemented with hygromycin B or puromycin.  Approximately 4 weeks later, 
cell culture wells containing viable cells were identified via microscopy and 
expanded. 
 
2.2.2  Transient transfection of adherent eukaryotic cell lines       
5 x 105 cells were seeded on to 6 well plates in 2 ml of antibiotic free DMEM 
and incubated overnight at 37°C.  Cells were transf ected with plasmid DNA 
using LipofectamineTM 2000 reagent (Invitrogen).  For BZLF1 transactivation 
assays, 293 cells were cotransfected with 0.5 µg pGL3EA, 1 µg pBK2CMV-
BZLF1 and 0.5 µg pCMV19-βgal.  For replication assays, 293-ZKO cells were 
transfected with 1 µg pBK2CMV-BZLF1 and 0.5 µg pCMV19-βgal.  The DNA 
was diluted to 250 µl with unsupplemented DMEM.  10 µl of LipofectamineTM 
2000 reagent was diluted to 250 µl with unsupplemented DMEM and incubated 
for 5 min at room temperature (RT).  The diluted DNA and LipofectamineTM 
2000 reagent were mixed and incubated for 20 min at RT.  The transfection 
mixture was added gently to the cells and incubated at 37°C.  48 hours after 
transfection the cells were harvested with ice-cold phosphate buffered saline 
(PBS).  Cells were centrifuged (490 x g, 4 °C, 5 mi n) and washed in ice-cold 
PBS.  Cell pellets were snap frozen on dry ice and stored at -80°C or processed 
immediately.   
  
2.3  Quantitative assays  
 
2.3.1  Luciferase assay  
Cells were harvested by centrifugation (490 x g, 4°C, 5 min) and the 
supernatant removed.  The cell pellet was washed with ice-cold PBS and lysed 
in 100 µl 1x reporter lysis buffer (Promega) for 10 min at RT.  Cell debris was 
removed by centrifugation (13000 rpm, RT, 5 min) in a microcentrifuge.  A 20 µl 
sample (5 µl for 293 transfections) of supernatant was assayed for 10 seconds 
on a Berthold Autolumat luminometer with 100 µl of luciferase assay substrate 
(Promega). 
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2.3.2  β-galactosidase assay  
To correct for differences in transfection efficiency in transient transfections, 
cells were co-transfected with 0.5 µg of pCMV19-βgal plasmid.  Cell extracts 
were prepared as described in section 2.3.1 and 10 µl of each sample was 
added to a well of a 96 well plate and analysed for β-galactosidase activity.  150 
µl chlorophenolred-β-D-galactopyranoside (CPRG) (Roche) was added to each 
sample; after a colour change was detected the absorbance was measured at 
570 nm using an ELISA plate reader (Antos Labtec Instruments).  Luciferase 
values were divided by the β-galactosidase values to control for transfection 
efficiency.          
 
2.3.3  Bradford Assay 
Protein concentrations of AK2003 cell lysates were determined to normalise 
luciferase data to the amount of cell extract analysed.  The luciferase samples 
were diluted 20 fold in 1x Reporter Lysis Buffer (Promega).  10 µl of diluted 
sample was added to a well of a 96 well plate.  Different amounts of bovine 
serum albumin (BSA) (0, 0.125, 0.25, 5, 7.5 and 10 µg) were added to other 
wells in the plate and served as protein standards.  200 µl Bio-Rad Protein 
Assay Solution was added to each well and incubated at RT for 5 min.  
Samples were assayed at a wavelength of 595 nm on an ELISA plate reader.      
 
2.4  Preparation of RIPA lysates 
 
Cells were harvested by centrifugation (490 x g, 4°C, 5 min) and the 
supernatant removed.  The cell pellet was washed twice with ice-cold PBS and 
lysed in two volumes of RIPA lysis buffer (150 mM NaCl, 1% (v/v) Nonidet-P40 
(NP40), 0.5% (v/v) deoxycholic acid, 0.1% (w/v) SDS , 50 mM Tris-Cl pH 8.0), 
supplemented with 1 mM PMSF and CompleteTM protease inhibitors (Roche).  
Cells were lysed for 15 min on ice and centrifuged to pellet cell debris (14000 
rpm, 4°C, 5 min).  The supernatant was harvested.   
The protein concentrations were determined using the DC Protein Assay 
System (Bio-Rad) which is based on the Lowry assay (Lowry et al., 1951).  2 µl 
of sample was further diluted with 18 µl of RIPA lysis buffer.  100 µl working A 
solution (98% Reagent A, 2% Reagent S) was added followed by 800 µl 
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Reagent B.  Samples were vortexed and incubated at RT for 15 min.  Different 
amounts of bovine serum albumin (0, 0.78, 1.56, 3.12, 6.25, 12.5, 25 and 50 µg) 
were treated similarly to serve as a standard.  Samples were assayed at a 
wavelength of 750 nm on a Helios Beta photometer (Unicam).  Protein extracts 
were combined with 2x SDS sample buffer (250 mM Tris-Cl pH 6.8, 20 mM 
dithiothreitol (DTT), 2% (w/v) SDS, 10% glycerol, 0.01% (w/v) bromophenol 
blue), incubated at 100°C for 5 min and analysed by  SDS-PAGE.   
 
2.5  Gel electrophoresis 
 
2.5.1  Agarose gel electrophoresis 
0.8 - 2% (w/v) agarose (Invitrogen) gels were prepared in 1x TBE buffer (93mM 
Tris-Cl, pH 8.8, 50 mM boric acid, 2 mM EDTA).  The agarose was dissolved by 
heating and poured into a gel casting tray after addition of 0.5 µg/ml ethidium 
bromide.  Gel loading buffer (10% sucrose, 20 mM EDTA, 0.02% bromophenol 
blue, 0.02% xylene cyanol FF) was added to the DNA samples and 
electrophoresis performed in 1x TBE at 100 V.  The nucleic acid fragments 
were visualised using a Syngene transilluminator ultra-violet (UV) light source 
and the Genesnap software.   
 
2.5.2  Extraction of DNA from agarose gels  
During cloning procedures, plasmids were cut with restriction enzymes and the 
resulting fragments separated by agarose gel electrophoresis.  A gel slice 
containing the required DNA was excised from the agarose gels following 
visualisation under UV light and the DNA extracted using the QIAquick Gel 
Extraction Kit (Qiagen).  The agarose was dissolved in 3 volumes of buffer QG 
at 50°C for 10 min.  The sample was applied onto a QIAquick spin column and 
centrifuged in a microcentrifuge (13000 rpm, RT, 1 min) to bind the DNA to the 
column.  The column was washed with 750 µl buffer PE and the DNA eluted 
with 30 µl buffer EB (10 mM Tris-Cl, pH 8.5).    
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2.5.3  Polyacrylamide gel electrophoresis 
Protein separation was performed by sodium dodecyl sulphate - polyacrylamide 
gel electrophoresis (SDS-PAGE) using the BioRad Mini Protean II system (Bio-
Rad).  Gels were composed of either a 10% or 15% resolving gel (10% or 15% 
acrylamide, 375 mM Tris-Cl pH 8.8, 0.1% (w/v) SDS) and a 5% stacking gel 
(5% acrylamide, 125 mM Tris-Cl pH 6.8, 0.1% (w/v) SDS).  Gels were 
polymerised with 10 µl NNN’N’-tetramethylethylenediamine (TEMED) and 50 µl 
10% (w/v) ammonium persulphate (APS), per 10 ml gel volume.  SDS-PAGE 
was used to analyse in vitro translation products and proteins from cell extracts.  
A fraction of the translation products or 50 µg protein was mixed with 2x SDS 
sample buffer (250 mM Tris-Cl pH 6.8, 20 mM DTT, 2% (w/v) SDS, 10% 
glycerol, 0.01% (w/v) bromophenol blue), boiled for 5 min and loaded in the 
stacking gel.  Samples were run along with the Full Range Rainbow Molecular 
Weight Marker (Amersham).  Electrophoresis was performed at 150 V for 1 
hour with SDS running buffer (400 mM glycine, 50 mM Tris-Cl, 0.1% (w/v) 
SDS).   
 
2.6  DNA extraction from eukaryotic cells 
 
2.6.1  Total DNA extraction for Southern blot analysis 
5 x 106 - 1 x 107 cells were harvested by centrifugation (490 x g, 4°C, 5 min) and 
washed with ice-cold PBS.  Cells were resuspended in 850 µl of buffer NET (0.1 
M NaCl,10 mM Tris-Cl pH 7.5, 1 mM EDTA), 90 µl of 10% (w/v) SDS was 
added and proteinase K to a final concentration of 0.3 mg/ml.  Cells were lysed 
by mixing on a rotor overnight at RT.  The DNA was extracted twice with phenol 
chloroform and once with chloroform.  After the addition of either phenol 
chloroform or chloroform the samples were mixed vigorously by vortexing and 
centrifuged (9000 rpm, RT, 10 min) in a Sorval RC 5C Plus centrifuge.  The 
upper aqueous phase was transferred to a fresh tube.  The DNA was 
precipitated with 1/10 volume of 3 M sodium acetate and 2.5 volumes of 100% 
ethanol at -20°C for 30 min and then centrifuged as  above.  The supernatant 
was removed.  The DNA pellet was washed with 70% ethanol and allowed to air 
dry.  The pellet was resuspended in 50 µl of Tris-EDTA (TE) buffer (10 mM Tris-
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Cl pH 8.5, 1 mM EDTA).  10 µl of DNA was digested with EcoRI in a total 
volume of 50 µl (32.5 µl water, 5 µl 10x EcoRI buffer, 2.5 µl EcoRI).  
 
2.6.2  Total DNA extraction for quantitative real-time PCR 
Cells were harvested by centrifugation (490 x g, 4°C, 5 min) and washed with 
ice-cold PBS.  Total cellular DNA was extracted using the DNeasy Blood and 
Tissue Kit (Qiagen) as per instructions.  Cells were resuspended in 250 µl of 
PBS.  A 50 µl sample was removed for Western blot analysis.  20 µl proteinase 
K and 4 µl RNase A (100 mg/ml) were added to the remaining 200 µl of cells.  
The sample was mixed by vortexing and incubated at RT for 2 min.  200 µl 
Buffer AL (SDS-buffer) was added and the sample was lysed at 56°C for 10 
min.  DNA was purified by a spin column procedure and eluted in 200 µl of 
elution buffer.         
 
2.7  Blotting techniques 
 
2.7.1  Western blotting  
Proteins were separated by SDS-PAGE and transferred to nitrocellulose 
membranes (Schleicher & Schuell) at 100 V for 1 hour in transfer buffer (190 
mM glycine, 25 mM Tris-base, 0.05% (w/v) SDS, 25% (v/v) ethanol).  The 
nitrocellulose membrane was placed on top of the gel which was subsequently 
sandwiched between three layers of 3MM Whatman paper and a sponge on 
each side.  After the transfer, the membranes were blocked for 1 hour at RT in 
blocking buffer (PBS, 0.05% Tween-20, 5% (w/v) milk powder (Marvel)).  The 
membranes were incubated with the primary antibody (BZLF1: BZ-1 (Santa 
Cruz) diluted 1:500 or Z185 diluted 1:500, BMRF1: EA-D (Chemicon) diluted 
1:5000, BdRF1: VCA-p40 diluted 1:1000, Actin: anti β-actin clone AC-15 
(Sigma) diluted 1:20000) in blocking buffer at 4°C overnight.  After incubation 
the membranes were washed 3 times for 5 min in wash buffer (PBS, 0.05% 
Tween-20).  The secondary antibody linked to horseradish peroxidase (HRP 
conjugated sheep anti-mouse IgG (GE healthcare) diluted 1:2000 in blocking 
buffer) was added to the membranes and incubated for 1 hour at RT.  
Membranes were washed 3 times as before and proteins visualised using 
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ECLTM Western blotting detection reagents (Amersham) and exposed on 
Hyperfilm (Fujifilm).   
 
2.7.2  Southern blotting  
Random prime labelling  
Probes were labelled using the Amersham Megaprime kit.  25 ng of probe DNA 
(pGL2 for pHEBo plasmids) and random nanomer primers were boiled for 5 min 
in a total volume of 33 µl, in water, and cooled on ice.  10 µl labelling buffer, 2 µl 
[α-32P]-dCTP (10 mCi/ml, 3000 Ci/mmol) and 2 µl Klenow DNA polymerase (1 
U/µl) were added and incubated for 10 min at 37°C.  The reaction was stopped 
by adding 5 µl of 0.5 M EDTA.  Unincorporated [α-32P]-dCTP was removed 
using Micro Bio-Spin 30 chromatography columns (BioRad) and the labelled 
probe was boiled for 5 min.   
 
Southern blot analysis 
EcoRI digested DNA was loaded onto a 1% agarose gel and electrophoresed at 
5 V/cm.  The gel was denatured in 1.5 M NaCl, 0.5 M NaOH at RT for 20 min 
and neutralised by washing three times for 20 min in 1.5 M NaCl, 1 M Tris-Cl pH 
8.0.  Fractionated DNA was transferred to nitrocellulose membranes (Schleicher 
& Schuell) using the method of Southern (Southern, 1975).  The nitrocellulose 
was rinsed in 6x SSC (20x SSC: 3M NaCl, 300mM Na-citrate), air dried and 
baked in a vacuum oven at 80°C for 2 hours to cross link the DNA to the 
membrane.   
The membrane was prehybridised with 0.2 ml/cm2 of prehybridisation buffer (1 
M NaCl, 100 mM Na-citrate, 0.1% Ficoll, 0.1% polyvinylpyrolidone, 0.1% BSA, 
0.1% denatured salmon sperm DNA (Sigma)) at 65°C fo r 3 hours.  This solution 
was removed and replaced with 0.05 ml/cm2 of fresh prehybridisation buffer 
containing the radioactive labelled probe.  Hybridisation was performed 
overnight at 65°C.  The hybridisation solution was discarded and the membrane 
washed two times for 10 min at RT with 2x SSC, 0.2% SDS, followed by two 
washes with 0.1x SSC, 0.2% SDS at 65°C for 30 min.  The membrane was 
finally air dried, exposed to a phosphoimager screen (Molecular Dynamics) and 
analysed using the phosphoimager software ImageQuaNT (Molecular 
Dynamics).   
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2.8  Flow cytometry  
 
2.5 x 106 – 5 x 106 cells were harvested by centrifugation (490 x g, 4°C, 5 min), 
washed with ice-cold PBS and resuspended in 1 ml ice-cold methanol (100%).  
Cells were fixed in methanol at -20°C for 24 hours.   Cells were washed with 5 
ml staining buffer (PBS, 1% (w/v) BSA, 0.1% (w/v) sodium azide) and 
resuspended in 1 ml staining buffer.  The cells were incubated at RT for 1 hour 
for rehydration.  Cells were washed two times in staining buffer and incubated 
with the primary antibody (BZLF1: BZ-1 diluted 1:200 in 100 µl staining buffer) 
at 4°C for 1 hour.  Cells were washed twice and inc ubated with the secondary 
antibody (FITC conjugated anti-mouse IgG (Sigma) diluted 1:200 in 100 µl 
staining buffer) at 4°C for 1 hour, protected from light.  The cells were again 
harvested, washed twice and resuspended in 500 µl staining buffer.  The 
proportion of induced cells was determined by flow cytometry using a Beckton-
Dickinson FACSort flow cytometer and CellQuest software. 
 
2.9  Bacterial transformation and DNA isolation  
 
2.9.1  Preparation of CaCl2 competent bacteria 
1 ml of an overnight culture of E. coli XL1 blue was used to inoculate 50 ml of 
fresh LB medium and grown to an OD600 of 0.4, at 37°C with shaking.  The 
bacteria were harvested by centrifugation (3750 rpm, 4°C, 15 min) in a 
Beckham-Coulter Allegra 6R centrifuge, resuspended in 25 ml of 50 mM CaCl2 
and left on ice for 30 min.  Cells were harvested and resuspended in 5 ml of 50 
mM CaCl2 and 15% glycerol.  500 µl aliquots were snap frozen on dry ice and 
stored at -80°C.         
 
2.9.2  Transformation of bacteria  
Competent E. coli XL1 blue cells were thawed on ice.  100 µl bacteria and 2 µl 
ligation reaction (or 100 ng vector DNA) were incubated on ice for 30 min.  The 
bacteria were heat shocked at 42°C for 45 seconds a nd incubated on ice for 2 
min.  500 µl prewarmed LB medium was added and the sample incubated at 
37°C for 1 hour with shaking.  The cultures were sp read onto LB-agar plates 
containing an appropriate antibiotic selection and incubated overnight at 37°C. 
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2.9.3  Isolation of plasmid DNA - small scale DNA preparation   
Small scale DNA preparations were performed using a QIAprep Spin Miniprep 
Kit (Qiagen).  Transformed colonies were picked and inoculated into 3 ml of LB 
medium containing an appropriate antibiotic selection.  The cultures were 
incubated at 37°C overnight with shaking.  1.5 ml o f overnight culture was 
centrifuged (5000 rpm, 4°C, 5 min) in a microcentri fuge.  The cell pellet was 
resuspended in 250 µl buffer P1 (50 mM Tris-Cl pH 8.0 , 10 mM EDTA, 100 
µg/ml RNAseA).  250 µl buffer P2 (200 mM NaOH, 1% (w/v) SDS) was added, 
mixed and cells lysed at RT for 5 min.  350 µl buffer N3 (3 M potassium acetate 
pH 5.8) was added for neutralisation and precipitation.  The sample was 
centrifuged (13000 rpm, RT, 10 min) in a microcentrifuge and the supernatant 
transferred to a QIAprep column.  The column was centrifuged for 1 min as 
above and washed with 750 µl buffer PE.  The DNA was eluted with 30 µl buffer 
EB.   
 
2.9.4  Isolation of plasmid DNA – large scale DNA preparation 
Large scale DNA preparations were performed using a QIAgen Plasmid Maxi 
Kit (Qiagen).  250 ml of LB medium containing the appropriate antibiotic 
selection was inoculated with 250 µl of overnight culture and incubated at 37°C 
for 16 hours with shaking.  The bacteria were harvested by centrifugation (3750 
rpm, 4°C, 15 min) in a Beckham-Coulter Allegra 6R c entrifuge.  All subsequent 
centrifugation steps were performed in the same centrifuge.  The bacterial pellet 
was resuspended in 10 ml buffer P1.  10 ml buffer P2 was added and the 
solution mixed thoroughly.  The cells were lysed for 5 min at RT.  Genomic DNA 
and proteins were precipitated by addition of 10 ml chilled buffer P3 (3 M 
potassium acetate pH 5.5), followed by incubation on ice for 20 min.  The 
sample was centrifuged (3750 rpm, 4°C, 30 min) and the supernatant applied to 
a QIAgen-tip 500 column which was equilibrated with 10 ml buffer QBT (750 
mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol).  After washing, the 
DNA was eluted with 15 ml buffer QF (1.25 M NaCl, 50 mM Tris-Cl pH 5.8, 15% 
(v/v) isopropanol).  10.5 ml of isopropanol was added to precipitate the DNA 
and the sample was centrifuged (3750 rpm, 4°C, 1 ho ur).  The DNA pellet was 
washed with 5 ml 70% (v/v) ethanol and centrifuged again for 30 min.  The 
pellet was air-dried and dissolved in 500 µl of TE buffer.   
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2.10  RNA techniques 
 
2.10.1  Total RNA extraction 
Total RNA was isolated from Akata cells using Trizol Reagent (Invitrogen).  6 x 
106 cells were harvested by centrifugation (490 x g, 4°C, 5 min).  Cell pellets 
were lysed in 1 ml of Trizol by repetitive pipetting.  The homogenised samples 
were incubated at RT for 5 min.  200 µl of chloroform was added and the 
sample was shaken vigorously by hand for 15 sec.  The sample was incubated 
at RT for 3 min and then centrifuged at 12000 x g for 15 min at 4°C.  Following 
centrifugation the mixture separates into a lower red phenol chloroform phase, 
an interphase, and a colourless upper aqueous phase.  RNA remains 
exclusively in the aqueous phase.  The aqueous phase was transferred into a 
fresh tube.  1 ml of isopropanol was added and the sample was incubated at RT 
for 10 min to precipitate the RNA.  The RNA was harvested by centrifugation 
(12000 x g, 4°C, 10 min) and washed with 1 ml 75% e thanol.  The pellet was air 
dried and resuspended in 30 µl of DEPC treated water.  RNA samples were 
digested with RQ1 RNase-Free DNase (Promega) to remove DNA from the 
samples prior to RT-PCR.  30 µl was digested with 5 µl of DNaseI (1 U/µl) in a 
final volume of 50 µl at 37°C for 30 min.  The RNA was phenol chloroform 
extracted.       
 
2.10.2  Reverse transcriptase PCR  
cDNA was synthesised using the Protoscript First Strand cDNA Synthesis Kit 
(New England Biolabs).  1 µg total cell RNA was mixed with 2 µl (100 pmol) 
oligo dT primer (dT23VN), 4 µl dNTP (10 nmol) and the reaction volume 
adjusted to 16 µl with DEPC-treated water.  The reaction was incubated at 70°C 
for 5 min and promptly put on ice.  The following reagents were added to the 
reaction mix; 2 µl RT buffer, 1 µl RNase inhibitor (10 U/µl) and 1 µl M-MuLV 
reverse transcriptase (25 U/µl).  The reaction was incubated at 42°C for 1 hour 
followed by 95°C for 5 min to terminate the reactio n.  The reaction was diluted 
to 50 µl with water. 
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2.11  DNA amplification and mutagenesis 
 
2.11.1  Polymerase chain reaction (PCR) 
DNA fragments were amplified by PCR on a Gene Amp PCR System 9700 
(Applied Biosystems) and using Taq DNA polymerase (Promega).  Primers 
were designed with similar melting temperatures (TM).  The TM was calculated 
using the following formula below (n is the length of the primer in bp): 
 
TM = 81.5 + 0.41(%GC) – 675/n 
 
The reaction was set up as follows: 
 
10x Reaction Buffer   10 µl 
25 mM MgCl2   3 µl 
Forward Primer (10 µM)  2 µl  
Reverse Primer (10 µM)   2 µl 
dNTP mix (10 µM)   1.25 µl 
cDNA template    5 µl 
Taq DNA polymerase (5 U/µl) 0.5 µl 
Sterile water    26.25 µl 
 
The PCR was performed according to the following thermal cycling conditions: 
 
Segment    Cycles Temperature  Time 
Initial denaturation   1  95°C   2 min 
 
Denaturation   20-25  95°C   30 sec 
Annealing     55°C   30 sec 
Extension      72°C   1 min 
 
Final extension   1  72°C   5 min  
Hold       1  4°C   indefinite  
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2.11.2  Quantitative real-time PCR (QPCR) 
QPCR analysis was performed on an ABI 7700 Sequence Detection System 
(Applied Biosystems) and data was analysed using S.D.S. 1.9.1 software.  DNA 
amplification was performed with ABsoluteTM QPCR SYBR Green ROX Mix 
(Thermo Scientific).  The mix contains Thermo-Start DNA polymerase, reaction 
buffer, dNTPs, SYBR green and ROX, a passive dye for normalisation of data.  
QPCR reactions were performed in a 96 well plate format using primers specific 
for the Rp promoter and actin as a reference gene (Wang et al., 2005). 
 
The reaction was set up as follows: 
 
SYBR green mix   12.5 µl  
Forward Primer   100 nM (Rp) / 150nM (Actin) 
Reverse Primer  100 nM (Rp) / 150nM (Actin)  
Genomic DNA template   3 ng  
Sterile water   to 25 µl 
 
The QPCR was performed according to the following thermal cycling conditions: 
 
Segment    Cycles Temperature  Time 
Enzyme activation   1  95°C   15 min 
 
Denaturation   40  95°C   15 sec 
Annealing     60°C   30 sec 
Extension      72°C   30 sec 
 
Data was analysed using the Pfaffl method (Pfaffl, 2001).  The efficiency of the 
amplification was calculated for each primer using serial dilutions of template 
DNA.  Efficiency was calculated by plotting Ct values for each dilution against 
concentration.  The slope of the line is a measure of efficiency (E) where: 
 
E = 10(-1/slope) 
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The fold change in the target gene was calculated based on the cycle difference 
(∆Ct) and results were corrected with the loading control using the following 
formula: 
 
Fold change = (Etarget)∆Ct target (control-treated) / (Eref)∆Ct ref (control-treated) 
 
 
2.11.3  Site directed mutagenesis  
DNA mutations were introduced using the QuikChange Site-Directed 
Mutagenesis Kit (Stratagene) and performed on the Gene Amp PCR system 
9700 (Applied Biosystems).  Sets of complementary primers were designed with 
the required mutations, flanked by unmodified nucleotide sequence.  The 
primers were 25 to 45 bases in length and had a melting temperature (TM) 
greater than or equal to 78°C, which was calculated  using the formula below (n 
is the length of the primer in bp): 
 
TM = 81.5 + 0.41(%GC) – 675/n - % mismatch 
 
The reaction was set up as follows: 
 
10x Reaction buffer    5 µl 
Template DNA (10 ng/µl)    2 µl 
Forward primer (50 ng/µl)    2.2 µl 
Reverse primer (50 ng/µl)    2.2 µl 
Nucleotide mix    1 µl 
PfuTurbo DNA polymerase (2.5 U/µl) 1 µl 
Nuclease-free water   36.6 µl    
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The PCR was performed according to the following thermal cycling conditions: 
 
Segment    Cycles Temperature  Time 
Initial denaturation   1  95°C   30 sec 
 
Denaturation   12-18  95°C   30 sec 
Annealing     55°C   1 min 
Extension      68°C   1 min/kb 
 
For point mutations the reaction was run for 12 cycles and for amino acid 
changes the reaction was run for 18 cycles.  Following cycling the reaction was 
cooled on ice.  Parental methylated plasmid DNA was digested by adding 1 µl 
of the restriction enzyme DpnI (10 U/µl) to the reaction and incubating at 37°C 
for 1 hour.  1 µl of DpnI digested DNA was transformed into 50 µl of 
supercompetent E. coli XL1 blue cells (Stratagene) and mutations screened by 
restriction enzyme digestion of plasmid DNA and sequencing.   
 
2.12  Enzymatic reactions 
 
2.12.1  Digestion of DNA with restriction enzymes  
Digestions were performed with New England Biolabs restriction enzymes (10 - 
20 U/µl), buffers and BSA where required.  Up to 10 µg of DNA was digested in 
a total volume of 50 µl, with 2 µl of enzyme, for 1 to 2 hours at the 
recommended temperatures.  In double digestion the volume of enzyme did not 
exceed 10% of the total volume.       
 
2.12.2  Ligations with T4 DNA ligase  
Ligations were performed with vector and insert in a ratio of 1:3.  The amount of 
insert was calculated using the following formula: 
 
 ng insert = 3 x (size of insert (kb) x ng vector / size of vector (kb)) 
 
Ligations were performed in a final volume of 10 µl, with 1 µl T4 DNA ligase, 
and incubated at 16°C overnight.   
 78 
2.13  In vitro transcription and translation 
 
In vitro transcription and translation were performed using TNT Coupled 
Reticulocyte Lysate System (Promega).  The reaction was set up as follows on 
ice (50 µl reactions were used for immunoprecipitation assays): 
 
TNT Rabbit Reticulocyte Lysate   12.5 µl 
TNT Reaction Buffer     1 µl 
TNT RNA polymerase (T3 or SP6)  0.5 µl 
Amino acid mixture minus methionine (1 mM) 0.5 µl 
[35S]methionine      1 µl 
RNasin Ribonuclease Inhibitor    0.5 µl 
DNA template (0.5 µg/µl)    1 µl 
Nuclease free water     8 µl 
 
The reaction was incubated at 30°C for 90 min.  5 µ l of the reaction mixture was 
removed and diluted to 50 µl in SDS sample buffer.  Samples were boiled for 5 
min and proteins separated by SDS-PAGE (0.75 mm gel spacers).  The gel was 
fixed in 45% (v/v) ethanol, 10% (v/v) acetic acid for 30 min, changing the fixing 
solution every 10 min.  The gel was then washed 3 times for 20 min in 7% (v/v) 
acetic acid, 7% (v/v) ethanol, 1% (v/v) glycerol.  The gel was vacuum dried in a 
Bio-Rad gel drier at 80°C for 45 min and exposed to  a phosphoimager screen to 
monitor [35S]methionine incorporation.     
 
2.14  Immunoprecipitation 
 
BZLF1 and mutated BZLF1 proteins were immunoprecipitated from 
[35S]methionine labelled in vitro translation products.  The lysates (20 - 40 µl) 
were diluted up to 1 ml in buffer ELB (250 mM NaCl, 50 mM HEPES pH 7.9, 5 
mM EDTA, 0.1% (v/v) NP40, 1 mM PMSF, 0.5 mM DTT, supplemented with 
CompleteTM protease inhibitors (Roche)).  Lysates were precleared before 
immunoprecipitation by incubation with protein A agarose beads (Sigma), 
prewashed in buffer ELB, at 4°C for 30 min on a rot ating mixer.  The beads 
were removed by centrifugation (13000 rpm, 4°C, 1 m in) and the precleared 
lysate transferred to a clean tube.  All remaining centrifugation steps were 
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performed at 5000 rpm for 30 sec after which samples were placed immediately 
on ice.  Protein A agarose beads were labelled with rabbit anti-mouse Ig 
antibody (Sigma), which acted as a bridging antibody to improve 
immunoprecipitation.  300 µl of beads (1:1 slurry in ELB) were incubated with 35 
µl of bridging antibody at 4°C for 30 min on a rota ting mixer.  The beads were 
washed 5 times with ELB and 25 µl pre-labelled beads were used in each 
immunoprecipitation.  The precleared lysate was divided into the appropriate 
number of samples and incubated with the primary antibody (BZ1 diluted 1:10, 
Z185 diluted 1:10, Rb diluted 1:50) at 4°C for 20 m in on a rotating mixer.  25 µl 
pre-labelled beads were added to each sample and incubated at 4°C overnight 
on a rotating mixer.  The beads were harvested and washed 5 times with ELB.  
After washing, the proteins bound to the beads were eluted in SDS sample 
buffer at 100°C for 5 min and analysed by SDS-PAGE with autoradiography or 
phosphoimager analysis.                      
 
2.15  Electrophoretic mobility shift assays: 
 
2.15.1  Preparation of nuclear extracts 
AK2003 cells were split 1:2 for 2 days prior to induction with anti-IgG.  2 hours 
prior to induction cells were harvested (490 x g, 4°C, 5 min) and resuspended in 
fresh supplemented medium at 1 x 106 cells/ml.  Cells were induced with anti-
IgG for 10 min.  4 x 107 control and anti-IgG treated cells were harvested and 
washed with PBS followed by 500 µl buffer A (10 mM HEPES pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF).  All buffers used for nuclear 
extraction were supplemented with CompleteTM protease inhibitors (Roche) and 
phosphatase inhibitor cocktails (Sigma).  Cells were then resuspended in 100 µl 
buffer A containing 0.1% (v/v) NP40, incubated on ice for 5 min and centrifuged 
(5800 x g, 4°C, 30 sec).  The supernatant was disca rded and nuclei were 
resuspended in 50 µl Buffer B (20 mM HEPES pH 7.9, 0.42 M NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 10 mM KCl, 25% (v/v) glycerol, 0.5 mM PMSF, 1 mM 
DTT) and incubated at 4°C for 15 min on a rotating mixer.  Cell debris was 
removed by centrifugation (11600 x g, 4°C, 10 min).   The concentration of the 
crude nuclear extract was determined using the DC Protein Assay System (Bio-
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Rad).  Aliquots of nuclear extracts were snap frozen on dry ice and stored at -
80°C. 
 
2.15.2  Labelling of dsDNA probe       
Complementary oligonucleotides were diluted to 0.02 µg/µl in 1x NEB Buffer 4 
and annealed by incubation at 80°C for 10 min and c ooling slowly to RT.  
Oligonucleotides were labelled with [γ-32P]-ATP (Perkin Elmer) using T4 
polynucleotide kinase (PNK) enzyme (New England Biolabs).  100 ng double 
stranded oligonucleotide was mixed with 2 µl T4 PNK, 2 µl PNK buffer and 2 µl 
[γ-32P]-ATP in a final volume of 50 µl and incubated at 37°C for 30 min.  
Unincorporated nucleotides were removed using Micro Bio-Spin 30 
chromatography columns (BioRad) and the probe was stored at -20°C. 
 
2.15.3  EMSA binding reaction  
A total reaction volume of 18 µl containing 10 µg nuclear extract (or 2 µl in vitro 
translated protein for DNA binding assays), competitor oligonucleotides, 
antibodies (if required), 9.75 µl buffer D (20 mM HEPES pH 7.9, 0.1 M KCl, 0.2 
mM EDTA, 20% glycerol, 0.5 mM PMSF, 0.5 mM DTT), 6.5 µg BSA, 2.5 µg 
polydeoxyinosinic-deoxycytidylic acid (polydIdC) and 10 mM DTT was 
incubated at RT for 5 minutes.  In BZLF1 DNA binding assays all reactions 
contained 100 fold excess of ds458 competitor oligonucleotide to eliminate non-
specific binding.  2 µl [γ-32P]-labelled probe was added to the reaction mixture 
and incubated at RT for 30 minutes.  A non-denaturing 4% polyacrylamide gel 
was pre-run in 0.5x TBE at 100 V for 30 min at 4°C.   Samples were loaded onto 
the gel and electrophoresed at 175 V for 2.5 hours at 4°C.  The gel was fixed in 
fixing buffer (10% acetic acid, 45% ethanol) and vacuum dried in a Bio-Rad gel 
drier at 80°C for 2 hours.  The gel was exposed to a phophoimager screen 
(Molecular Dynamics), scanned using a Molecular Dynamics scanner and data 
analysed using ImageQuant software.     
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2.16  Plasmids 
 
2.16.1  Zp promoter plasmids 
pHEBo:Zp-luc 
Initial cloning of the pHEBo:Zp-luc plasmid was performed by Peter Jenkins and 
Ulrich Binné.  The luciferase reporter gene was excised from pGL2 (Promega) 
and cloned downstream of the wild type -552 Zp promoter from the plasmid 
p294:Zp-552Xwt (Jenkins et al., 2000), both being inserted between the BamHI 
and SalI sites of pHEBo (Yates et al., 1984), to create pHEBo:Zp-luc.  A 
corresponding negative control vector pHEBo-luc was created without the Zp 
promoter. 
 
pHEBo:Zp-luc mutants 
Point mutations were introduced into the Zp promoter in pBluescript II SK 
(Stratagene), containing the Zp -552 to +12 region of the promoter, by site 
directed mutagenesis.  The BamHI, XhoI fragment containing the mutated Zp 
promoter region was excised and ligated into the BamHI and XhoI sites of 
pHEBo-luc.  All of the mutations were confirmed by sequencing.         
 
2.16.2  BZLF1 expression plasmids 
pBK2CMV 
pBK2CMV is a modified version of the pBKCMV (Stratagene) plasmid (modified 
by Paul J. Farrell).  The modification was performed to remove an additional 
methionine codon in the lac promoter which may cause preinitiation to occur 
from the CMV promoter.  The lac promoter is located between the CMV 
promoter and the multiple cloning site in pBKCMV.  pBKCMV was digested with 
NheI and SacI.  This removed the T3 promoter so an adaptor was cloned in to 
re-introduce the T3 promoter site.  The forward and reverse oligonucleotides for 
the adaptor are shown.  BZLF1 was then cloned between the BamHI and 
EcoRI sites giving pBK2CMV-BZLF1. 
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Forward: 
5’-CTAGCGCTCGAAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCT-3’ 
Reverse: 
5’-CCAGCTTTTGTTCCCTTTAGTGAGGGTTAATTTCGAGCG-3’ 
 
pBK2CMV-BZLF1 mutants  
Site directed mutagenesis of BZLF1 was performed in SP64-EB1 which 
contains the BZLF1 gene under the control of the SP6 promoter.  The BamHI, 
EcoRI fragment which contains the BZLF1 gene was excised and ligated into 
the BamHI and EcoRI sites of pBK2CMV.  Mutations were confirmed by 
sequencing.   
 
Puro-OriP:ZHT 
Cloning of the Puro-OriP:ZHT expression plasmid was performed by Claudio 
Elgueta.  The ZHT gene from of pcDNA3-ZHT (Johannsen et al., 2004) was 
cloned under the control of the CMV promoter of Puro-OriP.  The Puro-OriP 
plasmid is based on pRG201 (a gift from Richard Greaves).  The B95-8 EBV 
oriP was subcloned into the pBluescript KS (Stratagene) EcoRI and PstI 
restriction sites.  The oriP was then excised as an EcoRI, BamHI fragment and 
cloned between the BglII and EcoRI sites of pRG201.  pRG201 contains a 
puromycin resistance cassette cloned into the polylinker of a pUC vector.  
 
2.16.3  shRNA plasmids  
pHEBo:SUPER-stuffer 
Initial cloning of the pHEBo:SUPER-stuffer plasmid was performed by Paul J. 
Farrell.  The HindIII site was removed from pHEBo by restriction digestion with 
HindIII.  The overhanging ends were filled with Klenow DNA polymerase and 
the blunt ends were ligated, resulting in the plasmid pHEBo∆HindIII.  The 
BamHI, XhoI fragment of pSuper (OligoEngine), containing the H1 promoter 
and polylinker, was cloned between the BamHI and SalI sites of 
pHEBo∆HindIII, to produce pHEBo:Super.  The BglII and HindIII sites in 
pHEBo:Super were separated, using a 545 bp stuffer fragment inserted in the 
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HindIII site, to allow efficient cutting and the resulting plasmid was named 
pHEBo:SUPER-Stuffer.   
shRNA oligonucleotides were cloned between the BglII and HindIII sites of 
pHEBo:SUPER-stuffer.  Expression of the shRNA sequence is driven by the 
RNA polymerase H1 promoter.        
 
2.17  Primers and siRNA sequences 
 
2.17.1  PCR primers 
XBP-1 
Forward: 5’-CCTTGTAGTTGAGAACCAGG-3’ 
Reverse: 5’-CAGAATGCCCAACAGGATATC-3’ 
 
GAPDH 
Forward: 5’-TGCCTCCTGCACCACCAACT-3’ 
Reverse: 5’-CGCCTGCTTCACCACCTTC-3’ 
 
2.17.2  QPCR primers 
Rp 
Forward: 5’-CGGAAACCCTGCGAGACTAC-3’ 
Reverse: 5’-GCCCTGTCGTCGGGAGATA-3’ 
 
Actin 
Forward: 5’-AACCCAGCCACACCACAAAG-3’ 
Reverse: 5’-CACTGACTTGAGACCAGTTGAATAAAA-3’ 
 
2.17.3  EMSA probes 
Complementary oligonucleotides were annealed and used as probes in EMSAs.  
The sense strands of the oligonucleotides are: 
 
M site: 5’-CTTCATGAGTCAGTGCTTC-3’ 
ds458: 5’-GCGAAGCACTCTCGAGTGAAGGTGAC-3’ 
ZID:    5’-CACACCTAAATTTAGCACGT-3’ 
Site 2:  5’-ACTTCTGAAAACTGCCTCCT-3’ 
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Site 7:  5’-AGAGGAGGCTGGTGCCTTGG-3’ 
 
2.17.4  Zp mutagenesis primers 
Complementary oligonucleotides were used in the mutagenesis experiments.  
The sense strands of these oligonucleotides are:   
 
Mutant 1   
5’-TGTCTGCTGCATGCCATGCAGAATTCAACTGGGCTGTCTATTT-3’ 
 
Mutant 2   
5’-GCTTATTTTAGACACTTCTGAATTCTGCCTCCTCCTCTTTTAGAA-3’ 
 
Mutant 3 
5’-ATTGCTAATGTACCTCATAGAGGTACCTAAATTTAGCACGTCCCA-3’ 
 
Mutant 4 
5’-TACCTCATAGACACACCTAAGCTTAGCACGTCCCAAACCATG-3’ 
 
Mutant 5 
5’-CACACCTAAATTTAGCACGTCGACAACCATGACATCACAGAGGAG-3’ 
 
Mutant 6 
5’-AAACCATGACATCACAGAGGTACCTGGTGCCTTGGCTTTAAAG-3’ 
 
Mutant 7 
5’-CATCACAGAGGAGGCTGGAAGCTTGGCTTTAAAGGGGAGA-3’ 
 
Mutant 8 
5’-GGTGCCTTGGCTTTAAAGGGGTACCGTTAGACAGGTAACTCACTA-3’ 
 
Mutant (16/17) 
5’-TACCTCATAGACACACCTAAATTTAGTGCGTCCCAAACCATG-3’  
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Mutant (7/14) 
5’-TACCTCATAGACACACCGAAATTTCGCACGTCCCAAACCATG-3’  
 
2.17.5  BZLF1 mutagenesis primers 
The sense strands of the complementary oligonucleotides are: 
 
S208A 
5’-GAGGTGGCTGCTGCCAAAGCATCTGAAAATGACAGGC-3’ 
 
S208E 
5’-GAGGTGGCTGCTGCCAAAGAATCTGAAAATGACAGGC-3’ 
 
S209E 
5’-GTGGCTGCTGCCAAATCAGAGGAAAATGACAGGCTGCGC-3’  
 
S208T 
5’-GAGGTGGCTGCTGCCAAAACATCTGAAAATGACAGGC-3’ 
 
S208D 
5’-GAGGTGGCTGCTGCCAAAGACTCTGAAAATGACAGGCTGC-3’ 
 
S208N 
5’-GAGGTGGCTGCTGCCAAAAACTCTGAAAATGACAGGCTGC-3’ 
 
S208K 
5’-GAGGTGGCTGCTGCCAAAAAATCTGAAAATGACAGGCTGC-3’ 
 
D236N 
5’-CCATTATCCCCCGGACACCAAATGTTTTACACGAGGATCTCTT-3’ 
 
D236K 
5’-CCATTATCCCCCGGACACCAAAGGTTTTACACGAGGATCTCTT-3’ 
 
 86 
R215A 
5’-CATCTGAAAATGACAGGCTGGCCCTCCTGTTGAAGCAGATGTG-3’ 
 
2.17.6  shRNA oligonucleotides 
 
XBP-1:303 
 
Forward: 5’-GATCCCCGACTGCCAGAGATCGAAAGTTCAAGAGACTTTC 
GATCTCTGGCAGTCTTTTTGGAAA-3’ 
Reverse: 5’-AGCTTTTCCAAAAAGACTGCCAGAGATCGAAAGTCTCTTGA 
ACTTTCGATCTCTGGCAGTCGGG-3’ 
 
XBP-1:346 
 
Forward: 5’-GATCCCCCAGCAAGTGGTAGATTTAGTTCAAGAGACTAAAT 
CTACCACTTGCTGTTTTTGGAAA-3’ 
Reverse: 5’-AGCTTTTCCAAAAACAGCAAGTGGTAGATTTAGTCTCTTGA 
ACTAAATCTACCACTTGCTGGGG-3’ 
 
XBP-1:435 
 
Forward:      5’-GATCCCCCCAGGAGTTAAGACAGCGCTTCAAGAGAGCGCT 
   GTCTTAACTCCTGG TTTTTGGAAA-3’ 
Reverse:      5’-AGCTTTTCCAAAAACCAGGAGTTAAGACAGCGCTCTCTTGA 
   AGCGCTGTCTTAACTCCTGGGGG-3’ 
  
XBP-1:648 
 
Forward: 5’-GATCCCCCTTGGACCCAGTCATGTTCTTCAAGAGAGAACA 
TGACTGGGTCCAAGTTTTTGGAAA-3’ 
Reverse:  5’-AGCTTTTCCAAAAACTTGGACCCAGTCATGTTCTCTCTTGA 
   AGAACATGACTGGGTCCAAGGGG-3’ 
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XBP-1:958 
 
Forward:  5’-GATCCCCCCTGTAGAAGATGACCTCGTTCAAGAGACGAGG 
   TCATCTTCTACAGGTTTTTGGAAA 
Reverse:      5’-AGCTTTTCCAAAAACCTGTAGAAGATGACCTCGTCTCTTGA 
   ACGAGGTCATCTTCTACAGGGGG-3’ 
 
PSC 
 
Forward:  5’-GATCCCCGCGCGCTTTGTAGGATTCGTTCAAGAGACGAAT 
   CCTACAAAGCGCGCTTTTTGGAAA-3’ 
Reverse:  5’-AGCTTTTCCAAAAAGCGCGCTTTGTAGGATTCGTCTCTTG 
   AACGAATCCTACAAAGCGCGCGGG-3’ 
 
 
2.17.7  siRNA sequences 
 
XBP-1 
Sense:  5’-ACAGCAAGUGGUAGAUUUATT-3’ 
Antisense: 5’-UAAAUCUACCACUUGCUGUTT-3' 
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3.  Regulation of the Zp promoter 
 
3.1  Introduction  
 
Lytic cycle reactivation is an essential part of the EBV life cycle; the latent virus 
must reactivate into the lytic cycle in order to produce infectious virus particles.  
The immediate early gene BZLF1 mediates the switch from latency to the lytic 
cycle.  Expression of BZLF1 is tightly regulated during latency, protecting the 
virus from reactivation in the absence of signalling.  Evidence suggests that Zp, 
the BZLF1 promoter, is protected from reactivation during latency by a 
repressive chromatin structure (Jenkins et al., 2000).  Transcription factors 
bound to the Zp promoter become modified in response to signalling, relieving 
the repressive chromatin structure at Zp, allowing transcription of the BZLF1 
gene and lytic cycle reactivation (Figure 3.1A) (Bryant & Farrell, 2002). 
Regulation of the Zp promoter has been studied extensively and several 
binding sites for both cellular and viral transcription factors have been identified 
(reviewed in chapter 1).  These cis-regulatory elements were divided into three 
categories: the positive regulatory elements (ZI, ZII, ZIIIA), the negative 
regulatory elements (ZIV and ZV) and the autoactivation elements (ZIIIA and 
ZIIIB).   
These studies on Zp regulation focused on regions of the promoter 
protected in footprinting assays but there are still significant regions that have 
not been examined in mutagenesis experiments.  Also, the ZID site was not 
mutated in the pHEBo:Zp-luc system and quantitative analysis of this element 
has never been reported.  In my investigation ZID is mutated in the pHEBo:Zp-
luc reporter plasmid to complete the quantitative analysis of the known promoter 
elements in the presence of the endogenous genome and additional regions of 
the promoter are examined for their contribution to Zp activity.  In addition, the 
putative XBP-1 binding sites are examined for their contribution to Zp activity.  
One XBP-1 site overlaps the ZII CRE site and bound purified XBP-1s in EMSAs 
(Sun & Thorley-Lawson, 2007).  The second site is immediately upstream, in 
between the ZID and ZII sites, and overlaps the single CpG motif in the -221 
region of the promoter (Figure 3.1B).  The ZII site was previously characterised 
in quantitative reporter assays and is important for the rapid early activation of 
the promoter in response to anti-IgG (Binne et al., 2002).  Here the second 
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XBP-1 binding site is mutated to determine its contribution to Zp activation.  
XBP-1 splicing is also examined in Akata BL cells, a well established system for 
studying lytic cycle reactivation. 
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3.2  Results 
 
3.2.1  Mutagenesis of the Zp promoter 
In order to complete the kinetic analysis of Zp regulation, additional 
mutagenesis was performed using the pHEBo:Zp-luc reporter plasmid (Binne et 
al., 2002).  The pHEBo:Zp-luc plasmid contains the luciferase reporter gene 
under the control of the Zp promoter.  The plasmid contains -552 to +12 bp 
relative to the transcription start site.  pHEBo:Zp-luc also contains an oriP 
sequence which allows maintenance of the plasmid in cells containing EBNA1.  
EBNA1 binds to the oriP sequence attaching the plasmid to the host 
chromosome, as it does with the EBV genome itself (Rawlins et al., 1985).  The 
plasmid also confers hygromycin and ampicillin drug resistance, allowing for 
selection in both eukaryotic and prokaryotic cells.  The pHEBo:Zp-luc system 
has been shown to accurately mimic regulation of Zp in EBV infected cells, 
reaching maximum levels of activity at 12 hours post induction (Binne et al., 
2002). 
Nine novel mutations were individually introduced into the -221 region of 
the Zp promoter in the pHEBo:Zp-luc reporter plasmid (Figure 3.1).  The aims 
were to determine if the known promoter elements account for the regulation at 
Zp, to perform quantitative analysis of the ZID promoter site and to examine the 
contribution of the putative XBP-1 binding sites to lytic cycle reactivation.  
Based on these criteria, point mutations were introduced in between the known 
promoter elements and a number of mutations were also focused around the 
ZID and ZII region, mutating the ZID site and second XBP-1 binding site.  This 
region was heavily protected in footprinting studies and has overlapping binding 
sites for several transcription factors (Flemington & Speck, 1990d).  The 
mutated promoter plasmids were referred to as Mutants 1 to 8 and Mutant CG.   
The wild type pHEBo:Zp-luc plasmid, mutated promoter plasmids and an 
empty vector control were transfected into AK2003 cells, an EBV positive BL 
cell line, by electroporation.  Stable cell lines were selected over four to eight 
weeks by hygromycin selection.  Three individual cell lines were selected for 
each plasmid and the mutations were tested for their impact on anti-IgG 
responsiveness in luciferase assays.  The cell lines were induced with anti-IgG, 
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harvested at different time points post induction over a 12 hour time course and 
cell lysates were analysed for luciferase activity (Figure 3.4).  
 
 
  
  
       -240      -230   Sph1         -210      -200  <----ZIA----->   <----ZIB--- 
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Figure 3.1.  Zp promoter mutations 
(A)  Schematic representation of the Zp promoter elements in the -221 region of the promoter.  
Signalling from the B-cell receptor (BCR) complex in response to anti-IgG modifies transcription 
factors bound to Zp promoter elements.  These events include dephosphorylation of MEF2D 
and phosphorylation of CREB and ATF.  X’s denote the approximate locations of pHEBo:Zp-luc 
mutations 1 - 8 used in this study.  (B)  Sequence of Zp -221 promoter region.  The ZIA, ZIB, 
ZIC, ZID, ZIIIA, ZIIIB, ZII and ZV promoter elements are shown.  Sequences altered in site 
directed mutants 1 - 8 (M1 - 8) and the XhoI site are indicated below the nucleotide sequence.  
The CpG motif which overlaps the XBP-1 binding site is underlined and the mutated sequence 
is below (Mutant CG).  The start of the BZLF1 protein sequence is shown in one letter amino 
acid code above the nucleotide sequence.  The TATA box sequence TTTAAA is also identified.       
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Luciferase activity in this system corresponds directly to Zp promoter 
activity in response to anti-IgG.  In all of the luciferase assays in this chapter, 
each time point represents the average value of three clones assayed 
independently and in duplicate.  Therefore there are at least six determinations 
behind each data point.  The results were also normalised to protein 
concentration, percent of lytic cycle induction and plasmid copy number.  There 
were only minor variations in these factors but the normalisation greatly 
improved the reproducibility of the data between cell lines. 
The percent induction for each cell line was assayed by flow cytometry at 
24 hours.  Cells were fixed in methanol and stained for BZLF1 with the BZ1 
monoclonal antibody and a secondary FITC-conjugated antibody.  Background 
staining was set to 1% in secondary only stained cells and gating was used to 
exclude dead cells.  The percent induction was determined for each cell line, 
measured as an increase in fluorescence in BZLF1 stained cells compared to 
secondary only stained cells.  Figure 3.2 shows a representative flow cytometry 
experiment.  In all cell lines, 10 to 15% of the cells were induced by anti-IgG.   
 
 
Figure 3.2.  FACS analysis to determine frequency of induction  
Cells were induced with anti-IgG for 24 hours and stained for BZLF1 with BZ-1 antibody and an 
anti-mouse IgG FITC-conjugate.  In anti-mouse FITC only stained cells the background staining 
was set to 1%.  An increase in fluorescence was observed in BZ-1 stained cells (12%).   Dead 
cells and cell debris were excluded through gating (R1).      
BZ-1 
12% 
anti-mouse-FITC 
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Figure 3.3.  Southern blot of Zp mutants to compare plasmid copy number 
Top:  Southern blot analysis of AK2003 stable cells lines carrying Zp mutant plasmids (Mut1 - 
5).  pHEBo:Zp-luc plasmids were probed with pGL2 DNA.  The marker on the right is the wild 
type pHEBo:Zp-luc plasmid (vector).  Zp mutants that incorporated an additional EcoRI 
restriction site at the mutation (Mut1 and Mut2) gave shorter fragments.  pHEBo-luc (luc) lacks 
Zp and gave a shorter fragment than the wild type (wt).  Bottom:  Total DNA was digested with 
EcoRI restriction enzyme and fractionated on a 1% agarose gel. 
 
The luciferase data was corrected for plasmid copy number in each cell 
line by Southern blot analysis.  Total DNA was extracted from the cells, 
digested with EcoRI and fractionated on an agarose gel.  The wild type 
pHEBo:Zp-luc plasmid was also digested and included as a control.  The 
reporter plasmids were detected with a probe from the pGL2 plasmid against 
the luciferase reporter gene.  Phosphoimager analysis was used to compare 
plasmid copy number relative to the wild type samples.  Figure 3.3 shows a 
representative blot with pHEBo:Zp-luc Mutants 1 to 5.  Zp mutations that 
incorporated an additional EcoRI restriction site gave shorter fragments than 
the wild type (Mutants 1 and 2).  There were less than two fold changes in 
plasmid copy number in all experiments. 
Loading 
control 
wt Mut3 luc Mut4 Mut1 Mut2 Mut5 vector 
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3.2.2  pHEBo-Zp-luc mutations 
Because of the large numbers of cell lines required to analyse the Zp mutations, 
cell lines were divided into two groups, Mutants 1 to 5 and Mutants 6 to 8 
(Figure 3.4A and 3.4B respectively).  Mutant CG was analysed separately 
(Figure 3.5).  In each experiment mutant clones were analysed along with the 
wild type promoter plasmid and an empty vector control.  In all experiments 
luciferase activity of the wild type plasmid rose rapidly after anti-IgG treatment 
and increased steadily up to 12 hours post induction.  Luciferase activity for the 
empty vector control remained low throughout the time course and reached a 
maximum of 9% activity relative to the wild type, although, at early time points 
(2 to 6 hours) there was very little induction.  
The Mutant 1, 6 and 8 mutations caused minor changes in promoter 
activity relative to the wild type with maximum decreases in luciferase activity of 
20 to 30% throughout the time course, indicating that these regions of the 
promoter contribute moderately to promoter activity.   The Mutant 2 and Mutant 
3 mutations caused 50% and 40% decreases in promoter activity respectively, 
at 2, 4 and 8 hours.  Mutant 4, which carries a mutation in the ZID promoter site 
(Figure 3.1), was severely impaired in promoter activity at the early time points, 
with an 80% decrease in activity at 2 hours and a 70% decrease at 4 hours, 
relative to the wild type promoter plasmid.  Luciferase activity increased at the 
later time points but continued to lag behind the wild type.  Mutant 7 also had 
low promoter activity with a 60% reduction in activity at 2 and 4 hours and a 
40% reduction at 8 and 12 hours relative to the wild type.  Mutant CG, which 
carries a mutation in the second putative XBP-1 binding and the single CpG 
motif in the -221 promoter region, caused a 2.5 fold increase in basal 
transcription but had little effect on anti-IgG induction (Figure 3.5).   
The anti-IgG time course was repeated with a selection of mutant cell 
lines, Mutants 1 to 4 and Mutant 7 (Figure 3.4C).  The results were similar to the 
previous experiments.  A 30 to 40% reduction in promoter activity was found in 
Mutant 1 cell lines.  The Mutant 2 mutation again caused a 50% decrease in 
promoter activity relative to the wild type promoter plasmid.  Mutant 3 only 
caused a 20% reduction in promoter activity at 2, 4 and 8 hours, less than the 
previous experiment.  Mutant 4 cell lines again had very low promoter activity at 
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2 and 4 hours with an 80 to 90% reduction in activity.  Mutant 7 cell lines had a 
70% reduction in promoter activity at 2 and 4 hours. 
 
Figure 3.4.  Luciferase assay for pHEBo:Zp-luc Mutants 1 - 8   
(A)  Luciferase assay of AK2003 cells lines carrying pHEBo:Zp-luc Mutants 1 - 5 (Mut1 - 5) 
compared to wild type Zp (WT) and the empty vector control (luc).  Cells were treated with anti-
IgG and harvested at the times indicated.  The luciferase activity in kilo-relative light units 
(kRLU) was normalised for protein concentration, plasmid copy number and proportion of cells 
induced.  The results represent the average for three clones assayed in duplicate.  (B)  
Luciferase assay for AK2003 cells transfected with pHEBo:Zp-luc Mutants 6 - 8 (Mut6 - 8).  (C)  
Repeat luciferase assays for AK2003 cells carrying pHEBo:Zp-luc Mutants 1 - 4 and Mutant 7.  
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Figure 3.5.  Luciferase assay for pHEBo:Zp-luc Mutant CG 
Luciferase activity of AK2003 cells carrying pHEBo:Zp-luc Mutant CG (MutCG) compared to 
wild type Zp (WT) and the empty vector control (luc).  (A)  Comparison of basal expression 
levels of luciferase activity.  Untreated cells were assayed for luciferase activity in kilo-relative 
light units (kRLU).  (B)  AK2003 cell lines were treated with anti-IgG and harvested at the time 
points indicated.  The luciferase activity was normalised as in Figure 3.4.  The results represent 
the average for three clones assayed in duplicate.   
 
The Mutant 2, 4 and 7 mutations caused the most significant decreases 
in promoter activity in response to anti-IgG induction.  Mutant 2 and Mutant 7 
lagged behind the wild type at all of the time points.  Mutant 2 introduced a 
mutation in between the ZIB and ZIC promoter elements and Mutant 7 
introduced a mutation in between the ZII element and the TATA box (Figure 
3.1).  Mutant 4 on the other hand had very low promoter activity at the early 
time points but activity increased after 4 hours.  Mutant 4 introduced a mutation 
in the ZID promoter site. 
It was previously shown that ZID is important during reactivation (Jenkins 
et al., 2000) but this site was never mutated in a quantitative system.  Here it is 
demonstrated that the ZID promoter site is functionally important during the 
early stages of Zp activation but unlike the MIA/B and MIC mutants, activity 
seemed to recover at the later time points (Binne et al., 2002).   
The Mutant 2 and Mutant 7 mutations also caused significant decreases 
in transcription, indicating that these promoter regions contribute to Zp promoter 
regulation.  Although, these sites do not appear to be essential as pHEBo:Zp-
luc constructs with mutations in these regions retained significant Zp activity in 
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response to anti-IgG.  Rather than performing extensive mutagenesis in these 
regions, electrophoretic mobility shift assays (EMSAs) were used to determine if 
any factors bind to these sites, as it would only be possible to do follow up 
studies on the sites if factors could be identified.     
Double stranded oligonucleotides were designed spanning the regions in 
between ZIB and ZIC (Site 2), ZII and the TATA box (Site 7) and the ZID 
element (ZID), encompassing the sites mutated in Mutant 2, Mutant 7 and 
Mutant 4 respectively.  Site 2, Site 7 and ZID were labelled and used as probes 
in EMSAs to test their ability to bind factors in both control and anti-IgG treated 
AK2003 nuclear extracts. 
No specific factors bound to either the Site 2 or Site 7 probes indicating 
that these sites do not bind any transcription factors in Akata cells or the 
conditions in this assay were not suitable for their detection (Figure 3.6).  One 
specific complex was detected binding to the ZID probe in both control and anti-
IgG nuclear extracts, observed as a shift in the labelled DNA probe (Figure 
3.7A).  The shift was specific since it was competed away with 100 fold excess 
of the same non-radioactive sequence but not with 100 fold excess of an 
unrelated non-specific competitor or the sequence containing the Mutant 4 
mutation.  An additional faster migrating complex was also observed but this 
complex was non-specific.     
These results were consistent with the observation that the DNA 
footprinting profile in this region did not change with anti-IgG induction 
(Flemington & Speck, 1990d).  The ZID site was previously reported to bind 
MEF2D, Sp1 and Sp3 and four separate complexes were observed in EMSAs 
with DG75 nuclear extracts, one corresponding to the MEF2D-DNA complex 
and the other three corresponding to both Sp1- and Sp3-DNA complexes (Liu et 
al., 1997a; Liu et al., 1997b).  Only one specific complex was detected in this 
assay and it was specifically supershifted with an anti-MEF2 antibody but not 
with a control (Rb) antibody (Figure 3.7B).   
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Figure 3.6.  Electrophoretic mobility shift assays with Site 2 and Site 7 probes   
Nuclear extracts from control (C) and anti-IgG (Ig) treated AK2003 nuclear extracts were tested 
for their ability to bind to Site 2 and Site 7 probes.  Binding was competed with 100 fold excess 
of unlabelled wild type competitor (WT), a non-specific competitor (NS) or oligonucleotides 
containing the Mutant 2 and Mutant 7 mutations (Mut).  No specific complexes were identified 
binding to either of these sites.   
- + - - - - - + - 
- + - - - - - + - 
- + - - - - - + - WT comp 
NS comp 
Mut comp 
Extract C C C Ig Ig Ig Ig C - 
Labelled probe 
      Site 2                          Site 7 
- + - - - - - + - 
- + - - - - - + - 
- + - - - - - + - 
C C C Ig Ig Ig Ig C - 
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Figure 3.7.  EMSAs with an oligonucleotide spanning the ZID site 
(A)  Nuclear extracts from AK2003 cells, uninduced (C) or induced with anti-IgG (Ig) for 10 
minutes, were tested for their ability to bind a ZID probe (double stranded; 
CACACCTAAATTTAGCACGT).  Complexes were tested for specificity by competition with 100 
fold excess of unlabelled ZID oligonucleotide (WT comp), a non-specific oligonucleotide (NS 
comp) or the ZID oligonucleotide containing the Mutant 4 mutation (Mut-4 comp).  (B)  The ZID 
complex was supershifted with an anti-MEF2 antibody but not with two control antibodies.  
Competition was performed as above.  Specific complexes and the supershifted complex are 
marked by arrows.         
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3.2.3 The ZID MEF2 binding site maps to the CTAAATTTAG 
palindrome 
The ZID and ZII promoter region contains multiple binding sites for several 
transcription factors including ATF1, CREB, XBP-1, MEF2D, Sp1 and Sp3.  
Many of these binding sites overlap so it is difficult to relate the function of 
specific factors to Zp regulation.  The ZID MEF2 binding site was therefore 
mapped in detail, using competition EMSAs, to define this binding site and 
separate it from the adjacent ZIIR and ZII binding sites.   
The competition assays tested the ability of a panel of non-radioactive 
ZID mutant double stranded oligonucleotides to compete with binding of Akata 
nuclear extracts to the labelled ZID probe in EMSAs.  In the first set of 
experiments pairs of consecutive bases were mutated along the sequence and 
wild type binding was competed with either 100 fold excess of the wild type 
double stranded non-radioactive sequence or mutated sequences (Figure 3.8, 
top panel).  The wild type sequence competed away binding of the labelled 
probe.  Mutation of nucleotides required for binding, affected the ability of these 
sequences to compete with wild type binding activity. For example, 100 fold 
excess of the ZID 10/11 sequence, with the corresponding Mutant 4 mutation, 
was unable to compete away binding of the labelled probe, indicating that these 
bases are essential for binding.  On the other hand, ZID 4/5 competed away 
binding as well as the wild type competitor, indicating that these bases do not 
form part of the binding site.  Mutation of consecutive nucleotides along the ZID 
sequence mapped the MEF2 binding site to the palindrome TAAATTTA (7-14). 
The competition EMSAs were repeated with a selection of mutated 
sequences to confirm the binding site.  Competition assays were also 
performed with oligonucleotides where individual bases in the ZID probe were 
mutated, from bases 6 to 15, and a double mutant where bases 6 and 15 were 
mutated (Figure 3.8, bottom panel).  The bases at positions 7, 12, 13, and 14 
were the most important bases in the binding site when individually mutated and 
sequences containing these mutations were unable to compete with binding of 
the ZID probe.  When bases 6 and 15 were individually mutated binding was 
competed away almost as well as with the wild type sequence but when both 
were mutated together they had a larger effect on complex formation, indicating 
that these bases contribute slightly to the binding site. 
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Figure 3.8.  Mapping of ZID MEF2D binding site using competition EMSAs 
Assays were performed with nuclear extract from uninduced AK2003 cells and the labelled ZID 
probe.  ZID binding was competed with 100 fold excess of unlabelled oligonucleotides with 
mutations spanning the ZID probe.  The numbers above each lane indicate the bases mutated 
in the competition oligonucleotide.  The mutations are indicated below the ZID probe sequence.  
Complexes were tested for specificity by competition with 100 fold excess of unlabelled ZID 
oligonucleotide (WT) or a non-specific oligonucleotide (ns).  No extract was present in the free 
probe lanes (Probe).    
ZID probe:  1CACACCTAAATTTAGCACGT20 
                     .......................         
mutations:  1TGTGTTGCGGCCGCATGATC20 
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  In summary, these results indicated the maximum binding site required 
for binding of MEF2D to the promoter site is the palindrome CTAAATTTAG and 
other nucleotides in this region are not required.  Having fine mapped the ZID 
MEF2 binding site in vitro, the binding site was confirmed using the pHEBo:Zp-
luc reporter assay.  Additional mutations were introduced into the pHEBo:Zp-luc 
reporter plasmid and the mutated plasmids were stably transfected into AK2003 
cells. 
 
Figure 3.9.  Confirmation of ZID MEF2D binding site function 
Luciferase activity of AK2003 cells carrying pHEBo:Zp-luc plasmids with mutations in the ZID 
promoter site compared to wild type Zp (WT) and the empty vector control (luc).  AK2003 cell 
lines were treated with anti-IgG and harvested at the time points indicated.  The luciferase 
activity in kilo-relative light units (kRLU) was normalised as in Figure 3.4.  The results represent 
the average for three clones assayed in duplicate.   
 
The promoter mutations were tested for their impact on anti-IgG 
responsiveness (Figure 3.9).  Wild type promoter activity rose rapidly after anti-
IgG treatment and continued to increase until 12 hours post induction.  
Luciferase activity from the empty vector control remained low throughout the 
experiment.  Mutation of nucleotides corresponding to the ZID probe 16/17 sites 
(Mut(16/17)), which lie outside the palindrome, had little effect on luciferase 
activity compared to the wild type throughout the time course.  On the other 
hand, mutations corresponding to nucleotides 7/14 in the ZID probe (Mut(7/14)), 
which were identified as core nucleotides in the binding site, caused a 
significant decrease in promoter activity at the early time points, relative to the 
wild type promoter plasmid.  Promoter activity was reduced by 70% 2 and 4 
h post induction 
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hours post induction but began to catch up with the wild type promoter at the 
later time points, paralleling the activity of the Mutant 4 plasmid.  These results 
confirmed that the ZID MEF2D binding site maps to the CTAAATTTAG 
palindrome and binding does not require nucleotides outside this region.   
The role of MEF2D in lytic cycle reactivation in the Akata system was 
investigated previously (Bryant & Farrell, 2002).  MEF2D becomes rapidly 
dephosphorylated after anti-IgG treatment in Akata BL cell lines.  The 
dephosphorylated form of MEF2D is associated with histone acetylation and 
relief of repressive chromatin structures, and is believed to play a key role in 
lytic cycle reactivation.  Data presented here provides the first quantitative study 
on the temporal importance of the ZID MEF2 site.  
 
3.2.4  XBP-1 splicing is induced rapidly in response to anti-IgG 
induction  
The plasma cell transcription factor XBP-1s was recently implicated in Zp 
activation (Bhende et al., 2007; Sun & Thorley-Lawson, 2007) but the 
involvement of XBP-1 in lytic cycle induction in the Akata system has not been 
studied.  There are no reports of XBP-1 splicing in response to anti-IgG 
induction at the early time points associated with lytic reactivation in Akata cells.  
However, previous studies in B cell lymphoma cell lines indicated that XBP-1s 
activation can occur prior to significant upregulation of immunoglobulin 
production (Gass et al., 2002) and BCR signalling was identified as a UPR 
trigger (Skalet et al., 2005).   
Previous studies demonstrated XBP-1 splicing in response to BCR 
signalling between 12 and 24 hours.  In primary B cells, XBP-1 splicing was 
increased 24 hours post anti-Ig treatment (Skalet et al., 2005).  Also, in mouse 
B cell lymphoma cell lines, anti-Ig antibodies increased XBP-1s proteins levels 
after 12 hours induction (Yan et al., 2008).  Zp activation in Akata cells is a rapid 
process, however, and between 12 and 24 hours post induction the late lytic 
cycle is already in progress.  It is also of note that XBP-1 splicing increased in 
response to antigen induced apoptosis in primary B cells (Yan et al., 2008).  
Anti-Ig was previously shown to induce apoptosis in EBV negative BL cell lines 
but the EBV genome was associated with protection from cell death in Akata 
cells (Inman et al., 2001).  
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In order to determine if XBP-1s could be involved in the rapid early 
induction of the lytic cycle in Akata cells, first it was necessary to determine if 
XBP-1 splicing is activated at these early time points relevant to Zp reactivation.  
XBP-1 splicing was examined in response to anti-IgG induction in AK2003 cells 
by RT-PCR analysis, with primers specific for XBP-1 and GAPDH as a control.  
The XBP-1 RT-PCR primers distinguish between the spliced and unspliced 
transcripts by amplifying across the XBP-1 intron (Figure 3.10A).  XBP-1 mRNA 
contains two open reading frames, ORF1 and ORF2.  In unstressed cells XBP-
1u is encoded from ORF1.  In response to ER stress, IRE1 excises the 26 bp 
intron containing a PstI restriction enzyme site.  This results in a frameshift and 
fusion of ORF1 and ORF2, which encodes the larger and transcriptionally active 
form of the protein, XBP-1s.  Amplification across the XBP-1 intron produced a 
249 bp amplicon from XBP-1u mRNA and a 223 bp amplicon from XBP-1s 
mRNA.  PstI restriction digestion was used to distinguish between the two 
forms; only the XBP-1u amplicon contains the PstI restriction site and digestion 
results in two smaller bands.      
AK2003 cells were treated with anti-IgG and cells were harvested at 
different times post induction over a 48 hour time course.  Cells were also 
separately treated with 2mM DTT for 1 hour to induce ER stress.  The XBP-1 
PCR products were digested with PstI restriction enzyme and both undigested 
and digested products were fractionated on an agarose gel along with the 
GAPDH controls (Figure 3.10B).  In uninduced AK2003 cells, the XBP-1u 
amplicon was detected and was digested with PstI.  Low basal expression of 
XBP-1s was also detected.  Treatment of AK2003 cells with DTT resulted in 
efficient XBP-1s processing, indicating that the machinery required for detecting 
ER stress and processing XBP-1 mRNA is functional in Akata cells.  An 
increase in the XBP-1s transcript was observed after 30 minutes of anti-IgG 
treatment.  XBP-1s expression peaked at 2 hours and was not detectable by 4 
hours.  This suggests that XBP-1 splicing is induced rapidly after anti-IgG 
treatment in Akata BL cell lines but its expression is transient.  Similar results 
were found in EBV negative AK31 cells indicating that the presence of EBV 
does not substantially influence splicing of XBP-1 transcripts in response to 
anti-IgG treatment.   
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Figure 3.10.  RT-PCR analysis of XBP-1 splicing in AK2003 cells 
(A)  Schematic representation of unspliced and spliced forms of XBP-1 mRNA and protein 
coding regions.  XBP-1u is encoded from ORF1.  Splicing of the 26 bp intron generates a 
frameshift and fusion of ORF1 and ORF2 yielding the larger protein product, XBP-1s.  RT-PCR 
primers (P1 and P2) are indicated above the protein coding regions and the sizes of the 
respective PCR amplicons are indicated.  Only the XBP-1u amplicon contains a PstI restriction 
site.  (B)  RT-PCR analysis of XBP-1 splicing in AK2003 cells in response to anti-IgG induction.  
Cells were treated with anti-IgG and harvested at the time points indicated.  Total RNA was 
extracted and reverse transcribed into cDNA.  cDNA was amplified with primers specific for 
XBP-1 (Top) and GAPDH (bottom).  XBP-1 PCR products were digested with PstI restriction 
enzyme overnight.  PstI only digests the XBP-1u amplicon.   
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  Most of the primary events involved in Zp reactivation occur within just 30 
minutes of anti-IgG treatment in Akata cells (Bryant & Farrell, 2002).  MEF2D 
becomes dephosphorylated within 10 minutes of anti-IgG induction and BZLF1 
binds to Zp within 30 minutes.  Here XBP-1 splicing was induced rapidly after 
anti-IgG treatment and in a similar time course to these primary events in Zp 
reactivation, suggesting a potential role for XBP-1s in reactivation in the Akata 
system.  To try to examine the role of XBP-1s in lytic cycle reactivation some 
preliminary XBP-1 knockdown experiments were performed.  These techniques 
require further optimisation as efficient XBP-1 knockdown was not achieved. 
Five small hairpin RNA (shRNA) constructs were designed targeting 
XBP-1 mRNA and were cloned into the pHEBo:Super expression plasmid.  The 
pHEBo:Super plasmid contains an oriP sequence and the hygromycin 
resistance gene allowing stable transfection of the plasmid into EBV infected 
cells.  The shRNA constructs are transcribed from a H1 RNA polymerase 
promoter.  The five constructs and a control shRNA construct, that does not 
target any specific sequences, were transfected into AK2003 cell lines by 
electroporation and cells were selected with hygromycin.  Cells were harvested 
3 days post selection and XBP-1 expression was monitored by RT-PCR 
analysis (Figure 3.11A).  None of the constructs affected XBP-1 expression.   
The next approach was to try to knock down XBP-1 with a small 
interfering RNA (siRNA) targeted against XBP-1 (Bhende et al., 2007).  20, 40 
and 80 pmoles of XBP-1 siRNA and a control siRNA were transfected into 
AK2003 cells by electroporation.  XBP-1 expression was monitored 3 and 6 
days post transfection (Figure 3.11B).  The siRNA had no effect on XBP-1 
mRNA.  Experiments were repeated with increasing amounts of XBP-1 siRNA 
but again had no effect on XBP-1 transcripts.       
The most likely explanation for these results is that transfection 
efficiencies in the AK2003 cells were too low to achieve detectable levels of 
knockdown.  Due to time restriction it was not possible to improve the 
transfection protocol in these cells.  Given the transient expression of XBP-1s in 
response to anti-IgG induction it would be interesting to study the role of this 
factor in the Akata system and determine its contribution to lytic cycle 
reactivation.   
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Figure 3.11.  RT-PCR analysis of shRNA and siRNA transfected AK2003 cells 
(A)  AK2003 cells were transfected with 5 shRNA constructs targeting XBP-1 mRNA or a control 
shRNA construct for 3 days.  (B) 5 x 106 cells were transfected with 20, 40 or 80 pmoles of an 
siRNA directed against XBP-1 (X) or equal amounts of a control siRNA (C) for 3 and 6 days.    
 
3.2.5  An inducible BZLF1 expression system in AK2003 cells 
The Zp promoter is protected from reactivation during latency and evidence 
suggests that the Zp promoter is regulated by a repressive chromatin structure 
(Jenkins et al., 2000).  Transfection of BZLF1 into EBV infected cells results in 
expression of the early genes BRLF1 and BMRF1 but the endogenous Zp 
promoter is initially protected from reactivation in the absence of signal 
transduction (Kolman et al., 1996; Le Roux et al., 1996).  This is in contrast with 
transient transfection assays where the Zp responds to BZLF1 activation 
(Flemington & Speck, 1990a).  Histone acetylation is a key event during 
activation of the Zp promoter and the importance of the MEF2D protein in the 
recruitment of histone acetylases during viral reactivation has been established 
(Bryant & Farrell, 2002; Jenkins et al., 2000).   
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The aim of this part of the work was to develop a suitable system to 
study the repressive chromatin structure at Zp, present in the endogenous 
genome.  By reconstituting this repressive chromatin structure on stably 
transfected Zp reporter plasmids it might be possible to map promoter elements 
involved in establishing the repressive state, which can be identified by the 
resistance to BZLF1 activation.  An inducible BZLF1 expression system, 
independent of BCR signalling, was developed in AK2003 cell lines using a 
hormone binding domain fusion protein for BZLF1.  The system was based on 
the pcDNA3-ZHT plasmid which codes for the B95-8 BZLF1 protein fused to a 
318 amino acid mutant murine estrogen receptor (ZHT), which is unable to bind 
estrogen but retains normal affinity for 4-hydroxytamoxifen (4HT), a synthetic 
ligand (Johannsen et al., 2004; Littlewood et al., 1995).  The ZHT fusion protein 
remains inactive in the cytoplasm in the absence of 4HT, where it is 
sequestered by intracellular polypeptides forming inhibitory complexes.  Binding 
of 4HT releases the ZHT fusion protein from the inhibitory complexes and 
translocates it to the nucleus, where it is stabilised and becomes functionally 
active (Johannsen et al., 2004).   
The ZHT fusion protein was cloned from pcDNA3-ZHT into a puromycin 
resistant vector containing the oriP sequence (Puro:oriP), allowing maintenance 
of the plasmid in EBV infected cells (by C. Elgueta).  The Puro:oriP-ZHT 
plasmid was transfected into AK2003 cells by electroporation and stable cell 
lines were isolated by puromycin selection over several weeks (AKZHT).   
The AKZHT cell lines were treated with anti-IgG or 4HT for 16 hours and 
cell lysates were Western blotted for BZLF1 expression (Figure 3.12).  In 
untreated cells the ZHT fusion protein was expressed but endogenous BZLF1 
expression was not detectable.  In cells treated with 4HT, ZHT expression 
increased as the protein was translocated to the nucleus but there was no 
detectable increase in endogenous BZLF1, indicating that the ZHT fusion 
protein is unable to activate the endogenous Zp promoter.  Anti-IgG treatment 
increased expression of endogenous BZLF1, confirming the presence of the 
latent genome in these cells.  Expression of the ZHT fusion protein also 
increased in response to anti-IgG.  The fusion protein should not have access to 
the endogenous Zp promoter after anti-IgG treatment as the protein is 
sequestered in the cytoplasm in the absence of 4HT.  Therefore the increase in 
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ZHT expression in response to anti-IgG should not have affected endogenous 
BZLF1 expression.  B95-8ZHT cells were treated with 4HT as a control.  Lytic 
gene expression is not regulated as tightly in this marmoset LCL and the 
endogenous Zp promoter is readily activated by BZLF1.  Activation of the ZHT 
fusion protein leads to expression of endogenous B95-8 BZLF1. 
  In the Puro:oriP plasmid the ZHT protein is under the control of the 
CMV promoter.  The CMV promoter contains an AP1 site which is responsive to 
anti-IgG and explains the increase in ZHT expression in response to anti-IgG 
treatment.  To confirm that increased levels of ZHT did not cause an increase in 
endogenous BZLF1 expression, AKZHT cells were treated with TPA and cell 
lysates were Western blotted for BZLF1 expression (Figure 3.13).  TPA 
activates via AP1 promoter elements but is unable to induce BZLF1 expression 
in Akata cells (Shimizu & Takada, 1993).  TPA caused an increase in ZHT 
expression in the absence of 4HT but did not increase the levels of endogenous 
BZLF1.   
The AKZHT cell lysates were also blotted for BMRF1 expression (Figure 
3.12).  BMRF1 was not expressed in control cells but was expressed after both 
anti-IgG and 4HT treatment.  Similar BMRF1 expression levels were detected in 
clone 1 (c1) cell lines treated with either anti-IgG or 4HT.  In clone 2 (c2) cell 
lines BMRF1 expression was lower with 4HT treatment.  The AKZHT clone 1 
cell line was used for the remaining experiments.    
 
Figure 3.12.  Western blot analysis of AKZHT and B95-8ZHT cell lines 
Cells were treated with anti-IgG or 4HT for 16 hours.  Cell lysates were analysed by Western 
blotting for BZLF1 (Top) and BMRF1 (Bottom).  The ZHT fusion protein and endogenous BZLF1 
are indicated.   
C Ig HT C Ig HT C HT
AKZHT.c1 AKZHT.c2 B958
ZHT
BZLF1
BMRF1
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Figure 3.13.  Western blot analysis of AKZHT cells in response to TPA 
AKZHT cells were treated with TPA and harvested at the time points indicated.  B95-8ZHT 
(B958) cells were treated with 4HT as a control.  Cell lysates were analysed by Western blotting 
for BZLF1.  The ZHT fusion protein and endogenous BZLF1 are indicated. 
 
These results indicated that the ZHT fusion protein is functional in 
AK2003 cells and as shown previously BZLF1 can transactivate early gene 
expression but is unable to activate the endogenous Zp promoter (Kolman et 
al., 1996; Le Roux et al., 1996).  To further analyse this inducible BZLF1 
expression system, AKZHT cells were treated with anti-IgG or 4HT for 12, 24 
and 48 hours and cell lysates were Western blotted for immediate early 
(BZLF1), early (BMRF1) and late (BdRF1) gene expression (Figure 3.14).  
Endogenous BZLF1 expression was detectable after 24 and 48 hours treatment 
with 4HT but expression levels were significantly less than those detected after 
anti-IgG treatment.  BMRF1 expression had increased by 12 hours in 4HT 
treated cells and reached equivalent expression levels as anti-IgG treated cells 
by 24 hours.  BdRF1 expression was not detectable in either anti-IgG or 4HT 
treated cell at 12 hours.  Expression was lower in 4HT treated cell than anti-IgG 
treated cells at 24 hours but levels were equivalent at 48 hours.   
These results indicate that the ZHT fusion protein can cause induction of 
both early and late gene promoters but not the endogenous Zp promoter, as 
reported previously for the wild type BZLF1 protein (Kolman et al., 1996; Le 
Roux et al., 1996).  Therefore the ZHT fusion protein accurately mimics BZLF1 
activity in response to 4HT activation and provides a new system to study 
repression at the Zp promoter in AK2003 cells.  This novel system allows 
expression of ZHT in the absence of signalling from the BCR and due to its 
0h 4h2h 6h 4HT
ZHT
BZLF1
TPA
AKZHT B958
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stable expression can be used to study the repressive chromatin structure at Zp 
on the latent genome.         
 
Figure 3.14.  ZHT induces early and late gene expression in AKZHT cells   
AKZHT cells were uninduced (C) or induced with anti-IgG (Ig) or 4HT (HT) and harvested at the 
time points indicated.  Cell lysates were analysed by Western blotting for BZLF1, BMRF1, 
BdRF1 and actin (loading control).     
 
Having established a stable cell line expressing the ZHT fusion protein 
the next step would be to reconstitute the repressive chromatin structure at Zp 
on a stably transfected reporter plasmid.  The ZHT fusion protein would be used 
to test if Zp regulation was correctly reconstituted.  If achieved, mutagenesis of 
the promoter would map regions required to maintain latency and relieve the 
repressive chromatin structure at Zp during reactivation. Preliminary 
experiments were performed to try to develop a system stably expressing both 
the ZHT fusion protein and a stably transfected Zp reporter plasmid but some 
problems were encountered with plasmid stability in these cell lines.     
The AKZHT cell line was subsequently transfected with the pHEBo:Zp-
luc reporter plasmid and stable cell lines were selected with both hygromycin 
and puromycin.  Stable transfection was essential in order to maintain a 
chromatin structure similar to that of the endogenous Zp promoter.  However, 
the stable cell lines lost expression of the ZHT fusion protein over time (data not 
ZHT
BZLF1
BMRF1
BdRF1
Actin
C Ig HT Ig HT Ig HT
12h 24h 48h
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shown), possibly due to selective pressure on the cells to maintain three oriP 
constructs; the EBV genome, Puro:oriP-ZHT and pHEBo:Zp-luc.   
The next approach was to integrate the pcDNA3-ZHT plasmid into the 
EBV genome as in the original B95-8ZHT cell line (Johannsen et al., 2004).  
This would eliminate the pressure on the cells to maintain multiple oriP 
plasmids.  pcDNA3-ZHT was linearised by restriction digestion with SalІ.  A 
puromycin resistant plasmid, pRG201, was also linearised by restriction 
digestion with XhoІ.  Both plasmids were cotransfected into AK2003 cells by 
electroporation in a ratio of 10:1 (ZHT:puromycin).  Stable cell lines were 
established with puromycin selection but when the cell lines were analysed, 
none expressed the ZHT protein (data not shown).   
The final approach was to revert back to an older system based on the 
p294:Zp-552 plasmid which was used to study Zp regulation in EBV negative 
Akata cells (Jenkins et al., 2000).  The plasmid contains the BZLF1 gene under 
the control of the Zp promoter.  It also contains an oriP sequence, a hygromycin 
resistance gene and an EBNA1 expression cassette, allowing plasmid 
maintenance in the absence of EBV.  EBV negative AK31 cells were 
transfected with the Puro:oriP-ZHT plasmid and following selection of stable cell 
lines, they were subsequently transfected with p294:Zp-552.  Stable cell lines 
were selected but again problems were encountered with plasmid maintenance 
in this system (data not shown).   
It is possible that the ZHT plasmid is slightly toxic in Akata cells and 
cotransfection with another oriP plasmid selects against ZHT protein 
expression.  Due to problems with plasmid maintenance further experiments 
were not conducted but this AKZHT system provides a novel approach to study 
repression at Zp, using physiological levels of the proteins and promoters, and 
could be developed further in the future. 
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3.3  Discussion  
 
BZLF1 is the immediate early gene in EBV and mediates the switch between 
latency and the lytic cycle.  Several promoter elements that bind both cellular 
and viral transcription factors have been identified, involved in both silencing 
and reactivation of the Zp promoter.  BCR signalling leads to modification of 
these factors and studies have shown that chromatin remodelling plays an 
important role in lytic cycle reactivation (Bryant & Farrell, 2002; Jenkins et al., 
2000). 
This study used a luciferase reporter system, based on the pHEBo:Zp-
luc reporter plasmid, to study the kinetics of Zp regulation.  The presence of the 
endogenous EBV genome provides all the trans-acting factors that regulate the 
promoter and the use of stably transfected cell lines allows the plasmids to 
establish a chromatin structure similar to the promoter on the viral genome.  
This system was previously used to study the effect of mutations in several 
known promoter elements and was shown to accurately mimic Zp regulation in 
EBV infected cells in response to anti-IgG treatment (Binne et al., 2002).  
Previous studies on Zp regulation focused on regions of the promoter 
protected in footprinting studies.  The main regulatory elements at Zp were 
identified in the -221 region of the promoter with the distal region of the 
promoter (-552 to -221) contributing minimally to Zp regulation.  The distal 
region of the promoter was reported to possess a negative regulatory role 
(Daibata et al., 1994; Shimizu & Takada, 1993) but it was concluded that this 
region does not account for the repressed state at Zp during latency (Jenkins et 
al., 2000).   
In order to determine if there were any additional regulatory domains at 
Zp further mutagenesis of the promoter was performed in the pHEBo:Zp-luc 
reporter plasmid.  Nine mutations were introduced in between the known 
promoter elements in the -221 region of the promoter and also around the ZID 
and ZII promoter region.  Most of the mutations had little effect on promoter 
activity in response to anti-IgG binding, suggesting that the important regulatory 
sites in Zp have been identified.  However, Mutants 2, 4 and 7 caused 
significant reductions in promoter activity, indicating that these sites contribute 
to Zp activity.   
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Mutant 2 introduced a mutation between the ZIB and ZIC elements and 
Mutant 7 introduced a mutation between the ZII site and the TATA box (Figure 
3.1).  No specific factors were detected binding to either of these regions in 
EMSAs.  It is therefore unclear why mutation of these sites caused a substantial 
reduction in luciferase activity.  There are two possibilities to be considered.  
The first possibility is simply that the assay conditions were not suitable for 
detecting the factors that bind to these sites and hence stable complexes could 
not be formed.  The second possibility is that there are no factors binding to 
these sites and the mutations are affecting binding of factors to adjacent 
promoter elements.  This could account for the decrease in promoter activity 
without any detectable binding to these regions in EMSAs.  The results indicate 
that these sites contribute to Zp activation but neither of the sites is essential as 
the mutants still retained significant levels of promoter activity in the reporter 
assays.  Since no factors were detected, further mutagenesis was not 
performed in these regions.   
Mutant 4 introduced a mutation into the ZID promoter site (Figure 3.1).  
ZID was originally identified in footprinting studies as a member of the ZI 
binding sites and can bind MEF2D, Sp1 and Sp3 (Flemington & Speck, 1990d; 
Liu et al., 1997a; Liu et al., 1997b).  Previous studies on ZID gave varying 
results with regard to its importance in Zp activation.  Deletion analysis of the Zp 
promoter indicated that ZID contributes minimally to Zp promoter activity in 
response to both anti-IgG and TPA (Daibata et al., 1994; Flemington & Speck, 
1990d).  Mutation of ZID in stably transfected episomes expressing BZLF1 
caused a significant reduction in anti-IgG responsiveness, indicating that ZID 
contributes to Zp activation (Jenkins et al., 2000).  Quantitative studies were 
never performed on the ZID site.  Here it is clearly demonstrated that ZID is 
functionally important during the early stages of Zp activation, in the presence of 
the endogenous EBV genome. 
These early time points are essential when studying Zp activation as 
factors bound to Zp become rapidly modified in response to anti-IgG induction 
(Bryant & Farrell, 2002).  Previous studies measured Zp activity 24 to 48 hours 
post induction and therefore did not reveal the effects of the ZID mutation on the 
early activation of Zp.  Autoactivation of the promoter occurs 3 hours post 
induction as pHEBo:Zp-luc plasmids carrying a mutation in the ZIIIB element 
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had similar activity to the wild type up to 3 hours but promoter activity 
decreased after this point (Binne et al., 2002).  Mutant 4 activity began to catch 
up with the wild type after 4 hours indicating that this site is important during the 
initial phase of activation, when no BZLF1 protein is present, but is dispensable 
at the later time points, perhaps due to expression of BZLF1 from the 
endogenous genome.  This differed from mutation of the other ZI elements 
(MIA/B and MIC), which rendered the Zp promoter unresponsive to anti-IgG 
induction at the early time points but activity only increased minimally at the 
later times (Binne et al., 2002).    
EMSAs were performed with a probe spanning the ZID promoter element 
to examine factors binding to this site in AK2003 nuclear extracts.  Previous 
EMSA analysis with DG75 nuclear extracts identified four ZID protein-DNA 
complexes (Borras et al., 1996).  One complex was identified as a MEF2D-DNA 
complex and the other three were identified as Sp1/Sp3-DNA complexes (Liu et 
al., 1997a; Liu et al., 1997b).  Only one specific complex was detected in the 
ZID EMSAs with AK2003 nuclear extracts and this complex was supershifted 
with an anti-MEF2 antibody.  This suggests that only MEF2D binds to this site in 
Akata cells and that the reduction in promoter activity in the pHEBo:Zp-luc 
Mutant 4 cell lines was due to disruption of MEF2D binding.   
Previous studies indicated that MEF2D plays a central role in lytic cycle 
reactivation in Akata cells by recruiting histone actetylase activity to the 
promoter in response to anti-IgG induction (Bryant & Farrell, 2002; Gruffat et al., 
2002).  On the other hand, no modification of either Sp1 or Sp3 was observed in 
Akata cells in response to anti-IgG induction and their physiological role in lytic 
cycle reactivation remains uncertain (Bryant & Farrell, 2002).  In the ZID 
element, the MEF2D and Sp1/Sp3 sites overlap and it is unlikely that these 
factors can occupy this promoter site at the same time.  It is therefore possible 
that the conditions in the Akata cells favour binding of MEF2D to this site.  
However, multiple complexes were previously detected binding to the ZIA/B site 
in EMSAs with Akata nuclear extracts, which has been shown to bind all three 
factors, and binding was detected in EMSAs to the ZIC site, which can bind Sp1 
and Sp3 (Bryant & Farrell, 2002).  It is possible that the conditions used in the 
EMSAs in this study were not suitable for detecting Sp1 and Sp3 binding and 
this could account for the absence of the additional three complexes.  Although, 
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the conditions used in the EMSAs were very similar to those used in the 
previous DG75 and Akata experiments (Borras et al., 1996; Bryant & Farrell, 
2002). 
pHEBo:Zp-luc Mutant 3 introduced a mutation overlapping the predicted 
Sp1 binding site in the ZID element (Figure 3.1), based on the binding sites 
identified in the ZIA and ZIC elements (Liu et al., 1997a).  The Mutant 3 
mutation had little effect on anti-IgG induction in the luciferase reporter assays, 
perhaps indicating that Sp1 and Sp3 do not play a significant role in anti-IgG 
induction through the ZID element in Akata cells. 
The ZID MEF2D binding site was mapped using competition EMSAs to 
distinguish this site from the surrounding ZII/ZIIR promoter region.  There is 
renewed interest in this region of the promoter since the discovery of the XBP-1 
binding sites.  The ZII/ZIIR region of the promoter contains overlapping binding 
sites for multiple transcription factors including ATF1, CREB and XBP-1 (Liu et 
al., 1998; Sun & Thorley-Lawson, 2007; Wang et al., 1997).  Competition 
EMSAs mapped the ZID binding site to the palindrome CTAAATTTAG at 
position -91 to -82 relative to the transcription start site, separating it from the 
adjacent ZII/ZIIR region.  The binding site was confirmed in luciferase reporter 
assays.  Having clarified the structure of the ZID MEF2D binding site, it was 
then possible to distinguish it from the surrounding binding sites and their role in 
the Akata system.   
Two putative XBP-1 motifs were identified in the ZII element, immediately 
downstream of the ZID site (Sun & Thorley-Lawson, 2007).  One motif overlaps 
the CRE binding site and by chance had already been mutated in the Zp MII 
mutation.  Quantitative analysis of the Zp promoter demonstrated that the ZII 
CRE site is important during the early stages of activation but is dispensable at 
the later time points (Binne et al., 2002).  Mutation of the second XBP-1 motif 
(Mutant CG mutation), upstream of the CRE binding site, had no effect on anti-
IgG responsiveness in AK2003 cells but caused a 2.5 fold increase in basal 
transcription.  This second XBP-1 binding site is in close proximity to the ZIIR 
site and also overlaps the only CpG motif in the -221 region of the promoter.  
The increase in basal transcription could be due to disruption of the ZIIR site or 
disruption of methylation at this CpG motif.  The ZIIR site was previously 
mutated in the Akata system and only caused a 1.6 fold increase in basal 
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transcription and had no effect on anti-IgG induction (Binne et al., 2002).  
Previous results also indicated that methylation of the promoter is not important 
for Zp regulation, which was reconstituted on Zp plasmids with no detectable 
DNA methylation (Jenkins et al., 2000).  Either way this is only a moderate 
repressive effect and could not account for the repressed state at the Zp 
promoter during latency.   
These results further highlight the complexity of the interactions in this 
region of the Zp promoter.  With so many overlapping binding sites it was not 
possible to decipher the exact factors binding to these regions or their effects on 
reactivation.  Therefore, in order to study the role of XBP-1 in lytic cycle 
induction another approach was required.    
There is a strong correlation between lytic cycle reactivation of EBV and 
plasma cell differentiation.  XBP-1s was implicated in lytic cycle reactivation in 
plasma cells in studies with multiple myeloma cell lines, where overexpression 
of XBP-1s upregulated endogenous BZLF1 transcripts (Sun & Thorley-Lawson, 
2007).  XBP-1 splicing was examined in response to anti-IgG induction in 
AK2003 cells.  Antigen stimulated memory cells differentiate towards the 
plasma cell stage and terminal differentiation, which is mimicked by crosslinking 
the BCR with anti-IgG.   
XBP-1 splicing was previously demonstrated in response to BCR 
signalling in primary B cells and mouse B cell lymphoma cell lines but these 
studies detected XBP-1 splicing 12 to 24 hours post induction (Gass et al., 
2002; Yan et al., 2008).  At these time points the entire lytic cascade is 
underway in Akata cells.  There were no previous studies on XBP-1 splicing in 
Akata cell lines and it was not known if XBP-1s is present during the initial 
events in lytic cycle reactivation.  XBP-1 splicing was monitored over a 48 hour 
time course in AK2003 cells in response to anti-IgG induction, focusing 
specifically around the early time points.  The results revealed that XBP-1s is 
induced rapidly in response to anti-IgG induction with an increase in detectable 
XBP-1s transcripts by 30 minutes.  Interestingly, this was a transient response.  
Splicing peaked at 2 hours post induction but there were no detectable XBP-1s 
transcripts by 4 hours.   
As already discussed, lytic cycle reactivation is a rapid process and the 
appearance of the transcriptionally active form of XBP-1 within 30 minutes of 
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anti-IgG treatment indicates that it could indeed play a role in Zp reactivation in 
the Akata system.  RT-PCR is only a semi-quantitative method and it is possible 
that there are increases even earlier than 30 minutes post anti-IgG treatment 
that could be detected using the more sensitive technique of QPCR.  The 
transient nature of XBP-1 splicing parallels the transient activation of the Zp 
promoter.  In nuclear run on studies in Akata cells, Zp transcription peaked 
between 1 and 2 hours after anti-IgG treatment and reduced again to basal 
levels of transcription by 4 hours (Mellinghoff et al., 1991).  Another study 
showed maximum levels of BZLF1 mRNA after 4 hours of anti-IgG treatment 
that returned to undetectable levels by 6 hours (Takada & Ono, 1989). 
XBP-1s activated endogenous BZLF1 transcripts in multiple myeloma 
cells (Sun & Thorley-Lawson, 2007) but required additional signalling to induce 
the lytic cycle in LCLs and epithelial cells (Bhende et al., 2007).  In order to 
determine if XBP-1s plays a direct role in lytic cycle reactivation in AK2003 
cells, knockdown experiments were conducted to test whether inhibiting XBP-1 
expression would affect lytic cycle induction in response to anti-IgG treatment.  
In these preliminary experiments none of the shRNA constructs or the siRNA 
tested had any effect on XBP-1 transcripts.  This was most likely due to low 
transfection efficiencies in the Akata cell lines, which are notoriously difficult to 
transfect.  It was not possible therefore to determine the role of XBP-1 in this 
system using this method of transfection.  If the transfection protocols were 
further optimised and other systems tested, such as Amaxa transfection, it may 
be possible to achieve higher transfection efficiencies in the AK2003 cells and 
see an effect on XBP-1 expression.  Given the transient expression of both 
XBP-1s and BZLF1 transcripts in response to anti-IgG, it is possible that the Zp 
promoter recruits this plasma cell specific transcription factor to contribute 
towards lytic cycle reactivation, a concept that will be investigated further in the 
future.     
Chromatin remodelling is an important factor in lytic cycle reactivation 
(Jenkins et al., 2000) and in order to fully understand Zp regulation it is 
necessary to determine how the repressive chromatin structure at Zp mediates 
latency and reactivation.  Repression at Zp is essential to ensure that the latent 
virus is not accidentally reactivated in the absence of the necessary signals but 
this repression must be overcome in response to lytic cycle reactivation.  To 
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understand this regulation it is necessary to map the promoter regions involved 
in maintaining this repressive state during latency and relieving it in response to 
viral reactivation. Firstly, however, a suitable system is required to study the 
repressive chromatin structure at Zp, present in the endogenous genome.       
An inducible BZLF1 expression system was developed in AK2003 cell 
lines, allowing BZLF1 expression in the absence of signal transduction from the 
BCR.  In AKZHT cell lines the ZHT fusion protein and endogenous BZLF1 were 
expressed at similar levels in response to 4HT and anti-IgG induction 
respectively, indicating that the ZHT protein was expressed at physiologically 
relevant levels.  The ZHT protein was functionally equivalent to BZLF1, inducing 
early and late gene expression in the absence of signal transduction and 
delayed BZLF1 expression.  Similar levels of late and early gene expression 
were achieved in AKZHT cell lines in response to both 4HT and anti-IgG 
treatment and the ZHT fusion protein was unable to activate the endogenous Zp 
promoter.     
There was a delay in early and late gene expression in response to 4HT 
treatment.  This may be because the ZHT protein is unable to reconstitute the 
rapid induction of the Zp promoter in response to BCR crosslinking.  It is also 
possible that endogenous BZLF1 is modified in response to BCR signalling and 
these modifications aid in transactivation of target promoters.  Despite this 
delay, the results with the ZHT fusion protein confirm the previous finding that 
BZLF1 cannot induce endogenous BZLF1 expression in the absence signalling 
events and demonstrate a conditional BZLF1 expression system that can be 
used to test the repressive state at Zp, present in the endogenous genome.  
These results indicate that the ZHT fusion protein accurately reconstitutes 
endogenous BZLF1 activity in Akata cells but the effect of strain differences 
between B95-8 and Akata BZLF1 have not been excluded.  There are eleven 
amino acid substitutions between the two proteins, most of which are located 
within the transactivation domain (Packham et al., 1993).  This could be 
checked in the future by making an Akata BZLF1 fusion protein and testing it in 
this system.        
Despite several efforts to establish stable cell lines expressing both the 
fusion protein and a Zp promoter plasmid, it was not possible to maintain ZHT 
protein expression in the presence of either of the Zp promoter plasmids tested.  
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The ZHT protein may be slightly toxic to the Akata cells and this may account 
for its lack of stability in the presence of additional oriP plasmids.  ZHT protein 
expression also decreased in AKZHT cells over time despite the fact that these 
cells still remained resistant to puromycin, indicating that the cells were 
selecting against ZHT expression.  The additional pressure on these cells to 
maintain multiple plasmids resulted in further repression of ZHT protein 
expression.  Due to the instability of this system it was not possible to perform 
further studies but this system may be adapted in the future.  This system 
provides a novel approach to study repression at Zp in the absence of 
signalling.  Since it is based on stably transfected cell lines, promoters can be 
assembled into nucleosomes and achieve chromatin structures comparable to 
endogenous promoters.   
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4.  Functional analysis of the BZLF1 structure  
 
4.1  Introduction 
 
Induction of BZLF1 is the first step in the reactivation of the lytic cycle of EBV 
(Amon et al., 2004; Countryman & Miller, 1985).  BZLF1 first acts as a 
sequence specific transcription factor, inducing other early lytic cycle genes.  As 
the lytic cycle progresses, BZLF1 also acts as a DNA replication factor and 
provides a lytic origin binding protein function for EBV replication (Schepers et 
al., 1993a).  It is unclear however how BZLF1 switches between these two 
functions during the lytic cycle.   
 bZIP transcription factors typically contain a transactivation domain, a 
basic DNA binding domain and an α-helical coiled-coil dimerisation domain 
(Landschulz et al., 1988).  BZLF1 is a bZIP transcription factor (Farrell et al., 
1989) and has sequence similarity to c-Fos and C/EBP in the dimerisation and 
DNA binding domains (Kouzarides et al., 1991).  BZLF1 differs from other 
members of the bZIP family as it lacks the characteristic leucine heptad repeat.  
However, comparing the coiled-coil of BZLF1 and C/EBPα, it was found that the 
dimerisation domain contains substitutions at the d positions that are sufficient 
for coiled-coil formation (Figure 4.1B) (Kouzarides et al., 1991).   
The crystal structure of the C-terminal domain of BZLF1 (residues 175-
236) in complex with the ZRE from the promoter of SM was solved and 
revealed an unusual structure, accounting for the stability of the BZLF1 
homodimer (Petosa et al., 2006; Sinclair, 2006).  The basic domain of BZLF1, 
like other bZIP proteins, contacts the major groove of the DNA via its basic 
residues but the α-helical coiled-coil, or zipper region, differs from other bZIP 
proteins.  The crystal structure revealed a complex set of interactions between 
the zipper region and C-terminal tail.  The zipper breaks at P223 and a hairpin 
turn forms from residues M221 to S224.  BZLF1 residues C-terminal to P223 
fold back against the coiled-coil, forming a four helix bundle, with stabilising 
interactions between tail residues 228 to 236 and residues halfway up the 
coiled-coil (Figure 4.1A).  Salt bridges are formed between residues in the 
zipper and the tail, K207-D236, D212-R233 and R215-D228.   
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A
B
190  195  200  205  210  215  220  225  230  235  240  245 (BZLF1)
.|....+....|....+....|....+....|....+....|....+....|....+
CRAKFKQLLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHEDLLNF
SRDKAKQRNVETQQKVLELTSDNDRLRKRVEQLSRELDTLRGIFRQLPESSLVKAMGNCA
abcdefgabcdefgabcdefgabcdefgabcdefgabcde
C/EBPα
BZLF1
heptad:          1                 2                 3                4          5               6     
Basic region BZLF1 coiled-coil BZLF1 tail
Heptad 2
Heptad 3
 
Figure 4.1.  Conserved SSENDRLR motif 
(A)  Interaction between the C-terminal tail and coiled-coil in the structure of the BZLF1-DNA 
complex (Petosa et al., 2006).  BZLF1 monomers are in green and yellow, and double stranded 
DNA is in cyan and blue.  Residues are shown on both monomers.  The boxed area shows the 
region spanned by the conserved SSENDRLR motif.  Cross sectional views of heptads 2 and 3 
are shown.  The dashed lines are hydrogen bonds.  (B)  Sequence alignment of the 
dimerisation domains of BZLF1 and C/EBPα.  The boxed area shows the conserved motif in 
BZLF1 and C/EBPα.  The heptad positions are indicated.    
 
This structure deviates from other leucine zipper proteins in which the 
coiled-coil region is much longer and accounts for the observation that BZLF1 
can only form homodimers (Kouzarides et al., 1991).  Detailed in vitro analysis 
of C-terminal residues was consistent with the crystal structure (Schelcher et 
al., 2007).  Chemical crosslinking experiments with the C-terminal region of 
BZLF1 confirmed that the C-terminal tail lies adjacent to the zipper region 
(Schelcher et al., 2007).  Biophysical analysis of synthetic peptides by analytical 
ultracentrifugation, used to test the stability of dimers, and thermal denaturation 
experiments supported a role for residues 221 to 230 in stabilising the zipper 
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structure and hence contributing to both dimerisation of BZLF1 and DNA 
binding ability. 
In their study, Kouzarides and co-workers identified an 8-residue motif in 
BZLF1 with striking sequence similarity to C/EBPα (BZLF1 sequence 
SSENDRLR, 208-215) (Figure 4.1) (Kouzarides et al., 1991).  This motif is 
located midway along the coiled-coil dimerisation region, precisely where the 
coiled-coil contacts the C-terminal tail, major contacts being made with K207, 
D212 and R215 (Petosa et al., 2006).  The coiled-coil of C/EBPα extends 
further than in BZLF1 and there is no indication of any similar C-terminal tail 
structure binding to the zipper region (Tahirov et al., 2001).  Given the different 
structures of BZLF1 and C/EBPα in this region, this conservation may be 
indicative of a common conserved functional domain, rather than a structurally 
significant motif.  The role of this conserved motif in BZLF1 function was 
investigated, examining the effects of individual mutations on the dual functions 
of BZLF1 in transactivation and DNA replication. 
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4.2  Results 
 
4.2.1  Conservation of the SSENDRLR motif is not due to 
conserved zipper-tail contacts 
In BZLF1, the SSENDRLR motif in the zipper region interacts with the C-
terminal tail, raising the possibility that the sequence conservation with C/EBP 
reflects the conservation of zipper-tail contacts.  To evaluate this possibility the 
dimerisation domain of BZLF1 was structurally aligned with the bZIP domain of 
C/EBPβ (PDB id 1GU5; 82% sequence identity with the C/EBPα bZIP domain) 
(Tahirov et al., 2001; Tahirov et al., 2002), which among the known C/EBP 
structures contains the most C-terminal residues (Figure 4.2A).  In the 
alignment, the coiled-coil of C/EBPβ extends three helical turns beyond that of 
BZLF1.  The straight line distances between the last coiled-coil residue in 
C/EBPβ and residues within the conserved motif varies from 28 to 41 Å.  The 
distances differ between the two monomers as the C/EBPβ homodimer is 
slightly asymmetric and also because the last ordered residue is L334 in 
monomer 1 but K332 in monomer 2 (Figure 4.2A).  The number of C-terminal 
residues to span the distance as an extended polypeptide was calculated 
assuming one residue/3.32 Å and a requirement for an additional two residues 
to change direction of the tail (Figure 4.2B and 4.2C).  11 to 15 residues are 
minimally required for the C/EBP polypeptide chain to fold back and contact the 
conserved motif, assuming a fully extended conformation.  13 to 15 residues 
are present in the C/EBP sequence C-terminal to the coiled-coil.  At most, only 
the last 2 to 4 residues in C/EBP might contact the conserved motif; but these 
residues show no resemblance to BZLF1 tail residues (residues 228-236) that 
contact the motif, and so the stereochemical nature of the interactions would 
necessarily differ.  This indicated that the sequence conservation between 
BZLF1 and C/EBP is not due to conservation of zipper-tail contacts.  
 
 
 
 
 125 
 
Figure 4.2.  BZLF1 and C/EBP dimerisation domains 
(A)  Structural alignment of BZLF1 (yellow and green monomers) and C/EBPβ (cyan and blue 
monomers) on DNA (grey).  Straight line distances between the end of the C/EBPβ coiled-coil 
and the conserved SSENDRLR residues are indicated.  BZLF1 residues in the conserved motif 
and C/EBPβ C-terminal residues are labelled.  (B)  Sequence alignment of the dimerisation 
domains of BZLF1, C/EBPα and C/EBPβ.  Residues conserved between BZLF1 and C/EBPα 
are shown in grey; C/EBPβ residues identical to those in C/EBPα are shown by dots.  C-
terminal residues underlined and shown in italics are missing from the crystal structures.  The 
conserved sequence motif is boxed and the BZLF1 tail residues with which it interacts are 
overlined in green.  (C)  Straight line (Cα-Cα) distances between the last ordered C/EBPβ 
residue and residues within the highly conserved motif.  Corresponding (Corresp.) residues in 
C/EBPα are listed.  The number of C-terminal residues required to span the distance as an 
extended polypeptide (assuming 1 residue/3.32 Å plus 2 residues to change direction) and the 
number extending beyond the coiled-coil are listed as residues needed and residues available 
respectively.     
 
4.2.2  Mutation of the conserved motif reveals the importance of 
residues for BZLF1 functions    
In order to investigate the function of the conserved residues within the 
SSENDRLR motif, BZLF1 residues 208 to 215 were individually mutated to 
alanine.  The serine residues at 208 and 209 were also mutated to glutamate.  
Three previously described mutants (Kouzarides et al., 1991) were used as 
A B 
C 
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additional controls, K207A, K207A/R213A and K207A/L214A.  It was previously 
shown that single point mutation of heptad d position residues, such as K207A, 
does not affect the ability of BZLF1 to bind DNA, whereas, mutation of two 
consecutive heptad d position residues which include L214, such as 
K207A/L214A, abolishes DNA binding (Kouzarides et al., 1991). The 
K207A/R213A mutant was used as a control for the double mutations, only 
mutating one heptad d residue, and should retain DNA binding.  The resulting 
proteins were tested for their ability to specifically bind to a known ZRE site in 
EMSAs, to form stable dimers in solution, to transactivate the promoter for 
BMRF1 and to induce EBV lytic DNA replication. 
Mutagenesis was performed in an SP64 expression vector containing the 
B95-8 BZLF1 gene.  BZLF1 was then cloned into the pBK2CMV expression 
vector, a modified version of pBKCMV (described in section 2.16).    Expression 
of BZLF1 in eukaryotic cells is driven by the CMV immediate early promoter and 
in vitro transcription is controlled by the T3 RNA polymerase promoter.  BZLF1 
was expressed in 293 cells from both the pBKCMV and pBK2CMV plasmids.  
Figure 4.3 shows Western blot analysis of BZLF1 protein expression.  BZLF1 
expressed from the pBK2CMV-BZLF1 plasmid corresponded to the size of 
endogenous B95-8 BZLF1.  BZLF1 expressed from the pBKCMV-BZLF1 
plasmid was slightly larger, indicating pre-initiation occurred from the additional 
methionine codon that was removed in the pBK2CMV plasmid.  The modified 
pBK2CMV plasmid was therefore used in subsequent experiments.     
 
Figure 4.3.  BZLF1 expression from pBKCMV based plasmids 
293 cells were transfected with either pBK2CMV-BZLF1 or pBKCMV-BZLF1.  B95-8ZHT cells 
were treated with 4HT for 24 hours.  Cell lysates were analysed by Western blotting for BZLF1. 
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In vitro DNA binding assay 
The BZLF1 mutant proteins were first tested for their ability to bind to DNA 
(Figure 4.4).  Wild type BZLF1 or mutant proteins were in vitro translated in 
rabbit reticulocyte lysates in the presence of [35S]methionine as a radioactive 
label.  As a control an empty vector not expressing BZLF1 was also translated.  
Products were separated by SDS-PAGE and analysed by autoradiography to 
monitor [35S]methionine incorporation.  The resulting proteins were tested for 
their ability to specifically bind to a known ZRE AP1 site (double stranded 
cttcaTGAGTCAgtgcttc; uppercase letters indicated the binding site) in EMSAs.  
The BZLF1-DNA complex was observed as a shift of the labelled DNA probe, 
which was not present in the empty vector control samples.  The EMSAs were 
repeated 2 to 3 times and the results were quantified by phosphoimager 
analysis.  Average results are shown with standard deviations.   
The BZLF1 mutant proteins were all expressed at similar levels (Figure 
4.4A) and all apart from K207A/L214A gave a measurable shift in the EMSAs 
(Figure 4.4B and 4.4C).  The shift was specific since it was competed away with 
100 fold excess of the same non-radioactive double stranded oligonucleotide as 
the probe but not with 100 fold excess of an unrelated non-specific 
oligonucleotide (ds458).  The mutations had mostly small effects in this assay, 
causing less than 2 fold changes in DNA binding.  The L214A mutant had only 
about 40% of the wild type binding activity and the K207A/L214A double mutant 
had a very low level of binding, as shown previously (Kouzarides et al., 1991).  
This is consistent with the importance of the corresponding heptad positions in 
stabilising the coiled-coil dimerisation interface.  The R215A mutant was tested 
in a separate DNA binding experiment.  Its expression was similar to the wild 
type protein (Figure 4.11A) but it did not bind significantly in EMSAs (Figure 
4.11B and 4.11C).  The crystal structure of BZLF1 indicates that R215 is a 
major contact residue with the C-terminal tail, interacting with D228, and also 
forms part of a hydrogen bond network between N211 and the C-terminal tail 
(Petosa et al., 2006).  Disruption of these stabilising interactions may account 
for its low DNA binding activity.  
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Figure 4.4.  DNA binding assay for BZLF1 K207 to L214 mutant proteins 
(A)  BZLF1, mutated BZLF1 or and empty vector control were in vitro translated in rabbit 
reticulocyte lysates with [35S]methionine as a radioactive label.  Products were fractionated by 
SDS-PAGE and analysed by autoradiography.  (B)  Equal amounts of in vitro translated 
products were tested for their ability to bind to DNA by EMSA analysis with a ZRE probe.  
BZLF1 binding occurred in the presence of 100 fold excess of a non-specific competitor (ns) but 
not in the presence of 100 fold excess of the same non-radioactive double stranded sequence 
(comp) used as the DNA probe.  (C)  Quantitation of EMSA results setting the level for BZLF1 at 
100%.     
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BZLF1 dimerisation assay 
The mutant proteins were tested for their ability to form dimers relative to wild 
type BZLF1.  This assay uses the Z185 monoclonal antibody, which recognises 
the N-terminal half of BZLF1 and is unable to immunoprecipitate the BZLF1 
BsmІ-C (residues 173-245) truncation mutant.  BsmІ-C contains the BZLF1 
DNA binding and dimerisation domains and can form dimers.  When wild type 
BZLF1 and BsmІ-C are cotranslated and then immunoprecipitated with the 
Z185 antibody, the BsmІ-C protein is indirectly immunoprecipitated through its 
interaction with the full length protein.  This assay was used to test the ability of 
the BZLF1 mutant proteins to form dimers by measuring their ability to indirectly 
immunoprecipitate BsmІ-C.  The SP64 expression vector was used for this 
assay as it gives higher expression levels of BZLF1 than the pBK2CMV 
expression vector.  
BZLF1 and individual BZLF1 mutant proteins were cotranslated with the 
BsmІ-C truncation mutant in the presence of [35S]methionine.  Wild type BZLF1, 
BsmІ-C and the empty expression vector were also individually translated.  The 
products were separated by SDS-PAGE and visualised by [35S]methionine 
incorporation (Figure 4.5A).  The cotranslated products expressed both the full 
length protein and the BsmІ-C truncation mutant, corresponding to the sizes of 
the individually translated proteins.  The empty vector control did not express 
either of these products.   
The in vitro translation products were immunoprecipitated with the Z185 
antibody and separated by SDS-PAGE (Figure 4.5B).  Wild type BZLF1 and 
BsmІ-C translation products were included on the gel for comparison.  The 
Z185 antibody immunoprecipitated each of the BZLF1 point mutants and the 
products were the same size as the wild type BZLF1 translation product.  
Samples that dimerised also contained an additional smaller band, 
corresponding to BsmІ-C, which was indirectly immunoprecipitated.  This band 
was not present in the BZLF1 control sample, which did not contain the BsmІ-C 
protein, or in the empty vector control.  The immunoprecipitated BsmІ-C band 
was not the same size as the BsmІ-C translation product, which migrated 
slightly faster on the SDS-PAGE gel (Figure 4.5B).  The in vitro translation 
product may be distorted on the gel due to large amounts of unlabelled 
haemoglobin present in the rabbit reticulocyte lysates.  Haemoglobin migrates 
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at about 15 KD on SDS-PAGE gels, just above the BsmІ-C protein, which is 
present at about 10 KD.  The immunoprecipitation protocol involves extensive 
washing, which would remove the haemoglobin from the samples.   
 
 
 
 
Figure 4.5.  Dimerisation assay for BZLF1 K207 to R215 mutants 
(A)  BZLF1 and mutated BZLF1 proteins were cotranslated with BsmI-C in rabbit reticulocyte 
lysates with [35S]methionine.  BZLF1 and BsmI-C were also individually translated.  The 
products were separated by SDS-PAGE and visualised by autoradiography.  (B)  The translated 
samples were immunoprecipitated with the Z185 antibody.  The proteins were separated by 
SDS-PAGE.  A fraction of the BZLF1 and BsmI-C translation products (IVT) were analysed on 
the gel.  The full length proteins and BsmI-C are indicated.  
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The expression levels of the BZLF1 point mutant proteins varied in the 
cotranslation assays (Figure 4.5A) so BsmІ-C pulldown was normalised for full 
length BZLF1 pulldown by phosphoimager analysis.  Most of the mutations 
allowed efficient dimerisation to occur but a number of the BZLF1 mutant 
proteins formed few dimers compared to the wild type protein.  E210A formed 
30% as many dimers as wild type BZLF1.  N211A and L214A only formed 20% 
as many dimers, and K207A/L214A and R215A formed 10% as many dimers.  
The inability of K207A/L214A and R215A to form dimers is consistent with their 
inability to bind DNA (Figure 4.4 and 4.11), as dimerisation is necessary for 
DNA binding to occur.  Some results were not consistent between the 
dimerisation and DNA binding assays.  E210A and N211A formed few dimers 
but bound to DNA as well if not better than the wild type.  Also L214A caused 
an 80% decrease in dimer formation but only a 40% decrease in DNA binding 
activity.  These inconsistencies may be due to different assay conditions (see 
discussion).  
 
BZLF1 transactivation assay 
The mutant proteins were next tested for their ability to transactivate the 
promoter for BMRF1 (EA) and to induce EBV lytic DNA replication.  Some of the 
BZLF1 mutant proteins were unstable in transfected cells (E210A, L214A, 
K207A/L214A and R215A) (Figure 4.6C, right panels), consistent with their 
inability to form dimers in solution, so the transactivation and replication data 
are only shown for mutants that gave protein expression levels similar to that of 
the wild type protein (Figure 4.6C, left panel).  All transactivation and replication 
assays for which results are presented in this chapter were repeated two times 
in triplicate with the exception of the SSENDRLR motif assay, which represents 
four data points.  In both transactivation and replication experiments the same 
samples were also assayed for BZLF1 expression by Western blotting with the 
Z185 antibody.  Averaged data with standard deviations from transactivation 
and replication assays are shown but just one representative Western blot is 
shown for the protein expression.     
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Figure 4.6.  Transactivation and replication assays for K207 to R215 mutants 
(A)  Results from the BZLF1 transactivation assay.  293 cells were cotransfected with 
expression vectors for BZLF1 mutants, the pGL3EA reporter plasmid and a β-galactosidase 
reference vector.  After 48 hours cell extracts were analysed for luciferase activity, expressed in 
kilo-relative light units (kRLU), and results were adjusted for transfection activity based on the β-
galactosidase reference values.  pGL3 was the empty luciferase vector and pBK2 the BZLF1 
expression vector.  (B)  BZLF1 replication assay.  293-ZKO cells were transfected with 
expression vectors for BZLF1 mutants or an empty vector control.  After 48 hours total DNA was 
extracted and EBV DNA amplification was analysed by QPCR with primers specific for the Rp 
promoter and actin.  Results are expressed as fold change (n-fold) in the level of EBV DNA, 
relative to that of the actin control.  (C)  Western blot analysis of BZLF1 expression in 
transfected 293 and 293-ZKO (ZKO) cells with the Z185 antibody 48 hours post transfection.   
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The transactivation assay involved cotransfection of 293 cells with a 
BZLF1 expression plasmid (pBK2CMV-BZLF1), a BMRF1 promoter luciferase 
reporter plasmid (pGL3EA) and a β-galactosidase expression plasmid 
(pCMV19-βgal).  After 48 hours cell extracts were analysed for luciferase 
activity and results were adjusted for transfection efficiency based on the β-
galactosidase reference values (Figure 4.6A).   
BZLF1 caused a 16 fold increase in luciferase activity from the pGL3EA 
plasmid relative to the empty expression vector (pBK2CMV) and less than a 2 
fold increase in luciferase activity from the pGL3 empty vector control, indicating 
that the increase in luciferase activity was due to transactivation of the BMRF1 
(EA) promoter by BZLF1.  Most mutants with protein expression levels similar to 
wild type BZLF1 (Figure 4.6C) exhibited only modest effects on transactivation, 
changes less than twofold compared to the wild type.  Mutation of S208 and 
S209 to alanine had little effect on transactivation whereas mutation of these 
two residues to glutamate caused 60% and 70% increases in transactivation 
respectively.  Mutation of D212 to alanine caused a 50% decrease in 
transactivation and mutation of R213 to alanine caused a 70% increase.  The 
heptad residues were also individually mutated to alanine.  K207A caused 
almost a twofold increase in transactivation and N211A caused a 50% 
decrease.  The L214A and K207A/L214A mutants were unstable (Figure 4.6C).  
The K207A/R213A control double mutant caused a slight increase in 
transactivation.   
 
BZLF1 DNA replication assay 
The EBV lytic replication assay used 293-ZKO cells which contain an EBV 
mutant lacking the BZLF1 gene (Feederle et al., 2000).  Transfection with a 
BZLF1 expression plasmid causes induction of the lytic cycle, resulting in lytic 
DNA replication and production of infectious virus particles.  The pBK2CMV-
BZLF1 expression vector was transfected into 293-ZKO cells causing 
replication of the EBV DNA which was measured by QPCR using specific 
primers for the Rp promoter and actin (Wang et al., 2005).  The results are 
expressed as the change in the level of EBV DNA, relative to that of the actin 
control (Figure 4.6B).   
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Transfection of wild type BZLF1 caused a 75 fold increase in EBV DNA.  
Mutation of S208 to alanine had little effect on DNA replication but the S208E 
mutant was severely impaired with only 10% of wild type activity.  On the other 
hand, similar mutation of the adjacent S209 to either alanine or glutamate had 
little effect on DNA replication.  The N211A mutation caused a 5 fold reduction 
in DNA replication, while mutation of D212 to alanine caused a 50% decrease.  
Substituting R213 with alanine had little effect but the K207A and K207A/R213A 
mutations both caused 50% decreases in replication.   
The S208E mutation had little effect on DNA binding and dimerisation, 
caused a slight increase in transactivation but severely impaired DNA 
replication, whereas, similar mutation of the adjacent S209 to glutamate had 
little effect in any of the assays.  According to the crystal structure, residue 
S208 directly contacts the C-terminal tail (Petosa et al., 2006).   More 
specifically, S208 forms hydrogen bonds with (monomer 1) or is in close 
proximity to (monomer 2) residue D236 in the tail region (S208 on monomer 2 
does not hydrogen bond with D236 on its C-terminal tail as the homodimer is 
slightly asymmetric and these residues are too far apart) (Figure 4.7A and 4.7B, 
top panel).  K207 also interacts with this region of the C-terminal tail forming an 
intermonomer salt bridge with D236 (Petosa et al., 2006).  K207 on monomer 2 
interacts with D236 on monomer 1 and K207 on the monomer 1 interacts with 
both D236 and T234 on the C-terminal tail of monomer 2 (Figure 4.1A).   
Since S208 interacts with the acidic residue D236, replacement of S208 
with an acidic glutamate may perturb the zipper-tail interface through an 
electrostatic repulsion effect (Figure 4.7B, middle panel).  The S208E mutation 
caused a slight increase in the transactivation assay but severe reduction in the 
replication assay, indicating that interaction of this region of the C-terminal tail 
and the coiled-coil of BZLF1 is required for DNA replication to occur but not for 
transactivation of the BMRF1 promoter.  The K207A mutation also allowed 
transactivation to occur but caused a 50% decrease in replication.  Mutation of 
K207 to alanine may also disrupt the zipper-tail interaction.   
A number of mutations caused decreases in both the transactivation and 
replication assays (Figure 4.6A and 4.6B).  Mutation of D212 to alanine, another 
contact residue with the C-terminal tail, caused 50% decreases in both 
transactivation and replication indicating that disruption of the zipper-tail 
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interface at this point affects both functions.  Disruption of this interaction did not 
affect either DNA binding or dimerisation.   
 
 
 
Figure 4.7.  Interaction between BZLF1 residues S208 and D236  
(A)  Interaction between the C-terminal tail and coiled-coil in the structure of the BZLF1-DNA 
complex (Petosa et al., 2006), BZLF1 monomers are in green and yellow, double stranded DNA 
is in grey.  The boxed area shows the region spanned by the conserved SSENDRLR motif and 
the hydrogen bond (dashed line) between S208 and D236.  The bracketed area marked by an 
asterisk is shown in panel B.  (B)  Cross-sectional view of the S208-D236 interaction.  The 
crystal structure of BZLF1 (top panel) and structural models of S208E (middle) and 
S208E/D236K (bottom) mutants are shown.  The predicted electrostatic repulsion is indicated 
by a double headed arrow.   
 
The N211A mutation caused a 50% decrease in transactivation and a 5 
fold decrease in replication, perhaps reflecting the central position of this 
residue within a hydrogen bond network that stabilises the interaction between 
the coiled-coil and the C-terminal tail (Petosa et al., 2006).  N211 is a highly 
conserved heptad a position residue in the bZIP family of proteins, where both 
asparagine residues share an intermonomer hydrogen bond.  Unique to BZLF1 
is an extended hydrogen bond network that links these residues to the C-
terminal tail (Petosa et al., 2006).  In the crystal structure of BZLF1, N211 
A B 
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interacts with E210 which in turn interacts with T234 (on the C-terminal tail) and 
R215 (Figure 4.1A, heptad 3).  Disruption of this hydrogen bond network in the 
N211A mutant may alter the structure of the dimerisation domain and account 
for its low transactivation and replication efficiencies.  The N211A mutation also 
caused a 5 fold reduction in dimer formation relative to the wild type in the 
dimerisation assay (Figure 4.5B).    
 
4.2.3  Truncation of the C-terminus to 228 prevents DNA 
replication but allows transactivation 
Mutation of S208 to glutamate allowed transactivation of the BMRF1 promoter 
to occur but prevented DNA replication, indicating that interaction between the 
C-terminal tail and the zipper region is important for EBV to achieve DNA 
replication.  A previous report demonstrated that truncation of the C-terminus to 
residue 230 does not affect transactivation but implicated C-terminal tail 
residues 221-230 in dimer stability and DNA binding ability (Schelcher et al., 
2007).  The I231Ter mutant was able to transactivate the BMRF1 promoter as 
well as the full length BZLF1 protein in 293-ZKO cells, indicating that tail 
residues C-terminal to I230 are not required for transactivation.  D228Ter 
caused a significant reduction in dimerisation, forming 10% as many dimers as 
full length BZLF1, but was not tested in the transactivation assay (Schelcher et 
al., 2007).   
The role of C-terminal tail residues in DNA binding, dimerisation, 
transactivation and replication was tested in the above assays with a number of 
BZLF1 truncation mutants, T234Ter, I231Ter (both a gift from Alison Sinclair), 
D228Ter and H199Ter.   
All of the truncation mutants were expressed in vitro (Figure 4.8A) but 
they did not bind well to the ZRE probe in EMSAs (Figure 4.8B and 4.8C).  The 
T234Ter, I231Ter and D228Ter truncations all caused 90% decreases in DNA 
binding relative to wild type BZLF1.  As expected H199Ter did not bind to the 
ZRE site as it lacks the dimerisation domain.  Some of these results were 
inconsistent with the study mentioned above where the I231Ter and T234Ter 
mutants bound DNA almost as well as wild type BZLF1 (Schelcher et al., 2007).  
Different oligonucleotides were used in that study spanning the Rp ZRE1 site, 
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the ZIIIB site and a different AP1 site context.  Translation products were also 
generated from wheat germ extracts rather than rabbit reticulocyte lysates.   
  The DNA binding results were not consistent with the dimerisation data.  
The BZLF1 truncation mutants were cotranslated with BsmІ-C and were 
subsequently immunoprecipitated with the Z185 antibody (Figure 4.9A and 4.9B 
respectively).  The expression levels of the truncated proteins differed in the 
cotranslated samples so BsmІ-C pulldown was corrected for differences in 
pulldown of the truncated proteins.  Similar results were found to Schelcher in 
the dimerisation assay (Schelcher et al., 2007).  The T234Ter and I231Ter 
truncation mutants dimerised almost as efficiently as the full length protein and 
the D228Ter truncation caused a 70% reduction in dimer formation.  H199Ter 
had similar background binding as the BsmІ-C control, indicating that the faint 
band present was a result of non-specific binding of BsmІ-C to the beads and 
not due to dimer formation.  
The BZLF1 truncation mutants were tested for their ability to 
transactivate the BMRF1 promoter and replicate viral DNA (Figure 4.10).  Wild 
type BZLF1 caused a 15 fold increase in luciferase activity from the pGL3EA 
plasmid, relative to the empty expression vector.  T234Ter, I231Ter and 
D228Ter all had similar transactivation efficiencies with approximately 50% of 
wild type activity (Figure 4.10A).  The truncated proteins were not as stable as 
full length BZLF1, accounting for the reduction in transactivation (Figure 4.10C).  
The results indicated that C-terminal residues 228 to 245 do not play a 
significant role in DNA binding and dimerisation in vivo despite their effects in 
the in vitro assays.  The H199Ter mutant, lacking the zipper region and C-
terminal tail, did not dimerise and hence could not transactivate the BMRF1 
promoter.  In the replication assay, wild type BZLF1 caused a 160 fold increase 
in DNA replication relative to the empty vector control but none of the truncation 
mutants were able to replicate viral DNA (Figure 4.10B).  These results 
indicated that this region of the C-terminal tail, from residue 228-245, is required 
for DNA replication to occur but not for transactivation.   
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Figure 4.8.  DNA binding assay for BZLF1 truncation mutants 
(A)  BZLF1 truncation mutants were in vitro translated in the presence of [35S]methionine.  
Products were fractionated by SDS-PAGE and analysed by autoradiography.  (B)  Equal 
amounts of in vitro translated products were tested for their ability to bind to DNA by EMSA 
analysis with a ZRE probe.  Binding was competed as described in Figure 4.4.  (C)  Quantitation 
of EMSA results setting the level for BZLF1 at 100%. 
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Figure 4.9.  Dimerisation assay for BZLF1 truncation mutants 
(A)  SDS-PAGE analysis of in vitro translation products.  BZLF1 truncation mutants were 
cotranslated with BsmI-C in rabbit reticulocyte lysates with [35S]methionine.  BZLF1 and BsmI-C 
were also individually translated.  (B)  The translated samples were immunoprecipitated with the 
Z185 antibody and the proteins were separated by SDS-PAGE.  A fraction of the BZLF1 and 
BsmI-C translation products (IVT) were analysed on the gel.  The truncation mutants and BsmI-
C are indicated.  
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Figure 4.10.  Transactivation and replication assays for BZLF1 truncation mutants 
(A)  Results from the BZLF1 transactivation assay.  293 cells were cotransfected with 
expression vectors for the BZLF1 truncation mutants, the pGL3EA reporter plasmid and a β-
galactosidase reference vector, and cell extracts were analysed for luciferase activity as 
described in Figure 4.6.  pGL3 was the empty luciferase vector and pBK2 was the BZLF1 
expression vector.  kRLU, kilo-relative light units.  (B)  Results from the BZLF1 replication 
assay.  293-ZKO cells were transfected with expression vectors for BZLF1 truncation mutants or 
an empty vector control and EBV DNA amplification was analysed by QPCR as described in 
Figure 4.6.  (C)  Western blot of transfected 293 and 293-ZKO (ZKO) cells.  Protein extracts 
were prepared 48 hours after transfection and equal amounts were analysed by Western 
blotting with the Z185 antibody for BZLF1.   
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4.2.4  The charge and size of the residue at position 208 affects 
DNA replication 
Mutation of S208 to glutamate gave the most interesting result in the 
mutagenesis experiments causing a large decrease in the replication assay and 
a slight increase in the transactivation assay, helping to differentiate between 
these dual functions of BZLF1.  Other amino acids were tested at position 208 
to determine the importance of this residue in both roles.  S208 was additionally 
mutated to threonine, aspartate, asparagine and lysine to determine the effect 
of the charge and size of the residue present at this position.   
The mutated proteins were expressed in vitro (Figure 4.11A) and the 
resulting proteins were tested for their ability to bind to DNA in EMSAs (Figure 
4.11B and 4.11C).  All of the mutant proteins caused a measurable shift of the 
labelled probe that was not present in the empty vector control.  The mutations 
had mostly small effects on DNA binding.  S208D caused an 80% increase in 
DNA binding but this correlated with higher levels of protein expression (Figure 
4.11A).  None of the mutations significantly affected the ability of the proteins to 
dimerise in solution (Figure 4.12) and had little effect on transactivation of the 
pGL3EA plasmid (Figure 4.13A).  Wild type BZLF1 caused a 13 fold increase in 
transactivation relative to the empty vector control.  S208K showed a 40% 
decrease in transactivation relative to the wild type BZLF1 protein but protein 
expression in these cells was also lower (Figure 4.13C).   
The S208 mutations caused more significant effects in the DNA 
replication assay (Figure 4.13B).  Wild type BZLF1 caused a 140 fold increase 
in replication relative to the empty vector.  Mutation of S208 to alanine did not 
affect DNA replication but the S208E mutation again caused a large reduction in 
the replication assay.  Introduction of a different acidic residue, in S208D, had 
similar but slightly less pronounced effects as S208E, causing 80% and 90% 
decreases in the replication assay respectively.  Both glutamate and aspartate 
contain acidic groups but glutamate has a slightly longer side chain.  The 
protein with the conservative mutation S208T differed little from the wild type, 
causing a 30% decrease in the replication assay.  Threonine has a slightly 
larger side chain than serine.  The S208N mutation caused a 60% reduction in 
DNA replication and introduction of the positively charged lysine residue at 
position 208, in the S208K mutant, caused a 50% decrease in DNA replication.  
 142 
The S208N mutant protein had 20% more replication activity than S208D.  
Asparagine contains an amine group instead of the negatively charged oxygen 
present in aspartate.  In summary, it appears from these results that both the 
charge and length of the side chain present at position 208 affects progression 
of the virus cycle through DNA replication but, for the residues tested, has little 
effect on transactivation of an early gene.  This indicates that the large 
decrease in replication caused by the S208E mutation was due to an 
electrostatic repulsion effect between the C-terminal tail and the zipper. 
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Figure 4.11.  DNA binding assay for BZLF1 S208 mutants 
(A)  BZLF1, the S208 mutants and the empty vector control were in vitro translated in rabbit 
reticulocyte lysates with [35S]methionine.  Products were fractionated by SDS-PAGE and 
analysed by autoradiography.  (B)  The in vitro translated proteins were tested for their ability to 
bind to DNA in EMSAs with a ZRE probe.  BZLF1 binding occurred in the presence of 100 fold 
excess of a non-specific competitor (ns) but not in the presence of 100 fold excess of the same 
non-radioactive double stranded sequence (comp) used as the DNA probe.  (C)  Quantitation of 
EMSA results setting the level for BZLF1 at 100%.  
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Figure 4.12.  Dimerisation assay for BZLF1 S208 mutants 
(A)  SDS-PAGE analysis of in vitro translation products.  BZLF1 and mutated BZLF1 proteins 
were cotranslated with BsmI-C in rabbit reticulocyte lysates with [35S]methionine.  BZLF1 and 
BsmI-C were also individually translated.  (B)  The translated samples were immunoprecipitated 
with the Z185 antibody and separated by SDS-PAGE along with a fraction of the BZLF1 and 
BsmI-C translation products (IVT).  The full length proteins and BsmI-C are indicated.  
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Figure 4.13.  Transactivation and replication assays for BZLF1 S208 mutants 
(A)  Results from the BZLF1 transactivation assay.  293 cells were cotransfected with 
expression vectors for BZLF1 mutants, the pGL3EA reporter plasmid and a β-galactosidase 
reference vector, and cell extracts were analysed for luciferase activity in kilo relative light units 
(kRLU), as described in Figure 4.6.  (B)  Results from the BZLF1 replication assay.  293-ZKO 
cells were transfected with expression vectors for BZLF1 mutants and an empty vector control.  
EBV DNA amplification was analysed by QPCR as described in Figure 4.6.  (C)  Western blot 
analysis of BZLF1 expression in transfected 293 and 293-ZKO (ZKO) cells with the Z185 
antibody, 48 hours post transfection.   
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4.2.5  The C-terminal tail must be bound to the zipper region for 
replication to occur 
In the crystal structure D236 in the C-terminal tail interacts with S208, indicating 
that introduction of the acidic glutamate in S208E might conflict with the 
similarly charged aspartate residue.  D236 was mutated to test if it would be 
possible to rescue some of the replication activity of the S208E mutant.  D236 
was mutated to alanine (a gift from Alison Sinclair), asparagine and lysine.  A 
number of double mutations were introduced, S208E/D236N and 
S208E/D236K, to try to rescue the S208E replication defect with a charge 
reversal mutation.  The mutant proteins were tested in each of the above 
assays.   
The D236 mutants were in vitro translated and cotranslated with BsmІ-C 
for the DNA binding and dimerisation assays respectively (Figures 4.14 and 
4.15).  None of the single or double point mutations tested significantly affected 
either DNA binding or dimerisation.  
The D236 single and double point mutants, S208A and S208E were then 
tested in both the transactivation and replication assays (Figure 4.16A and 
4.16B respectively).  Wild type BZLF1 caused a 14 fold increase in 
transactivation of the BMRF1 promoter and a 112 fold increase in DNA 
replication, relative to the empty vector controls.  S208A had no effect in either 
the transactivation or replication assays and in this set of experiments S208E 
caused almost a 2 fold increase in the transactivation assay and a 90% 
decrease in the replication assay compared to wild type BZLF1.  The D236 
single and double point mutations had little effect on transactivation of the 
BMRF1 promoter but caused varying decreases in the replication assays.  The 
proteins with these mutations exhibited similar levels of proteins expression 
(Figure 4.16C).  Mutation of D236 to alanine caused a 50% decrease in DNA 
replication and mutation to asparagine caused a 40% decrease, indicating the 
importance of this residue in replication.  Mutation of D236 alone to a positively 
charged lysine residue gave low replication activity but the double mutant 
S208E/D236K had 4.5 times the replication activity of the S208E mutant, 
suggesting that activity was rescued by restoration of a stable zipper-tail 
interaction (Figure 4.7B, bottom panel).  The double mutant S208E/D236N also 
compensated the S208E replication defect 4 fold.  
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Figure 4.14.  DNA binding assay for BZLF1 D236 mutants 
(A)  SDS-PAGE analysis of in vitro translation products.  BZLF1 and mutated BZLF1 proteins 
were in vitro translated in rabbit reticulocyte lysates with [35S]methionine.  (B)  Equal amounts of 
in vitro translated products were tested for their ability to bind to DNA by EMSA analysis with a 
ZRE probe, as in Figure 4.4.  (C)  Quantitation of EMSA results setting the level for BZLF1 at 
100%.  
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The replication activity did not return to wild type levels.  S208E/D236K 
had one third of the replication activity of the wild type protein, indicating that 
the correct protein conformation was not fully restored by the two 
complementary charge mutations.  However, these results strongly indicate that 
interaction between the C-terminal tail and the coiled-coil region of BZLF1 is 
required for EBV to achieve DNA replication and support this unusual aspect of 
the crystal structure.  
 
 
Figure 4.15.  Dimerisation assay for BZLF1 D236 mutants 
(A)  BZLF1 and the BZLF1 D236 mutants were cotranslated with BsmI-C in rabbit reticulocyte 
lysates with [35S]methionine.  Wild type BZLF1 and BsmI-C were also individually translated.  
The products were separated by SDS-PAGE and visualised by autoradiography.  (B)  The 
translated samples were immunoprecipitated with the Z185 antibody.  The proteins were 
separated by SDS-PAGE along with a fraction of the BZLF1 and BsmI-C translation products 
(IVT).  The full length proteins and BsmI-C are indicated.  
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Figure 4.16.  Compensation of S208 replication defect 
(A)  Results from the BZLF1 transactivation assay.  293 cells were cotransfected with 
expression vectors for BZLF1 mutants, the pGL3EA reporter plasmid and a β-galactosidase 
reference vector, and cell extracts were analysed for luciferase activity as described in Figure 
4.6.  (B)  Results from the BZLF1 replication assay.  293-ZKO cells were transfected with 
expression vectors for BZLF1 mutants and an empty vector control.  EBV DNA amplification 
was analysed by QPCR as described in Figure 4.6.  The S208E/D236K mutation compensated 
for the S208E replication defect, as indicated by the arrows.  (C)  Western blot analysis of 
BZLF1 expression in transfected 293 and 293-ZKO (ZKO) cells at 48 hours with the Z185 
antibody.   
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4.2.6  The BZ1 hybridoma antibody recognises part of the bZIP 
dimerisation domain 
Initial studies with the BZ1 hybridoma antibody suggested that the epitope for 
this monoclonal antibody resides in the dimerisation domain of BZLF1 and 
demonstrated that the antibody recognises both the active dimeric form and the 
inactive monomeric form of the protein (Young et al., 1991).  Western blot 
analysis of the BZLF1 mutant proteins, shown here, with the BZ1 antibody 
indicated that the epitope for the antibody includes residues present in the 
SSENDRLR motif and also residues in the C-terminal tail.  The BZ1 antibody 
reacts in both immunoblotting and immunoprecipitation assays and can 
supershift the BZLF1-DNA complex in EMSAs.  Epitope mapping with 
monoclonal antibodies has proven to be a valuable way of getting structural 
information about proteins in their native conformation in solution (Wade-Evans 
& Jenkins, 1985).  It was tested if epitope mapping with the BZ1 antibody could 
be used to probe the structure of the dimerisation domain of BZLF1.     
The SSENDRLR motif mutants and wild type BZLF1 were in vitro 
translated from the pBK2CMV expression vector in the presence of 
[35S]methionine.  The products were separated by SDS-PAGE and visualised by 
autoradiography (Figure 4.17A, top panel). All of the mutated proteins were 
expressed in vitro and had similar levels of expression.  The translation 
products were analysed by Western blotting the samples with both the BZ1 and 
Z185 antibodies.  The BZ1 antibody did not recognise the D212A, R213A or the 
K207A/R213A mutant proteins as well as wild type BZLF1, indicating that the 
epitope includes residues D212 and R213 (Figure 4.17A, middle panel).  The 
Z185 antibody, which recognises the N-terminal region of the protein, 
recognised all of the mutated proteins (Figure 4.17A, bottom panel). 
The BZLF1 truncation mutants H199Ter and D228Ter were in vitro 
translated (Figure 4.18A, top panel) and Western blot analysis indicated that the 
BZ1 antibody also recognises residues present in the C-terminal tail (Figure 
4.18B, middle panel).   The BZ1 antibody did not recognise the H199Ter mutant 
lacking the entire dimerisation domain.  The D228Ter mutant, which lacks C-
terminal tail residues 228-245, was recognised poorly in comparison to wild type 
BZLF1.  The Z185 antibody recognised both of the truncated proteins (Figure 
4.18, bottom panel).   
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The BZ1 antibody was tested for its ability to immunoprecipitate the 
BZLF1 point mutants and truncation mutants.  Unexpectedly, all of the BZLF1 
point mutants and the D228Ter truncation mutant were immunoprecipitated by 
the BZ1 antibody (Figure 4.17B and 4.18B respectively).  The antibody did not 
precipitate the H199Ter mutant as shown previously (Young et al., 1991).  None 
of the proteins were immunoprecipitated by an Rb monoclonal antibody which 
acted as a control.   
 
 
Figure 4.17.  BZ1 epitope mapping with BZLF1 SSENDRLR motif mutants 
(A)  BZLF1 and BZLF1 mutants were in vitro translated in rabbit reticulocyte lysates with 
[35S]methionine as a radioactive label.  Products were fractionated by SDS-PAGE and 
visualised by autoradiography (top panel).  Equal amounts of in vitro translated products were 
Western blotted with the BZ1 (middle) and Z185 (bottom) antibodies.  (B)  In vitro translated 
products (top) were immunoprecipitated with the BZ1 antibody (bottom).  The proteins were 
separated by SDS-PAGE and visualised by autoradiography.  
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Figure 4.18.  BZ1 epitope mapping with BZLF1 truncation mutants 
(A)  The BZLF1 truncation mutants were in vitro translated.  Products were separated by SDS-
PAGE and visualised by autoradiography (top panel) or Western blotted with the BZ1 (middle) 
and Z185 (bottom) antibodies.  (B)  In vitro translated products were immunoprecipitated with 
BZ1, Z185 and a control antibody (Rb).   
 
The ability of the BZ1 antibody to supershift BZLF1-DNA complexes in 
EMSAs was next tested (Figure 4.19).  As in the previous experiments the 
BZLF1-DNA complex was observed as a shift in the labelled DNA probe.  
Addition of the BZ1 antibody shifted the BZLF1-DNA complex further.  The 
supershifted band was not as intense as the BZLF1-DNA complex indicating 
that either some of the supershifted complex did not enter the gel or the BZ1 
antibody disrupted BZLF1-DNA complex formation.  Addition of the control T278 
antibody did not cause any supershift of the protein-DNA complex but did cause 
a slight increase in binding.   
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Figure 4.19.  BZLF1 supershift assays with BZ1 monoclonal antibody 
BZLF1 and BZLF1 mutants were in vitro translated in rabbit reticulocyte lysates.  Equal amounts 
of translated products were incubated with a ZRE probe, the BZ1 antibody or a non-specific 
antibody (T278).  BZLF1 (Z) specific complexes and supershifted complexes are marked by 
arrows.     
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Mutation of S208 and S209 to either alanine or glutamate did not affect 
the ability of the BZ1 antibody to supershift the protein-DNA complex.  Mutation 
of N211 to alanine and K207 to alanine also had small effects.  The E211A and 
L214A mutations affected the ability of BZ1 to supershift the protein-DNA 
complex.  The D212A and R213A mutants did not form any supershifted 
complexes in the presence of the BZ1 antibody and no protein-DNA complexes 
were present either.  It is unclear how the BZ1 antibody destroyed protein-DNA 
complex formation making results difficult to interpret.  The BZLF1 truncation 
mutants did not bind well to the ZRE in EMSAs so it was not possible to test the 
ability of the BZ1 antibody to supershift these complexes. 
 
 
 
 
 
 
 
Figure 4.20.  Spacefilling model of BZLF1-DNA complex 
Oblique view showing residues D212 and R213 on one side of the dimer.  Both residues are 
partly solvent exposed.  Double stranded DNA is shown in cyan and blue.    
 
D212 R213 
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  The crystal structure of BZLF1 indicates that residues D212 and R213 
are available for binding as both of these residues are exposed on the surface 
of the protein (Figure 4.20).  Western blot analysis of the mutated BZLF1 
proteins indicated that the BZ1 antibody epitope includes residues D212 and 
R213 and part of the C-terminal tail structure.  Also, the BZ1 antibody did not 
form any stable supershifted complex in the EMSAs when either of these 
residues were mutated.  However, the BZ1 antibody immunoprecipitated both 
the D212A and R213A mutants when they were in their native conformation.  
These conflicting results may be due to different assay conditions but indicated 
that it would not be possible to use this method to further study the structure of 
BZLF1. 
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4.3  Discussion 
 
BZLF1 functions as a transcriptional activator inducing lytic cycle reactivation 
(Rooney et al., 1989) and also acts as an origin binding protein, initiating viral 
DNA replication (Schepers et al., 1996).  Deletion mapping of the transactivation 
domain of BZLF1 identified distinct regions required for both functions of BZLF1 
(reviewed in chapter 1) (Flemington et al., 1992; Sarisky et al., 1996).  Activation 
of transcription involves direct interaction of the BZLF1 transactivation domain 
with the TFIID-TFIIA complex and BZLF1 has been shown to stabilise the 
preinitiation complex (Lieberman et al., 1997).  In addition, BZLF1 plays a central 
role in DNA replication, involving recruitment and assembly of the replication 
complex on oriLyt (Gao et al., 1998; Liao et al., 2001).  Domain swapping 
experiments with Gal4, c-Jun and VP16 showed that the transactivation domain 
of BZLF1 is essential for this process (Schepers et al., 1993a).   
It is unknown how BZLF1 switches between these two functions as the 
lytic cycle progresses.  One hypothesis is that phosphorylation of BZLF1 at S173 
is involved.  It was proposed that phosphorylation of S173 alters the DNA binding 
affinity of the protein, influencing its role as an origin binding protein (El-Guindy et 
al., 2007).  S173 was mapped as a casein II phosphorylation site in in vitro 
phosphorylation assays (Kolman et al., 1993).  Mutation of S173 affected the 
DNA binding affinity of BZLF1, altering its ability to immunoprecipitate oriLyt ZRE 
sites in ChIP assays and to initiate lytic viral DNA replication (El-Guindy et al., 
2007).     
The structure of BZLF1 has been studied extensively to try and gain 
insight into how this protein functions as both a transcriptional activator and a 
DNA replication factor.  Resolution of the crystal structure of BZLF1 bound to 
DNA confirmed that the dimerisation domain forms an α-helical coiled-coil.  It 
also revealed a novel C-terminal tail structure that runs anti-parallel to the helix 
which is involved in dimer stability (Petosa et al., 2006; Schelcher et al., 2007).  
However, in order to solve the crystal structure it was necessary to delete C-
terminal tail residues 237 to 245 and two point mutations, S186A and C189S, 
were introduced into the DNA binding domain.  These residues are important for 
BZLF1 functions.  Both S186 and C189 have been implicated in recognition of 
methylated DNA and C189 contributes to redox sensitivity of BZLF1 (Bhende et 
al., 2004; Karlsson et al., 2008a; Wang et al., 2005).  In this chapter a 
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conserved motif in the BZLF1 and C/EBP dimerisation domain was investigated 
for its contribution to BZLF1 functions and mutagenesis in this region validated 
aspects of the crystal structure.   
The conserved SSENDRLR motif in BZLF1 is located midway along the 
coiled-coil where major contacts are made with the C-terminal tail.  Initially it 
was necessary to determine if this sequence conservation reflected the 
conservation of zipper-tail contacts.  The crystal structures of a number of bZIP 
proteins bound to DNA have been solved, including the c-Fos/c-Jun 
heterodimer (Glover & Harrison, 1995), C/EBPα (Tahirov et al., 2001) and 
C/EBPβ (Tahirov et al., 2002).  From these structures there is no evidence to 
suggest that any of these proteins contain a C-terminal tail structure resembling 
that of BZLF1.  However, as for most of these structures, some of the C-
terminal tail residues were removed from C/EBP to enhance the solubility of the 
protein and to improve resolution of the structure.  Structural alignment of the 
dimerisation domains of BZLF1 and C/EBPβ and calculation of straight line 
distances between the conserved motif and tail residues, did not reveal any 
evidence for a C-terminal tail structure binding to this region in C/EBP.  It was 
therefore concluded that the sequence conservation of the SSENDRLR motif in 
BZLF1 and C/EBPα is not due to conservation of zipper-tail contacts and may 
have another function.   
Mutation of the SSENDRLR motif in BZLF1 revealed the importance of 
individual residues for specific BZLF1 functions.  Some of the mutations had 
effects on DNA binding and dimerisation but in a number of cases these results 
did not correlate.  Dimerisation is essential for DNA binding to occur so these 
inconsistencies may be due to different assay conditions.  The dimerisation 
assays were performed at higher salt concentrations than the DNA binding 
reactions and also in the presence of NP40 detergent.  The dimerisation assay 
was also based on immunoprecipitation of proteins whereas the DNA binding 
assay measured the stability of protein-DNA complexes following 
electrophoresis.  In addition, it should be noted that the dimerisation assay 
relies on dimerisation of the BZLF1 mutants with the BsmІ-C truncation mutant 
and this might affect dimer formation.  Overall, the dimerisation results were 
more consistent with the transactivation and replication data than the DNA 
binding results.  Differences between the DNA binding and transactivation 
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results may also be due to the use of different binding sites in these assays.  
The DNA binding assay was performed with an oligonucleotide spanning the 
AP1 site from the SM promoter whereas the transactivation assays were 
performed with the luciferase reporter gene under the control of the BMRF1 EA 
promoter.  It is possible that the different binding sites account for the different 
results in these assays.     
These assays confirmed the importance of heptad residues in dimer 
stability as shown previously (Kouzarides et al., 1991) and also highlighted the 
importance of other residues for specific BZLF1 functions.  Mutation of E210, 
N211, L214 and R215 all affected dimer stability in vitro.  A number of these 
mutants also formed unstable dimers in transient transfection assays correlating 
with the disruption of stabilising interactions identified in the crystal structure.  
For example, N211, which is a highly conserved residue in the bZIP family of 
proteins, was shown to form an extended hydrogen bond network in BZLF1 with 
the C-terminal tail (Petosa et al., 2006).  Mutation of N211 to alanine caused 
decreases in the dimerisation, transactivation and replication assays indicating 
that this residue contributes significantly to stability of the zipper structure.  Also, 
mutation of E210 caused a decrease in dimer stability and the R215A mutant 
protein was unable to form dimers or bind to DNA.  In the crystal structure E210 
and R215 form part of the hydrogen bond network with N211.  Proteins carrying 
mutations in these residues were unstable in transient transfection assays.  
R215 is also involved in stabilising interactions with the C-terminal tail, forming 
a salt bridge with D228.   
The L214A mutation caused both DNA binding and dimerisation 
deficiencies despite previous experiments indicating that mutation of L214 alone 
did not affect DNA binding (Kouzarides et al., 1991).  Despite this, the 
importance of this leucine residue was indicated as mutation of this residue in 
combination with another heptad d position residue obliterated DNA binding 
ability, as confirmed here.  The L214A mutant was also unstable in transient 
transfection assays.   
The transactivation and replication assays highlighted the importance of 
the S208 residue for progression of EBV DNA replication.  The S208E mutation 
allowed transactivation to occur but severely compromised replication 
efficiency.  S208E is the first point mutation and the first mutation in the coiled-
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coil that has this property of allowing transactivation but preventing DNA 
replication.  Residue K207 was also important for replication to occur as both 
K207A and K207A/R213A were compromised in the replication assay but not as 
severely as S208E.  It is important to remember that the replication assay used 
here measures both activation of early genes and DNA replication so the 
deficiency of S208E in the replication assay does not necessarily imply an effect 
on the DNA replication function of BZLF1.  It is possible that there could be a 
specific effect on expression of a delayed early gene that was not apparent in 
the transactivation assay.  The results however do suggest that S208 plays a 
significant role in achieving lytic cycle DNA replication.       
It was not possible to draw conclusions about the functional significance 
of this conserved motif in BZLF1 due to the additional stabilising interactions 
between the zipper and the C-terminal tail.  A number of the mutations affected 
protein stability probably due to disruption of the complex web of interactions 
between the C-terminal tail and the zipper region.  It was difficult therefore to 
determine if this motif has any additional role in either transactivation or 
replication, or if this conservation merely reflects the conservation of 
intramolecular contacts that form a stable zipper structure.  Mutation of this 
motif in C/EBP could give further insight into its function in C/EBP based 
assays, where results would not be obscured by the complex stabilising 
interactions present in BZLF1.  The results highlighted the importance of S208 
for DNA replication, which was further examined.     
Mutation of S208 to glutamate caused a slight increase in the 
transactivation assay and a large decrease in the replication assay.  It was 
hypothesised that introduction of this large acidic residue caused an 
electrostatic repulsion effect with D236, disrupting the interaction between the 
C-terminal tail and the zipper region.  These results indicated that this section of 
the C-terminal tail must be bound to the zipper for replication to occur but not for 
earlier transactivation events.   
Results from the C-terminal truncation mutants supported this hypothesis 
as the D228Ter mutant could not replicate EBV DNA but was able to 
transactivate the BMRF1 promoter.  This hypothesis was further tested by 
introducing different residues at position 208.  Both the size and charge of the 
residue affected the ability of BZLF1 to initiate DNA replication but had little 
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effect in the transactivation assay.  Residues with larger side chains caused 
more significant replication defects.  Both positive and negatively charged 
amino acids affected replication efficiency but residues with negatively charged 
side chains caused more significant effects, presumably by creating greater 
repulsion with the C-terminal tail.   
Of all the residues tested at position 208, glutamate, which contained the 
largest acidic side chain, caused the most significant decrease in the replication 
assay suggesting that the S208E replication defect was indeed due to 
electrostatic repulsion between the C-terminal tail and the zipper region.  
Mutation of D236 also affected the replication function of BZLF1 but not 
transactivation of the BMRF1 promoter.  All of the mutations introduced at 
position 236 repressed replication to some degree.  D236 may contribute 
significantly to the structure required for replication to occur or may be involved 
in binding to a replication specific transcription factor.   
Mutation of D236 to lysine rescued some of the low replication activity of 
S208E in the S208E/D236K double mutant, strongly suggesting that the 
interaction between the C-terminal tail and the zipper region is required for 
replication to occur.  The fact that the double mutations did not completely 
restore replication activity to wild type levels indicates that the correct protein 
structure was not fully restored by the complementary charge mutations.  The 
side chains of the two mutated residues may not be in the correct orientation to 
fully restore the zipper-tail contacts.  The serine residue at position 208, which 
has a small side chain, was replaced with a large bulky acidic group that is likely 
to distort other stabilising interactions in this region.  In the crystal structure 
D236 interacts with K207 in the zipper region forming a salt bridge (Petosa et 
al., 2006).  By introducing a basic residue at position 236, this interaction may 
be disrupted by repulsion between K236 and K207, contributing to the lower 
replication activity.  It is also possible that residues within the conserved motif 
have an additional role in replication.  D236, as well as S208, S209, D212 and 
R213 within SSENDRLR, is partly solvent exposed and may conceivably 
interact with a replication factor that recognises the hairpin structure of BZLF1.   
Whether or not there are additional roles for this region in replication, the 
data presented here indicates that the C-terminal tail of BZLF1 must be bound 
to the coiled-coil region to achieve EBV DNA replication and S208 plays a key 
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role in the BZLF1 structure required.  The reversal of the deleterious effects of 
the S208E mutation, by a compensatory mutation in the C-terminal tail, provides 
experimental support for the crystal structure and indicates that binding of the 
tail structure to the coiled-coil region is required for DNA replication to occur but 
not for earlier transcription activation events.  These results have recently been 
published (McDonald et al., 2009). 
Binding of the C-terminal tail to this region may create a binding site for a 
replication specific transcription factor that is not required for the earlier 
transcription activation events.  Recruitment of such a factor could be involved 
in switching BZLF1 from its transactivation to replication function.  BZLF1 has 
been shown to bind to a number of cellular factors in lytically replicating cells 
(Wiedmer et al., 2008).  Isolation of BZLF1 from cells undergoing lytic cycle 
replication identified cellular proteins that associate with BZLF1, including the 
mitochondrial single-stranded DNA binding protein mtSSB.  It was suggested 
that mtSSB plays a role in switching BZLF1 from a transcriptional activator to a 
replication protein, facilitating lytic replication and blocking mitochondrial DNA 
replication (Wiedmer et al., 2008).  Binding of residues C-terminal to 228 to the 
zipper region may create a binding site for a cellular factor that could facilitate 
the lytic to latent switch and play a key role in viral DNA replication.          
It was hypothesised that epitope mapping with the BZ1 hybridoma 
antibody could be used to probe the structure of the BZLF1 dimerisation 
domain.  This technique was previously used to map antigenic sites on p53 
(Wade-Evans & Jenkins, 1985).  Western blot analysis of BZLF1 SSENDRLR 
motif mutants and truncation mutants with the BZ1 antibody indicated that the 
epitope includes residues D212, R213 and part of the C-terminal tail.  According 
to the crystal structure both of these residues are partly solvent exposed and 
available for binding.  These preliminary yet promising results suggested that it 
may be possible to gain further insight into the zipper-tail interactions by epitope 
mapping with a series of mutants.  The conditions used in these assays vary 
considerably, however, and results between the assays did not correlate.  It was 
therefore concluded that this technique was not suitable for further investigation 
of zipper-tail interactions but did reveal additional information regarding the BZ1 
epitope. 
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5.  Achievements in this thesis   
 
In this thesis the regulation of the immediate early gene BZLF1 was examined 
from reactivation of its promoter Zp through to its role in transactivation and lytic 
DNA replication.  BZLF1 is essential for lytic cycle reactivation and is sufficient 
to induce the entire lytic cascade.   
 
Zp regulation:  
Initial studies on Zp regulation were mainly based on regions of the promoter 
protected in footprinting assays.  In this study additional regions of the promoter 
were identified that contribute to Zp activity in response to anti-IgG induction 
using luciferase reporter assays.  These sites are located between the ZIB and 
ZIC promoter elements and between the ZII element and the TATA box.  The 
ZID promoter element, which was reported to bind the transcription factors 
MEF2D, Sp1 and Sp3 (Liu et al., 1997a; Liu et al., 1997b), was for the first time 
demonstrated to be functionally important during the initial stages of Zp 
activation.  Mutation of ZID caused a significant reduction in luciferase activity at 
early time points but began to catch up with the wild type activity once BZLF1 
was expressed.  EMSA analysis indicated that the ZID site binds MEF2D in 
Akata BL cell lines and the binding site was mapped to the palindrome 
CTAAATTTAG in the ZID site.  MEF2D becomes dephosphorylated within 10 
minutes of anti-IgG treatment in Akata cells and is associated with histone 
acetylase recruitment (Bryant & Farrell, 2002).    
The plasma cell specific transcription factor XBP-1s has been implicated 
in lytic cycle reactivation but its role in the Akata system is unknown (Bhende et 
al., 2007; Sun & Thorley-Lawson, 2007).  Here XBP-1 splicing was found to 
occur within 30 minutes of anti-IgG treatment in Akata cells but was not 
detected after 4 hours.  The expression of XBP-1s parallels the transient 
induction of the Zp promoter, described previously (Mellinghoff et al., 1991; 
Takada & Ono, 1989), implicating XBP-1s as a potential mediator of lytic cycle 
induction in the Akata system. 
The Zp promoter is protected from reactivation during latency by a 
repressive chromatin structure.  An inducible BZLF1 expression system, based 
on the BZLF1 estrogen receptor fusion protein ZHT, was developed in Akata BL 
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cell lines to examine repressive chromatin structures at Zp.  ZHT expression in 
the resulting cell lines accurately reconstituted physiological BZLF1 expression 
levels and activity in response to 4HT, providing a suitable model to test 
repressive chromatin structures at Zp. 
 
Functional analysis of the BZLF1 structure: 
BZLF1 contains a bZIP DNA binding domain in which C-terminal tail residues 
fold back against the zipper region (Petosa et al., 2006).  Point mutagenesis in 
the zipper region revealed the importance of individual residues within the 
208SSENDRLR215 motif that is conserved in C/EBP for BZLF1 functions.  The 
E210A, N211A, L214A and R215A mutations all affected dimer stability, 
correlating with the disruption of stabilising interactions observed in the crystal 
structure.  Mutation of S208 to glutamate severely impaired lytic cycle DNA 
replication but had little effect on transactivation of an early gene promoter.  
Structural modelling predicted that mutation of S208 to glutamate would disrupt 
the interaction of the zipper region with the C-terminal tail, through an 
electrostatic repulsion between E208 and D236.  Restoration of DNA replication 
activity by the complementation of the two deleterious mutations, S208E and 
D236K, indicated that interaction of the C-terminal tail and the zipper region is 
required for EBV to achieve lytic cycle DNA replication, identifying a functional 
role for this structural feature unique to BZLF1.  These results were recently 
published (McDonald et al., 2009).          
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